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ABSTRACT 
Fluoxetine (Prozac®) is an antidepressant which selectively inhibits the 
reuptake of serotonin (5-HT) into presynaptic nerve terminals. Limited preclinical 
studies suggest that prenatal exposure to fluoxetine may affect progeny brain 
neurochemistry at doses which do not alter the physical development of the 
offspring. The dissertation objective was to identify and characterize 
neurochemical and functional changes in central serotonergic systems in 
prepubescent and adult male rat progeny produced by prenatal exposure to 
fluoxetine. 
Pregnant rats were administered saline or fluoxetine (10 mg/kg, s.c.) daily 
from gestational day 13 through 20. Neurochemical parameters assessed in the 
brains of offspring include: (1) 5-HT and 5-hydroxy indoleacetic acid (5-HIAA) 
content; (2) the density of 5-HT uptake sites; and (3) 5-HT1A and 5-HT2A receptors 
in specific neuroanatomic loci. The functional status of brain 5-HT pathways was 
assessed by investigating: (1) the ability of the 5-HT releasing drug p-
chloroamphetamine (PCA) to reduce 5-HT content and (2) the ability of the 5-HT,A 
agonist 8-0H-DPAT and the 5-HT 2A12c agonist DOI to elicit increases in plasma 
levels of adrenocorticotropic hormone (ACTH), corticosterone, and renin. 
Site-specific alterations in the density of 5-HT uptake sites were observed 
only in prepubescent offspring prenatally exposed to fluoxetine. In contrast, in 
both prepubescent and adult progeny prenatally exposed to fluoxetine, select 
v 
regional decreases were observed in brain 5-HT content. Basal 5-HIAA content 
was not altered by prenatal fluoxetine exposure. However, the magnitude of the 
PCA-induced reduction in midbrain 5-HT content was significantly attenuated in 
fluoxetine-exposed adult progeny, suggesting some alteration in uptake or release 
mechanisms. 
With respect to functional indices, basal levels of plasma hormones (ACTH, 
corticosterone and renin) were not altered by prenatal fluoxetine exposure. 
However, the ACTH response to DOI was significantly attenuated in adult but not 
in prepubescent progeny prenatally exposed to fluoxetine. In contrast, the 
neuroendocrine responses to 8-0H-DPAT were not affected by prenatal exposure 
to fluoxetine. Likewise, while numerous site-specific alterations in 5-HT2A 
receptors were observed in offspring prenatally exposed to fluoxetine, 5-HT,A 
receptors were minimally affected by the prenatal treatment. 
In summary, prenatal exposure to fluoxetine results in site-specific and age-
dependent alterations in brain 5-HT pathways in offspring in the absence of 
physical abnormalities. As dysfunction of 5-HT pathways is implicated in the 
etiology of various psychiatric disorders, these observed alterations may be of 
some clinical significance to human offspring prenatally exposed to fluoxetine. 
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CHAPTER I 
INTRODUCTION 
Fluoxetine (Prozac ®i is a member of the class of antidepressants known as 
Selective Serotonin Reuptake Inhibitors (SSRl's) as it preferentially inhibits the 
transport of serotonin (5-HT) into presynaptic nerve terminals without blocking the 
uptake of norepinephrine or dopamine. In addition, fluoxetine has negligible 
affinity for brain serotonergic, catecholaminergic, histaminergic, GABAergic, 
muscarinic, benzodiazepine, and opiate receptors (Peroutka and Snyder, 1980; 
Thomas et al., 1987; Fuller et al., 1991; Wong et al., 1991 ). Acutely, blockade of 
the 5-HT uptake site increases synaptic concentrations of 5-HT. Subchronic 
blockade of the 5-HT transporter in adult rats has been reported to result in a 
desensitization of inhibitory somatodendritic autoreceptors, thus enhancing 
serotonergic neurotransmission (Blier et al., 1990; de Montigny et al., 1990). This 
enhancement of serotonergic neurotransmission is linked to fluoxetine' s 
therapeutic efficacy. In addition, repeated administration of fluoxetine to adult 
male rats has been reported to alter the density and sensitivity of postsynaptic 
brain 5-HT receptors (e.g. 5-HT,, 5-HT,M and 5-HT2A12c; Wong and Bymaster, 
1981; Dumbrille-Ross and Tang, 1983; Wong et al., 1985; Welner et al., 1989; Li 
et al., 1993a, b), as well as to alter the concentration of brain 5-HT and 5-HIAA 
(5-hydroxy indoleacetic acid; a 5-HT metabolite; Hrdina, 1987; Baron et al., 1988; 
Sarkissian et al., 1990; Caccia et al., 1992). Thus, fluoxetine can markedly alter 
serotonergic neurotransmission in adult animals. 
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In humans, the high degree of selectivity of this drug for the 5-HT 
transporter produces less of the side effects commonly encountered with the 
tricyclic antidepressants and, in part, accounts for the widespread use of this drug 
as well as other similarly selective reuptake inhibitors such as paroxetine {Paxil®), 
sertraline (Zoloft®), and fluvoxamine (Luvox®). Although initially indicated for the 
treatment of depression, in recent years fluoxetine has been assessed for 
therapeutic efficacy in a variety of psychiatric conditions including obsessive-
compulsive (Fontaine and Chouinard, 1986, 1989; Pigott et al., 1990) and eating 
disorders (Pijl et al., 1991; Walsh and Devlin, 1992; Wise, 1992; Yen and Fuller, 
1992; Wood A., 1993), as well as a potential treatment for cocaine and alcohol 
abuse (Batki et al., 1993; Messiha , 1993). Because of fluoxetine's widespread 
use, it is likely that a large percentage of the population of patients taking this 
medication will be women of child bearing age. Yet, despite the potential for the 
exposure of human offspring to fluoxetine (or other SSRl's), to date, only a few 
studies have been published investigating the teratogenic potential of this widely 
prescribed medication. 
In humans, prenatal fluoxetine exposure did not result in an increased risk 
of malformations (Pastuszak et al., 1993). Studies in rats and rabbits also indicate 
that prenatal exposure to moderate doses (i.e. doses that were not toxic to the 
maternal animal) of fluoxetine does not produce any gross physical abnormalities in 
the offspring, nor does it affect fetal viability or litter size (Stanford and Patton, 
1993; Byrd and Markham, 1994; Cabrera and Battaglia, 1994; Vorhees et al., 
1994). In addition, two laboratories have examined the behavior of rat offspring 
prenatally exposed to fluoxetine in a variety of paradigms and found no adverse 
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consequences of fluoxetine exposure (Hoyt et al., 1989; Vorhees et al., 1994). In 
contrast to the absence of physical terata following prenatal fluoxetine exposure, 
other evidence indicates that prenatal exposure to fluoxetine can produce 
neurochemical alterations in offspring. Montero et al. (1990) reported that prenatal 
exposure to fluoxetine decreased [3H]imipramine binding to 5-HT uptake sites in 
the cortex of prepubescent rat offspring. Likewise, Romero et al. ( 1994) 
demonstrated that prenatal exposure to fluoxetine reduced cortical 5-HT 2A 
receptor-stimulated phosphoinositide hydrolysis in prepubescent, but not adult, 
progeny. These studies are consistent with data demonstrating that both 
fluoxetine and its active metabolite, norfluoxetine, cross the placenta and enter 
fetal brain tissue (Pohland et al., 1989). After infiltrating fetal brain tissue, 
fluoxetine may alter extracellular concentrations of 5-HT by interacting with 5-HT 
transporters present on developing neurons and glia. 
In fetal rats, 5-HT uptake sites have been demonstrated to be present as 
early as embryonic day 1 5 and evidence suggests that these sites may be hyper-
functional during brain development (Whitaker-Azmitia and Azmitia, 1986; 
Mercado and Hernandez-A., 1992; lvgy-May et al., 1994). In addition, several 5-
HT receptors (5-HT,A, 5-HT, 8 , 5-HT2A and 5-HT2cl have been reported to be 
present in fetal rat brain (Uzbekov et al., 1979; Bruinink et al., 1983; 
Whitaker-Azmitia et al., 1990a; Roth et al., 1991; Voigt et al., 1991; Hellendall et 
al., 1993; Hillion et al., 1993). The presence of 5-HT (Lidov and Molliver, 1982; 
Wallace and Lauder, 1983) and a variety of central 5-HT recognition sites during 
fetal rat development suggests that drugs which interact with, and modulate 5-HT 
systems in adults, also have potential sites of action in the fetus. Consistent with 
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this idea, several studies have demonstrated that during pregnancy, the 
administration of drugs which modulate serotonergic neurotransmission produce 
neurochemical alterations in brain 5-HT pathways in offspring. For example, 
alterations in pre- and/or postsynaptic components of brain 5-HT pathways have 
been reported following maternal administration of the 5-HT precursor L-tryptophan 
(Hernandez-Rodriguez and Chagoya, 1986), the serotonin synthesis inhibitor p-
chlorophenylalanine (Whitaker-Azmitia et al., 1987), directly acting serotonin 
agonists (Whitaker-Azmitia et al., 1987; Whitaker-Azmitia et al., 1990b), or 
monoamine oxidase inhibitors (Whitaker-Azmitia et al., 1994). Therefore, our 
hypothesis is that disruption of the regulation of 5-HT concentrations during fetal 
brain development by the administration of fluoxetine will result in neurochemical 
and functional alterations in brain 5-HT pathways in offspring. 
The objective of this dissertation is to identify and characterize 
neurochemical and functional alterations in central serotonergic systems in 
prepubescent (postnatal day 28; PD 28) and adult (PD 70) male rat progeny 
prenatally exposed to fluoxetine. Male animals were chosen for these experiments 
in order to prevent any confounding influence of hormonal cycling in 
postpubescent females. The characterization of fluoxetine-induced alterations at 
two developmental time points (PD 28 and PD 70) allowed for the determination of 
whether any observed alterations were limited to prepubescent progeny (i.e. 
present at PD 28, but not at PD 70), or persisted into adulthood (i.e. present at PD 
28 and PD 70). Alternatively, fluoxetine-induced alterations may become apparent 
only after the progeny mature (i.e. not present at PD 28, but present at PD 70). 
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The consequences of prenatal fluoxetine exposure on brain 5-HT pathways 
in progeny were assessed by determining the functional status of ( 1 ) presynaptic 
5-HT neurons and (2) postsynaptic 5-HT target tissues, and by (3) assessing the 
presence of alterations in the density of 5-HT recognition sites in specific 
neuroanatomic loci. The functional status of presynaptic 5-HT terminals was 
assessed by measuring basal levels of 5-HT and 5-HIAA, and by investigating the 
ability of the 5-HT releasing drug p-chloroamphetamine (PCA) to reduce 5-HT 
content. PCA enters the serotonergic nerve terminals via the 5-HT uptake site and 
then blocks 5-HT synthesis and stimulates the release of 5-HT, resulting in a 
significant decrease in regional 5-HT content (Fuller et al., 1965; Fuller, 1980, 
1992; Kuhn et al., 1985; Adell et al., 1989; Fattaccini et al., 1991; Rudnick and 
Wall, 1992). Differences in the magnitude of the reductions in regional 5-HT 
content, in control versus fluoxetine-exposed offspring, following PCA 
administration would indicate differences in the functional integrity of either the 5-
HT transport mechanism and/or the neurotransmitter release process. On the other 
hand, similar decreases in regional 5-HT content in control versus fluoxetine-
exposed offspring would indicate that prenatal fluoxetine does not produce global 
changes in 5-HT transport mechanisms or release processes in specific brain 
regions. In addition, the ratio of 5-HT:5-HIAA levels was determined as an index 
of serotonin turnover. 
The functional status of postsynaptic 5-HT,A and 5-HT2A receptors was 
assessed by measuring the ability of the selective 5-HT,A agonist 8-0H-DPAT (8-
hydroxy dipropylaminotetraline) and the 5-HT2A12c agonist DOI ( ± 4-iodo,2,5 
dimethoxy phenylisopropylamine) to elicit increases in plasma levels of 
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adrenocorticotropic hormone (ACTH), corticosterone, and renin the secretion of 
which can be regulated by central 5-HT pathways. 5-HT fibers which originate in 
the dorsal and median raphe nuclei innervate a number of forebrain areas and send 
collaterals to certain hypothalamic nuclei including the paraventricular nucleus 
(appendix 3). Some of these hypothalamic serotonergic nerve terminals stimulate 
ACTH and renin secretion (Karteszi et al., 1982; Van de Kar et al., 1985a). For 
example, the activation of hypothalamic 5-HT,A and 5-HT2A12c receptors has been 
reported to increase plasma ACTH and corticosterone levels (Koenig et al., 1987; 
Lorens and Van de Kar, 1987; Gilbert et al., 1988a,b; Calogero et al., 1989; 
Przegalinski et al., 1989; Alper, 1990; Fuller, 1990; Van de Kar, 1991 ), while the 
stimulation of central 5-HT 2A receptors has been reported to elevate plasma renin 
levels (Van de Kar et al., 1985b; Rittenhouse et al., 1990; Van de Kar, 1991 ). 
The ability of the selective 5-HT,A agonist 8-0H-DPAT and the 5-HT2A12c agonist 
DOI to elicit increases in plasma levels of ACTH, corticosterone, and renin provides 
an index of the functional status of hypothalamic 5-HT receptor subtypes. These 
studies may provide a peripheral marker of central serotonergic dysfunction in 
association with in utero exposure to fluoxetine. 
Lastly, the effect of prenatal exposure to fluoxetine on the regional 
innervation of 5-HT neurons, as well as on the density of 5-HT 1 A and 5-HT 2A 
receptor subtypes was determined by quantitative in vitro autoradiography. These 
studies can provide a comprehensive map of fluoxetine-induced alterations in pre-
and postsynaptic 5-HT recognition sites. All neurochemical parameters were 
assessed in brain regions receiving varying degrees of serotonergic innervation, as 
well as those brain regions rich in 5-HT immunoreactive perikarya. Herein we 
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report that prenatal exposure to fluoxetine produces site-specific and age-
dependent alterations in the neurochemical and functional status of both pre- and 
postsynaptic components of brain serotonin systems in male offspring. 
CHAPTER II 
REVIEW OF RELATED LITERATURE 
Ontogeny of the Serotonergic System in Rat Brain 
Cell Bodies 
The development of the serotonergic system in the rat embryo was first 
described using fluorescence histochemistry (Levitt and Moore, 1978; Olsen and 
Seiger, 1972; Seiger and Olsen, 1973). However, the fluorophore formed from 5-
HT photodecomposes rapidly, and a significant portion of the serotonergic 
innervation was not visualized with the histofluorescence method (Lidov et al., 
1980; Lidov and Molliver, 1982a,b). Subsequently, immunocytochemical 
procedures that provided more reliable and sensitive visualization were employed 
and form the basis of our current knowledge of the development of the 
serotonergic system in rat brain (Steinbusch et al., 1978; Lidov and Molliver, 
1982a,b; Wallace et al., 1982; Aitken and Tork, 1988; Konig et al., 1988). 
Overall, during the gestational period from GD 12-18, 5-HT immunoreactive cells 
will proliferate, form complex dendritic trees, and migrate to their permanent 
positions (Aitken and Tork, 1988). These changes are described briefly below. 
Serotonergic neurons first appear at GD 12 as a bilateral rostral cluster of 
cells just caudal to the mesencephalic flexure (Aitken and Tork, 1988). At this 
immature stage, the neurons are smooth, round, and have no dendrites (Lidov and 
Molliver, 1982a). By GD 14 the rostral cluster of cells enlarges and a caudal 
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cluster of scattered 5-HT immunoreactive neurons first appears in the medulla 
caudal to the pontine flexure (Lidov and Molliver, 1982a; Aitken and Tork, 1988). 
At GD 13-14 the serotonergic neurons no longer appear immature. During this 
stage, the neurons are sending out numerous dendritic processes away from the 
ventricular surface (Lidov and Molliver, 1982a; Wallace and Lauder, 1983; Aitken 
and Tork, 1988), and fine axonal processes cross the midline and may serve as a 
commissural connection between the bilateral 5-HT cell groups (Lidov and Molliver, 
1982a; Wallace and Lauder, 1983; Aitken and Tork, 1988). By GD 15, the 
genesis of the neurons in the B7-9 complex is essentially complete (Wallace and 
Lauder, 1983). At this stage, the 5-HT immunoreactive neurons can still be seen 
as two distinct groups, but they have increased in size and number. At this point 
there are also prominent bilateral bundles of ascending and descending 5-HT axons 
emerging from the rostral and caudal cell groups respectively (Lidov and Molliver, 
1982a; Aitken and Tork, 1988). By GD 16, 5-HT immunoreactive cells have 
become more numerous and less compact. Aggregations of cells within the rostral 
and caudal cell groups begin to form and are the first signs of the neuronal subsets 
that will later form distinct raphe nuclei (Lidov and Molliver, 1982a). For example, 
four subdivisions of the superior group are apparent: ( 1 ) the dorsal group will form 
the dorsal raphe; (2) the medial group, will form the median raphe and may 
contribute some neurons to the nucleus pontine centralis oralis and to the B9 cell 
group; (3) the transient lateral; and (4) ventro-lateral groups will form the B9 group 
and contribute to the raphe magnus. In addition, two divisions are now apparent 
in the inferior group which will form the raphe pallidus and obscurus (Lidov and 
Molliver, 1982a). At GD 17, the formation of a fused 5-HT immunoreactive 
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nucleus becomes apparent (Jacobs and Azmitia, 1992), and by GD 19 the 
distribution of serotonergic neurons in the brainstem is similar to that found in the 
adult (Lidov and Molliver, 1982a; for review see Tork, 1990). The development of 
serotonergic cell bodies is essentially complete by GD 19 (Lidov and Molliver, 
1982a). From GD 19 through the first postnatal week, there is a rapid growth of 
5-HT dendrites and a decrease in cellular packing density in individual nuclei but 
the overall morphology of the cell groups in the brainstem does not change (Lidov 
and Molliver, 1982a). 
Axonal Projections 
Since the caudal group of raphe nuclei primarily innervate the spinal cord, 
only the ascending projections from the rostral nuclei will be discussed. Similar to 
the development of the 5-HT cell bodies, the development of the ascending 
projections has been studied primarily using immunocytochemical techniques 
(Lidov and Molliver, 1982b; Wallace and Lauder, 1983; D' Amato et al., 1987; 
Aitken and Tork, 1988; Wallace and Lauder, 1992). 
As mentioned above, the first axonal projections are those which cross the 
midline and link the bilateral groups of rostral nuclei at about 12-13 days of 
gestation (Wallace and Lauder, 1983). At GD 14-15 axons have extended rostrally 
to the mesencephalic flexure. At this stage the serotonergic axons are 
unbranched, relatively uniform and have few varicosities; unlike the axons seen in 
adults which are finer, more varicose and twisted (Lidov and Molliver, 1982b). 
Growth cones stain intensely for 5-HT at this stage. By GD16, bilateral bundles of 
ascending 5-HT axons pass completely through the mesencephalon and can be 
seen at the border of the diencephalon and telencephalon (Lidov and Molliver, 
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1982b; Wallace and Lauder, 1983; Aitken and Tork, 1988). At this stage the 
number of 5-HT immunoreactive fibers increases in the lateral hypothalamus, 
reaching as far rostrally as the supraoptic region (Lauder, 1990). By GD 17, the 
ascending 5-HT axons in the medial forebrain bundle (MFB) innervate the basal 
forebrain and the rostral pole of the telencephalon (Lidov and Molliver, 1982b; 
Wallace and Lauder, 1983; Aitken and Tork, 1988). Although 5-HT fibers reach 
the frontal cortex by GD 17 (Lidov and Molliver, 1982a; Blue and Molliver, 1985), 
the adult cortical laminar pattern is not complete until approximately two weeks 
postnatally (Jacobs and Azmitia, 1992). The signals for terminal sprouting are not 
known, but have been suggested to be a function of the target cells rather than 
the 5-HT afferents themselves (Jacobs and Azmitia, 1992). At GD 18, there is an 
increase in 5-HT immunoreactivity in several areas of the hypothalamus (e.g. the 
mammillary complex, and the anterior hypothalamus; Wallace and Lauder, 1983), 
and by GD 19, the serotonergic pathways to all major divisions of the forebrain 
have been established. The layout of 5-HT projections is similar to GD 17, 
however, the axon density at GD 19 has increased (Lidov and Molliver, 1982b). 
At this stage, 5-HT fibers leaving the MFB form branches in which serotonergic 
axons travel along specific fiber bundles such as the fasciculus retroflexus, 
mammillotegmental tract, stria medullaris, supracallosal stria and external capsule. 
5-HT fibers have been suggested to use these other fibers as mechanical guides to 
innervate a target area; a process termed "epiphytic guidance" (Azmitia, 1978; 
Jacobs and Azmitia, 1992). At GD 19, synapses have been observed on dorsal 
raphe neurons which increase in number for several weeks postnatally (Lauder and 
Bloom, 1975). Axon density continues to increase through GD 21, and new 
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subcortical and hippocampal terminal fields develop. At GD 21, 5-HT axons can 
be seen in the cerebellum; the amygdala, as well as the paraventricular nucleus of 
the hypothalamus are densely innervated. In general, most areas of the brainstem 
are densely innervated by this stage (Lidov and Molliver, 1982b). 5-HT terminal 
field formation continues postnatally especially in the telencephalon, tectum and 
cerebellum (Lidov and Molliver, 1982b). 
In summary, the ontogeny of 5-HT axonal projections has been described 
by Lidov and Molliver (1982b) as occurring in 3 stages: (1) Initial axon elongation 
(GD 13-16). This phase overlaps considerably with the formation of raphe nuclei 
described above and ends when axons in the medial forebrain bundle first enter the 
basal forebrain; (2) The development of selective pathways (GD 15-19), which 
begins with the appearance of 5-HT fibers in the mamillo-tegmental tract and the 
fasciculus retroflexus at about GD 15, and ends when axons have reached the 
vicinity of all the structures in the brain that are to receive 5-HT innervation; and 
(3) terminal field development (GD 19-PD 21). In general, the development of 
terminal innervation is region specific (Lidov and Molliver, 1982b). Brain areas 
rostral to the pons develop terminal arborizations primarily postnatally, indicating 
that 5-HT axons do not innervate immature, primarily proliferative neuronal 
populations (Lidov and Molliver, 1982b). The rapid and dramatic development of 
serotonergic cell bodies and axonal projections from GD 13 through birth make this 
period of development particularly sensitive to perturbations in the serotonergic 
system. 
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Serotonin Recognition Sites, Synthesis and Degradation Enzymes 
Relatively few studies have investigated the presence of 5-HT receptors 
during perinatal development of the rat brain. Most of these studies have 
employed radioligand binding analysis in homogenates or synaptosomes. In 1979, 
Uzbekov et al. reported a high density of [3HJ5-HT binding sites in rat brain 
immediately postnatally. This finding was later confirmed by Fillion et al. ( 1982) 
and by Whitaker-Azmitia et al. (1987). Around the same time, Daval et al. (1987) 
demonstrated that 5-HT,A receptors were expressed in fetal rat brain in excess of 
adult levels. Similarly, high levels of 5-HT,A receptors were reported in human 
fetal brain in excess of adult levels (Bar-Peled et al., 1991 ). More recently, using 
more sensitive molecular biological techniques, Hillian et al., (1993) detected 5-
HT,A receptor mRNA in rat brain as early as GD 12. This group also noted that the 
concentration of 5-HT,A transcripts reached a maximum at GD 15 and then 
progressively decreased to low levels before birth. Interestingly, this peak in 5-
HT,A mRNA occurs at a time when target cells of 5-HT neurons are undergoing 
differentiation (Lauder and Krebs, 1978). Subsequently, Hillian et al. (1994) 
reported that 5-HT,A receptors were detectable in embryonic brain stem cultures 2 
days after mRNA was initially detected. In addition, 5-HT,A receptor protein and 
mRNA were localized to neuron-like cells but not in glial cells in brainstem cultures 
taken from GD 14-GD 16 rats (Hillian et al., 1994). The apparently selective 
localization of 5-HT,A receptors to neuronal cells is contradictory to previous 
reports (Whitaker-Azmitia and Azmitia, 1989; Hellendall et al., 1992). 5-HT18 
mRNA has also been identified in rat brain as early as GD 17 (Voigt et al., 1991 ). 
With respect to the 5-HT2 receptor family, Bruinink et al. (1983) identified 
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[ 3H]spiperone binding to 5-HT2A receptors as early as GD 15-16 in rat forebrain 
homogenates. In addition, Roth et al. ( 1991) demonstrated that 5-HT 2A receptors 
increased 8-fold between GD 17 and PD 13, while 5-HT2c receptors increased only 
2-fold between GD 17 and PD 27. This increase in 5-HT2A and 5-HT2c receptor 
number was also accompanied by increases in the level of mRNA for each receptor 
subtype. Consistent with these data, Pranzatelli (1993) also reported an increase 
in 5-HT 2c receptors in rat cortex and diencephalon during the preweanling period. 
Interestingly, the rank order of the density of 5-HT 2c receptors shifted from 
postnatal day 1 (brainstem > cortex > spinal cord) to postnatal day 28 (cortex 
diencephalon > spinal cord = brainstem = hippocampus). 5-HT3 receptors have 
been reported to be present during brain development in mice (Shtrom et al., 
1993). However, 5-HT3 receptors have not been identified in fetal rat brain. In 
addition, some indirect evidence (i.e. profile of 5-HT stimulation of adenylyl 
cyclase) suggests that 5-HT 4 receptors may be present and functional in fetal 
mouse and rat brain (Dumuis et al., 1988a,b; Enjalbert et al., 1978). However, no 
studies have definitively demonstrated the presence of 5-HT 4 receptors in fetal rat 
brain. 
In 1987, Whitaker-Azmitia et al. investigated the functional status of fetal 
rat 5-HT receptors by testing their ability to regulate in response to serotonergic 
perturbing agents. This group treated pregnant rats with either p-chloro-
phenylalanine (PCPA; a tryptophan hydroxylase inhibitor) or 5-methoxytryptamine 
(5-MT; a nonselective 5-HT agonist) and examined [3H]5-HT binding in forebrain 
and brain stem homogenates of postnatal progeny. The administration of PCPA 
increased [3H]5-HT binding in the forebrain and brain stem at PD 1 while 5-MT 
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administration decreased [3HJ5-HT binding in both areas at PD 1 . The 
demonstration that forebrain and brain stem 5-HT receptors respond to alterations 
in the serotonergic system during development indicates that fetal 5-HT receptors 
appear to be functional and capable of playing a role in neuronal development 
(Whitaker-Azmitia et al., 1987). This study also demonstrates that prenatal 
perturbation of the serotonergic system can result in postnatal alterations in 
progeny brain 5-HT systems. Further evidence of functional 5-HT1A receptors in 
fetal rat brain includes a study by Becquet et al. ( 1992) in which they reported that 
the 5-HT lA agonist 8-0H-DPAT inhibited the spontaneous and K +-evoked release of 
[ 3HJ5-HT in primary cultures from GD 14 rat raphe nuclei. 
In addition to 5-HT receptors, 5-HT uptake sites are present and functional 
in fetal rats. Whitaker-Azmitia and Azmitia (1986) demonstrated active 5-HT 
uptake in cultures composed of mesencephalic raphe cells (GD 14) and 
hippocampal cells (GD 18). More recently, Mercado and Hernandez (1992) 
isolated prenatal growth cone particles and found that fetal growth cone particles 
take up more [3H]5-HT per unit time than PD 5 growth cone particles. This 
apparent hyperactivity of prenatal 5-HT uptake systems in brain supports the 
importance of critically regulating extracellular 5-HT concentrations during the 
development of fetal rat brain. Consistent with this idea, lvgy-May et al. ( 1994), 
demonstrated that the 5-HT transporter is present on growth cones prior to 
synapse formation. In addition, this group reported that active 5-HT uptake into 
growth cone fractions (prepared from GD 20 rats) could be inhibited by fluoxetine. 
Other components of the serotonergic system that have been detected prior 
to birth include 5-hydroxytryptophan decarboxylase activity (Bennett and Giarman, 
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1965), monoamine oxidase activity (Shimizu and Morikawa, 1959; Nachmias, 
1960; Karki et al., 1962; Kurzepa and Bojanek, 1965), tryptophan 5-hydroxylase 
(Baker and Quay, 1969), and tryptophan (Hamon and Bourgoin, 1979; Blue and 
Molliver, 1987). 
The presence of functional central 5-HT recognition sites during fetal rat 
development suggests that drugs which interact with 5-HT systems in adults have 
potential sites of action in the fetus. 
Serotonin as a Developmental Signal 
In the 1960-70's Buznikov et al. measured 5-HT levels in non-mammalian 
species during the initial stages of embryogenesis and demonstrated that 5-HT 
concentrations fluctuate during the cell division cycle (Buznikov et al., 1964; 
Buznikov et al., 1972; Buznikov, 1973). Their study was one of the earliest 
reports to suggest that 5-HT might have a role in the regulation of development. 
Since these initial reports, many studies have detected high concentrations of 5-HT 
during development of the central nervous system prior to assuming its role as a 
neurotransmitter (for review see Buznikov, 1984). These and other more recent 
studies support a role for 5-HT as a developmental signal and/or trophic factor in 
several animal species. Some of the key reports on this topic are discussed below. 
In 1984, Haydon et al. reported that when 5-HT is placed directly adjacent 
to a growth cone of the pond snail Helisoma, a reversible retraction of the growth 
cone filopodia and lamellipodia was observed, as well as a decrease in the growth 
cone surface area and motility. By inhibiting neurite outgrowth, 5-HT was 
demonstrated to prevent the formation of electrical connections with other 
competent neurons. Similar results were reported by Davila-Garcia et al. in which 
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cultured raphe neurons of the rat exposed to 5-HT exhibited an inhibition of neurite 
outgrowth (Davila-Garcia et al., 1985). Conflicting reports on the role of 5-HT in 
development include a report by Liu and Lauder (1991 ). In this study, the 
presence of nialamide (a monoamine oxidase inhibitor) in cultures of rat embryonic 
neurons increased the neuronal soma area, the number of neurites, and neurite 
branching in 5-HT immunoreactive cells; although there was some evidence that 5-
HT inhibited the effects of nialamide. Other reports in vertebrate neuronal cultures 
report concentration dependent effects of 5-HT on neuronal outgrowth. Whitaker-
Azmitia et al., ( 1990b) demonstrated that in neuronal cultures derived from GD 13-
14 rat pups, low concentrations of a non-selective 5-HT agonist (5-MT; 1-100 nM) 
inhibited growth of 5-HT neurons. However, higher concentrations ( > 1,000 nM) 
stimulated growth (Whitaker-Azmitia et al., 1990b). Similarly, when 5-MT was 
given to pregnant rats from GD 12 to birth, there was an increase in terminal 
outgrowth in the forebrain (as measured by [3H]5HT uptake) at high doses but 
inhibited growth at low doses. These reports suggest that 5-HT may also act as a 
trophic stimulus for survival and growth of 5-HT cell bodies. 
In addition to its role in the growth of the pre-synaptic neuron, serotonin 
has also been demonstrated to initiate and amplify its own synthesis, as well as 
affect 5-HT target area development, and cellular proliferation. A stimulatory role 
of 5-HT on the expression of neurochemical markers of serotonergic neurons was 
reported in 1986 by De Vitry et al.. This group demonstrated that incubation of 
mouse embryonic hypothalamic cells with 8-0H-DPAT increased the intensity of 5-
HT immunoreactive staining and the number of 5-HT immunoreactive cells. The 
proposed autocrine stimulation was shown to be receptor-mediated as this effect 
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was blocked by co-incubation with the non-selective 5-HT antagonist, metergoline. 
In 1992, Chubakov et al. demonstrated that the morphological and functional 
development of hippocampal explants could be stimulated by the exogenous 
administration of 5-HT or by co-culture of hippocampal neurons with raphe nuclei. 
Likewise, the absence of 5-HT has been shown to result in an altered morphology 
of 5-HT target regions and retarded cell proliferation (Lauder and Krebs, 1978; 
Goldberg and Kater, 1989). 
Although the site(s) of action for serotonin's effects on developing nerve 
cells is(are) unknown, evidence suggests that serotonin's effects during 
development are regulated within growth cones and/or glial cells (Haydon et al., 
1984; Mattson and Kater, 1987; Aitken and Tork, 1988) presumably by activation 
of one or more 5-HT receptor subtypes. The evidence in support of growth cone 
regulation includes studies which demonstrated a high degree of 5-HT 
immunoreactivity in the growth cones of developing 5-HT neurons (Aitken and 
Tork, 1988). Also, when Helisoma growth cones are physically isolated they 
continue motile and elongation behaviors and remain sensitive to neurotransmitters 
(Haydon et al., 1984; Mattson and Kater, 1987). The report by Haydon et al. 
( 1 984) in Helisoma cultures also demonstrated that the focal application of 5-HT to 
either the neurite or the soma did not result in any inhibitory effects. 
Other evidence suggests an involvement of 5-HT,A receptors on glial cells in 
the role of 5-HT as a developmental signal. Glial cells have an active uptake 
system for 5-HT and contain 5-HT receptors, MAO, and other catabolizing and 
synthesizing enzymes and may be capable of releasing neurotransmitter (Katz and 
Kimelberg, 1985; Whitaker-Azmitia and Azmitia, 1986; Hansson et al., 1987). 
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Whitaker-Azmitia and Azmitia ( 1989) demonstrated that the stimulation of rat 
astroglial cells in culture with either 8-0H-DPAT or ipsapirone (selective 5-HT1A 
agonists) produces a conditioned medium which when used as an incubation 
medium for primary 5-HT neuron cultures increases serotonergic neuronal 
membrane surface area (as reflected by increased [3H]5HT uptake; 
Whitaker-Azmitia and Azmitia, 1989; Whitaker-Azmitia et al., 1990a,b). In 
contrast, TFMPP (trifluoro-methyl-phenyl-piperazine; a 5-HT18 agonist) did not 
produce a conditioned medium capable of altering neuronal membrane area. It has 
been suggested that, in vivo, astrocytes may be in contact with 5-HT cell bodies 
or terminals and may produce a factor which is important for neuronal survival or 
growth (Whitaker-Azmitia and Azmitia, 1989). The substance believed to be 
produced by the astrocytes is S-1008 protein (Azmitia et al., 1990; Jacobs and 
Azmitia, 1992). 
8-0H-DPAT has been shown to stimulate astrocytes to release S-1008 
which promotes growth of embryonic 5-HT neurons (Whitaker-Azmitia and 
Azmitia, 1989; Azmitia et al., 1990; Whitaker-Azmitia et al., 1990a). In addition, 
inactivation of S-1008 prevents the growth-stimulating effects of ipsapirone 
(Whitaker-Azmitia et al., 1990). It has recently been proposed that S-1008 
mediates the growth of serotonergic neurons by inhibiting the phosphorylation of 
the neuron-specific protein F1 /GAP 43 (Sheu et al., 1994). This protein is highly 
expressed in brain during periods of normal growth and is present in large 
quantities in midbrain rap he serotonergic neurons (Skene, 1989; Bendetti et al., 
1991; Meberg and Routtenberg, 1991). Based on their investigations, Whitaker-
Azmitia et al. (1990b) have speculated that the development of 5-HT neurons is 
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dependent on the balance between two high affinity 5-HT receptors one of which 
is localized on 5-HT neurons and regulates 5-HT release; stimulation of this 
unidentified 5-HT receptor subtype results in stunting of neurites or abnormal 
morphology. The second receptor is a 5-HT,A receptor localized on astroglial cells; 
stimulation of which results in the production of "factors" regulating the 
development of 5-HT neurons {Whitaker-Azmitia et al., 1990b). 
In addition to the controversy concerning the site of action of 5-HT, the 
signal transduction mechanism is unknown as well. Several second messenger 
systems {Ca+ 2 , cyclic nucleotides, phosphoinositides) have been suggested to be 
involved in mediating the effects of neurotransmitters on neurite outgrowth. For 
example, in the He/isoma neuron 819, 5-HT has been demonstrated to increase 
ca+ 2 influx into growth cones {Cohan et al., 1987), and the outgrowth inhibitory 
effects of 5-HT could be prevented by application of ca+ 2 blockers {Mattson and 
Kater, 1987). Other reports indicate that high ca+ 2 levels result in neurite 
retraction and eventual death {Choi, 1985; Cohan et al., 1987). In contrast, 
Nyakas et al. (1989) have reported that serotonergic neurons grown in low ca+ 2 
medium have smaller somas and fewer processes after 3 days in culture. 
Although cAMP {Shapiro, 1973; Schubert et al., 1978; Nirenberg and 
Wilson, 1984; Taylor-Hunter et al., 1987; Mattson et al., 1988) and inositol 
phospholipids {Spinelli and Ishii, 1983; Traynor, 1984; Reboulleau, 1986; 
Taylor-Hunter et al., 1987) have been implicated in the regulation of neuronal 
outgrowth and synaptogenesis, the reports have been conflicting. Some studies 
show that increases in intracellular cAMP levels enhance neurite extension in PC 
12 cells {Schubert et al., 1978), embryonic rat cortical cells {Shapiro, 1973), and 
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hippocampal pyramidal neurons (Mattson, 1988). On the other hand, in He/isoma 
B 1 9 neurons, elevations in cAMP inhibited neurite elongation and growth cone 
motility (Mattson, 1988). Similarly, phorbol activators have been found to 
promote neurite outgrowth (Spinelli and Ishii, 1983) in neuroblastoma cells, as well 
as cause a retraction of filopodia and lamellipodia (Taylor-Hunter et al., 1987). 
Outgrowth of neurites can also be affected by electrical activity (Marsh and 
Beams, 1946; Patel and Pao, 1982). Filopodia and lamellipodia of He/isoma 
neurons retracted and ceased elongation when action potentials were induced in 
these neurons (Cohan and Kater, 1986). Also, depolarization of Helisoma neurons 
by acetylcholine prevented the 5-HT induced inhibition of neurite outgrowth in B19 
neurons (McCobb and Kater, 1986; Mattson, 1988). 
Although there currently is no consensus on the exact role of 5-HT in 
development (trophic or inhibitory) nor the specific mechanisms involved or site(s) 
of action, it is clear that changes in 5-HT levels can result in alterations in the 
development of 5-HT axons and target areas. Therefore, the critical regulation of 
brain 5-HT levels during the development of central 5-HT systems is important to 
maintaining its integrity. 
The Administration of Selective Serotonin Reuptake 
Inhibitors to Adult Rats Alters Brain Neurochemistry 
Fluoxetine was first described in the scientific literature as a selective 5-HT 
uptake inhibitor in 1974 (Fuller et al., 1974). In 1988, fluoxetine (Prozac®) was 
approved for clinical use in the United States as a treatment for depression. To 
date, fluoxetine is currently being investigated for therapeutic efficacy in a variety 
of psychiatric disorders known to involve dysfunctional 5-HT systems. Because 
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fluoxetine is a highly selective compound, patients experience fewer side effects 
following a therapeutic regimen of fluoxetine versus those observed for non-
selective tricyclic antidepressants, and consequently compliance is generally 
greater for fluoxetine than for the tricyclic antidepressants. In addition, fluoxetine 
is less toxic (especially when taken in overdose) than its predecessors the tricyclic 
antidepressants. However, similar to the tricyclic antidepressants, fluoxetine (and 
other SSRls) requires at least 2 weeks of daily administration prior to the onset of 
significant clinical efficacy. Therefore, preclinical studies have investigated the 
consequences of acute (single administration), sub-chronic ( ~ 14 d), and chronic 
(;;::::: 21 d) administration of fluoxetine (and other SSRls) on brain monoamine 
systems. Some of the key studies will be described below. Most of the research 
has focused on understanding fluoxetine-induced alterations in brain 5-HT 
pathways in an attempt to elucidate fluoxetine's mechanism(s) of action, and 
achieve an understanding of the neurochemical processes involved in the etiology 
of depression and other psychiatric disorders. 
Acute Effects of Selective Serotonin Reuptake Inhibitors 
Recent microdialysis studies have revealed that the acute peripheral 
administration of the 5-HT uptake inhibitors citalopram ( 1 or 10 mg/kg), 
clomipramine (20 mg/kg) or fluvoxamine (10 mg/kg) results in a 2-6 fold increase 
in extracellular 5-HT concentrations in the dorsal raphe nucleus (lnvernizzi et al., 
1992; Bel and Artigas, 1992; Adell and Artigas, 1991 ). In contrast, the 
administration of a low (1 mg/kg) dose of citalopram did not alter extracellular 
levels of 5-HT in the frontal cortex (lnvernizzi et al., 1992). However, extracellular 
5-HT was significantly elevated in the frontal cortex following a high dose (10 
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mg/kg) of citalopram (lnvernizzi et al., 1992). Dose-dependent responses in 
extracellular 5-HT content were also observed in other brain regions innervated by 
5-HT neurons. For example, low doses of the 5-HT uptake inhibitors citalopram or 
paroxetine (0.5 mg/kg) decreased extracellular 5-HT concentrations in the 
hippocampus (Hjorth and Auerbach, 1994). However, higher doses of citalopram 
(5 mg/kg) or fluoxetine (10 mg/kg) increased extracellular 5-HT in the hippocampus 
(Hjorth, 1993; Sabol et al., 1992). Following a single administration of fluoxetine 
( 10 mg/kg) increases in extracellular 5-HT concentration have been reported in the 
striatum (Perry and Fuller, 1992; Rutter and Auerbach, 1993) and diencephalon 
(Rutter and Auerbach, 1993). The differential response of 5-HT cell body regions 
(e.g dorsal raphe) and terminal regions (e.g. cortex) to peripherally administered 5-
HT uptake inhibitors was unexpected as both cell body and terminal regions were 
equally sensitive to local administration of SSRls. Together, these studies 
suggested that the increase in extracellular 5-HT levels by low doses of SSRls in 
the dorsal raphe prevented the increase in 5-HT expected in terminal regions. 
Consistent with this hypothesis, Hutson et al., 1989 demonstrated that 8-0H-
DPAT applied locally to the dorsal raphe decreased extracellular 5-HT in the 
hippocampus. Therefore, it has been hypothesized that activation of 5-HT,A 
receptors in the dorsal raphe may mediate the inhibitory effect of SSRls on 
extracellular 5-HT in terminal regions. Subsequently, further evidence to support 
this theory was put forth using 5-HT1 antagonists. For example, lnvernizzi et al. 
( 1992) observed that increases in extracellular cortical 5-HT concentrations after 
peripheral citalopram administration could be elicited if rats were pretreated with 
methiothepin (a non-selective 5-HT1 antagonist). Using a more selective 5-HT1A 
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antagonist, Hjorth and Auerbach ( 1994) demonstrated that (-)WAY 100135 
abolished the decrease in 5-HT observed in the hippocampus following systemic 
injection of low doses of citalopram or paroxetine. Thus, low doses of SSRls 
increase extracellular 5-HT in cell body regions which activates presynaptic 
autoreceptors, inhibits neuronal firing, and inhibits the subsequent release of 5-HT 
into terminal areas. Thus, following acute administration of low doses of 5-HT 
uptake inhibitors, there is no significant elevation of extracellular 5-HT in terminal 
regions. However, the inhibitory effects of SSRls, mediated by the activation of 5-
HT 1A autoreceptors, can be overcome by the administration of higher doses of the 
uptake inhibitor. In summary, the nature of the effect of uptake inhibitors on 
extracellular 5-HT concentrations is region- and dose-specific. 
In contrast to the complexity of changes in extracellular 5-HT 
concentrations, extracellular 5-HIAA concentration is consistently reduced 
following acute SSRI administration. For example, 5-HIAA extracellular 5-HIAA 
concentrations were significantly reduced in the diencephalon following acute 
fluoxetine administration ( 10 mg/kg; Rutter and Auerbach, 1993). The reduction in 
extracellular 5-HIAA has also been reported to occur in the hippocampus following 
acute sertraline (11 mg/kg) administration (Manfridi et al., 1992). 
Subchronic and Chronic Effects of Selective Serotonin Reuptake Inhibitors 
In addition to investigating the effects of acute administration of SSRls, 
several studies have investigated the effects of subchronic and chronic 
administration of 5-HT uptake inhibitors such as fluoxetine on various aspects of 
brain serotonin systems in the rat. Similar to observations made following acute 
SSRI administration, the most consistent finding following subchronic and chronic 
SSRI exposure is a reduction in regional brain 5-HIAA content. For example, a 
single administration of either citalopram or fluoxetine decreases brain 5-HIAA 
content as measured by HPLC analysis {Baker and Goodrich, 1982; Baker and 
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Hoff, 1987; Hyttel, 1977b; Caccia et al., 1992). The reduction in 5-HIAA persists 
throughout the duration of the treatment (as long as 21 d; Caccia et al., 
1992;Hrdina, 1987; Baron, 1988) and can return to control values upon 
discontinuation of the drug {Caccia et al., 1992). The reduction in 5-HIAA content 
following acute, subchronic or chronic SSRI administration is believed to be the 
result of blockade of 5-HT reuptake and a consequent reduction in the reuptake of 
5-HT and its metabolism by intracellular monoamine oxidase (Beasley et al., 1992; 
Rutter and Auerbach, 1993; Frankfurt et al., 1994). In contrast to the consistent 
decrease in 5-HIAA observed after SSRI administration, brain 5-HT levels have 
been reported to either decrease or remain constant following subchronic or 
chronic SSRI administration. Some researchers have reported decreased brain 5-
HT content after a single dose of fluoxetine (20 mg/kg, i.p.; Savage, 1980) while 
others report no change in cortical 5-HT content following either 4, 7, or 16 day 
fluoxetine ( 10 mg/kg; Hrdina, 1987; Savage, 1980) administration but a reduction 
in 5-HT content after 21 days (Hrdina, 1987). In contrast, Caccia et al. ( 1992) 
reported decreased hippocampal and cortical 5-HT concentrations after 7 days of 
fluoxetine administration (15 mg/kg, i.p.). Thus, changes in brain 5-HT 
concentration following SSRls may be region and dose-dependent and appear to be 
dependent on the treatment regimen employed. 
With respect to changes in 5-HT receptors following subchronic and chronic 
administration of SSRls, results are dependent on the duration of the treatment and 
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the particular SSRI investigated. Some studies have reported that the 
administration of fluoxetine ( 10 mg/kg/day, i.p. or via minipump) or citalopram 
(dose, p.o.) for 14 days did not alter the density of 5-HT2A receptors (Baron et al., 
1988; Hyttel et al., 1984; Goodnough and Baker, 1994) in rat cortical 
homogenates. However, Eison et al. ( 1991), reported that the continuous 
administration of fluoxetine (20 mg/kg/day) via osmotic minipump for 14 days 
decreased 5-HT 2A receptors in rat cortex. Longer administration of fluoxetine ( 10 
mg/kg/day for 21-28 days) has been reported to result increased 5-HT 2A receptors 
in rat cortical homogenates (Dumbrille-Ross and Tang, 1983) and increase 5-
HT 2A12c receptors in the hypothalamus (Li et al, 1993a). Other reports using the 
same dose of fluoxetine, indicate a lack of changes in 5-HT2A receptors in cortical 
homogenates after 21 days of fluoxetine treatment (Peroutka and Snyder, 1980; 
Snyder and Peroutka, 1982). Similarly, Hyttel et al. (1984) reported a lack of 
changes in 5-HT 2A receptors in various brain regions after the administration of 
citalopram (dose, p.o. x 14d). Still other studies reported that paroxetine 
administration (5 mg/kg, i.p. x 21 d) decreased 5-HT 2A receptors. With respect to 
the sensitivity of the 5-HT 2 receptor subtypes, Kennet et al. ( 1994) reported that 
chronic administration of either fluoxetine or paroxetine ( 10 mg/kg, p.o.) 
attenuated the ability of mCPP to produce hypolocomotion suggesting a reduced 
responsivity of 5-HT2c128 receptor subtypes. 
No clear pattern of 5-HT, receptor changes following repeated SSRI 
exposure has emerged from the literature. A reduction in 5-HT, receptors has 
been observed after as few as three daily injections of fluoxetine (10 mg/kg, i.p.; 
Wong et al., 1985) and following longer administration of fluoxetine ( 10 mg/kg/day 
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for 24-28 days) in rat cortical homogenates (Dumbrille-Ross and Tang, 1983; 
Wong et al., 1985). In addition, using in vitro autoradiography, decreased 5-HT1A 
receptor density in the dorsal raphe nucleus was observed after long-term 
treatment (21 d) with fluoxetine (Welner et al., 1989). However, 5-HT 1A receptors 
were not altered in either the hippocampus or temporal cortex (Welner et al., 
1989), regions containing 5-HT1A receptors on non-serotonergic neurons. Other 
reports using the same dose of fluoxetine (10 mg/kg/day, i.p.) indicate a lack of 
change in 5-HT 1 receptors in cortical homogenates after 21 days of fluoxetine 
treatment (Peroutka and Snyder, 1980; Snyder and Peroutka, 1982). Likewise, 
data from our laboratory (Li et al., 1993b) indicate a lack of alterations in the 
density of 5-HT1A receptors in both the cortex and hypothalamus (Li et al., 1993a), 
following long-term (21 d) administration of fluoxetine (10 mg/kg, i.p.). However, 
a reduced neuroendocrine responsiveness of hypothalamic 5-HT1A receptors was 
observed following long-term (21 d) administration of fluoxetine to adult male rats. 
Likewise, in humans, chronic administration of fluoxetine resulted in an attenuated 
5-HT 1A-mediated increase in ACTH/cortisol release and hypothermic response. 
Alterations in the density of 5-HT uptake sites have also been reported 
following repeated administration of SSRls. Brunelle et al. ( 1987) reported that 
citalopram administration ( 10 mg/kg/day) for 15 days decreased the number of 
imipramine binding sites in rat cerebral cortex. In contrast, Hrdina and Vu (1993) 
using a more selective ligand ([3H]paroxetine) and more detailed autoradiographic 
techniques reported that chronic administration of fluoxetine ( 10 mg/kg) increased 
the density of 5-HT uptake sites in the frontoparietal cortex, striate cortex, CA 1 
area of the hippocampus and in the superior colliculus. In general, however, the 
changes in 5-HT uptake sites following fluoxetine administration are small in 
magnitude. 
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Other effects on brain 5-HT systems that have been associated with 5-HT 
uptake blockers include a reduction in 5-HT 7 receptors in the hypothalamus 
following 21 d administration of fluoxetine (5 mg/kg, p.a.; sleight et al., 1995). In 
addition, short-term administration of fluoxetine (10 mg/kg, i,p. x 4d) has been 
reported to result in a decrease in 5-HT turnover in the ventromedial nucleus and 
an increase in 5-HT turnover in the median raphe (Frankfurt et al., 1994). Lastly, 
chronic administration of fluoxetine has been reported to result in a decrease in the 
maximal rate of 5-HT uptake into cortical synaptosomes (Hrdina, 1987). 
Effects on other neurotransmitter systems include reports indicating that the 
administration of citalopram ( 15 d, 1 Omg/kg) increased alpha-1 receptors, and 
decreased beta-2 receptors in rat cerebral cortex (Brunello et al., 1987; Milne and 
Goa, 1991). These studies are in contrast to other reports with either citalopram 
or paroxetine which indicate either no change or a decrease in cortical adrenergic 
receptors (Hyttel et al., 1984; Nelson et al., 1989, 1990). In addition to changes 
in receptor density following 5-HT uptake blockers, Baron et al. ( 1 988) reported a 
decrease in beta adrenergic receptor-mediated cAMP production after subchronic 
fluoxetine administration ( 10 mg/kg, i.p., bid x 14 d). Other reports indicate no 
changes in beta receptor sensitivity (Schmidt and Thornberry, 1977; Mishra et al., 
1979) following a similar paradigm. In addition, Fluoxetine ( 10 to 30 mg/kg) 
administration for 21 days decreased dopamine content in the striatum and 
nucleus accumbens (Gardier et al., 1993; Caccia et al., 1992). Frankfurt et al. 
( 1994) administered fluoxetine ( 10 mg/kg, i.p.) for 4 days and observed an 
increase in norepinephrine in the dorsomedial nucleus of the hypothalamus, the 
dorsal raphe nucleus and the parietal motor cortex. 
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Other effects that have been associated with 5-HT uptake blockers include 
increased activity of metabolizing enzymes in astrocytes (Bal-Klara, 1989), 
increased corticotropin releasing hormone mRNA in the paraventricular nucleus and 
increased mineralocorticoid receptor mRNA in the hippocampus after 8 weeks but 
not 2 weeks of administration (Brady et al., 1992). Decreased plasma 
corticosterone levels have also been observed after 2 week of fluoxetine (5mg/kg, 
i.p.; Brady et al., 1992). 
In summary, these observations indicate that repeated administration of 
fluoxetine (and other SSRls) can markedly alter serotonergic neurotransmission in 
adult rats and may indirectly effect other neurotransmitter systems as well. 
Prenatal Exposure to Serotonin Uptake Inhibitors 
Unfortunately, there is currently a paucity of information available on the 
effects of prenatal exposure to 5-HT uptake inhibitors. One study in humans 
suggests that prenatal fluoxetine exposure does not result in an increased risk of 
malformations in the offspring at birth (Pastuszak et al., 1993). Other data, in 
humans (provided by officials at the Eli Lilly Company) are anecdotal and 
inconclusive (Shader, 1992a,b). Animal studies in rats and rabbits indicate that 
prenatal exposure to moderate doses of fluoxetine (i.e. doses which are not toxic 
to the maternal animal) does not result in any visually apparent physical 
abnormalities in offspring, nor does it affect fetal viability or litter size (Stanford 
and Patton, 1993; Byrd and Markham, 1994; Cabrera and Battaglia, 1994; 
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Vorhees et al., 1994). However, an increased frequency of skin hematomas was 
observed in fluoxetine-exposed rat offspring at birth (Stanford and Patton, 1993). 
The hematomas were absorbed within 3-5 days after birth and no other adverse 
vascular effects were observed in fluoxetine-exposed offspring. In mice, the 
administration of fluoxetine from GD 9 - 12 did not result in any evidence of 
embryotoxicity or growth retardation, however craniofacial abnormalities were 
prevalent (Shuey et al., 1992). 
A variety of behavioral measurements have also been assessed in 
fluoxetine-exposed rat offspring and include locomotor activity, acoustic startle 
response, passive avoidance responding, water maze task performance, nose-poke 
activity, and onset of cliff avoidance behavior (Hoyt et al., 1989; Vorhees et al., 
1994). No significant pattern of treatment-related changes was observed in 
fluoxetine-exposed offspring in any of the behavioral paradigms tested. In 
addition, Hoyt et al. (1989) did not find any adverse effects of fluoxetine-exposure 
on mating or fertility in rats. 
In contrast to the absence of physical terata or neurobehavioral toxicity in 
rats prenatally exposed to fluoxetine, other evidence indicates that prenatal 
exposure to fluoxetine can produce neurochemical alterations in offspring. 
Montero et al. ( 1990) reported that prenatal exposure to fluoxetine decreased 
[ 3H]imipramine binding to 5-HT uptake sites in the cortex of prepubescent rat 
offspring. Likewise, Romero et al. (1994) demonstrated that prenatal exposure to 
fluoxetine reduced cortical 5-HT 2A receptor-stimulated phosphoinositide hydrolysis 
in prepubescent, but not adult, progeny. These studies are consistent with data 
demonstrating that both fluoxetine and its active metabolite, norfluoxetine, cross 
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the placenta and enter fetal brain tissue (Pohland et al., 1 989). After infiltrating 
fetal brain tissue, fluoxetine may alter extracellular concentrations of 5-HT by 
interacting with 5-HT transporters present on developing neurons and glia. This 
disruption of 5-HT regulation during fetal development may be responsible for the 
neurochemical alterations observed in brain 5-HT pathways in offspring. 
Similar to the data reported above, prenatal exposure to a low dose of the 
5-HT uptake inhibitor zimelidine (3-5 mg/kg) did not alter litter size, progeny birth 
weight, or open field behavior (Grimm and Frieder, 1987; Del Rio et al., 1988). 
Likewise, no signs of pathological or morphological changes were observed in 
various internal organs in adult progeny prenatally exposed to zimelidine (Grimm 
and Frieder, 1987). However, early motor performance was altered by prenatal 
zimelidine exposure (Grimm and Frieder, 1987). This same group of researchers 
also reported a lack of effect of prenatal zimelidine exposure on active 5-HT uptake 
and spontaneous 5-HT release in frontal cortical synaptosomal preparations made 
from adult offspring. Consistent with these data, Del Rio et al. (1988) reported a 
lack of effect of prenatal zimelidine exposure on the density of cortical 5-HT 
uptake sites. Lastly, in rats and rabbits, prenatal exposure to moderate doses of 
the 5-HT uptake inhibitor paroxetine (4.3 mg/kg) did not produce any physical 
signs of teratogenicity. However, in rats, embryotoxicity was observed following 
prenatal exposure to high doses of paroxetine (43 mg/kg; Baldwin et al., 1989). 
To date, an extensive literature search of this area has revealed no other studies 
investigating the effects of prenatal administration of fluoxetine (Prozac®), 
paroxetine (Paxil®), sertraline (Zolott®), fluvoxamine (Luvox®), zimelidine or 
citalopram. Some data are available, however, on prenatal exposure to 
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clomipramine a tricyclic antidepressant with a high affinity for the 5-HT 
transporter. Although direct comparisons between prenatal exposure to 
clomipramine and the other aforementioned 5-HT uptake blockers is not possible, 
as clomipramine is metabolized to a compound which has norepinephrine uptake 
blocking activity, the effects of prenatal exposure to clomipramine serve to further 
illustrate that alterations in 5-HT systems during pregnancy can produce long-term 
changes in progeny in the absence of physical terata. 
De Ceballos et al. (1985) administered clomipramine (10 mg/kg/day, s.c.) to 
rats from GD 6 through pregnancy. While they did not observe any physical terata 
at birth, in prepubescent rats, the density of beta receptors in the cortex was 
decreased by 27%. With a similar treatment paradigm, Montero et al. (1991) 
found no changes in 5-HT18 receptor density while Del Rio et al. (1988) reported a 
30 % decrease in 5-HT 2A receptor density in the cortex, and De Ceballos et al. 
( 1985) reported no change in D2 receptor binding in the striatum following prenatal 
clomipramine. Likewise, preliminary data from our laboratory indicate that prenatal 
exposure to clomipramine (10 mg/kg, s.c., GD 13-20) did not alter male:female 
ratios per litter, or the total litter size. However, there was a 25 % decrease in 
hypothalamic 5-HT 2A12c receptors in adult male progeny (unpublished observations). 
In general, human case studies report that in utero exposure to clomipramine 
results in only minor transient symptoms and an absence of physical terata (Cowe 
et al., 1982; Ostergaard and Pedersen, 1982; Misri and Sivertz, 1991; Schimmel! 
et al., 1 991). No neurochemical data are available following in utero exposure to 
clomipramine or any other 5-HT uptake inhibitors in humans. While the detection 
of physical teratogenesis is important, elucidating the neurochemical teratogenic 
potential of the SSRls may be important with respect to clinical disorders 
associated with dysfunction of brain neurotransmitter systems. 
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CHAPTER Ill 
MATERIALS AND METHODS 
Animals 
Pregnant Sprague-Dawley rats weighing 280-320 g were obtained from Zivic 
Miller {Zelienople, PA) and were maintained in a temperature (22-24 ° C)-, humidity 
(50-55%)- and illumination (12:12 hr light/dark cycle, lights on at 07:00)-controlled 
facility. The determination of gestational day zero was carried out by the supplier, 
and was defined by the presence of a copulatory plug. All procedures were 
conducted in accordance with the NIH Guide for the Care and Use of Laboratory 
Animals and approved by the Loyola University Institutional Animal Care and Use 
Committee. 
Dams 
Pregnant rats arrived in the laboratory on either gestational day 5 
{experimental animals) or 7 {foster rats). In order to monitor nutritional intake, 
starting on gestational day 8 {GD 8), and continuing throughout the injection 
period, all experimental animals were placed on a nutritionally balanced liquid diet 
consisting of Vitamin Diet Fortification Mixture {ICN Nutritional Biochemicals, 
Cleveland, Ohio), Salt Mixture XIV {ICN Nutritional Biochemicals, Cleveland, Ohio), 
chocolate flavored Sustacal {Mead Johnson, Evansville, Ind.) and water {Riley et 
al., 1979). The foster rats had ad libitum access to rat chow {Teklab rodent lab 
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blocks, Harlan Teklab, Bartonville, IL) and water. Foster dams were weighed and 
received animal care identical to the experimental dams, but were not subjected to 
any experimental procedures. Experimental dams received injections of either 
0.9% saline (2ml/kg, s.c.) or fluoxetine (10 mg/kg/2ml, s.c.) daily (09:00) 
beginning on GD 13, and ending on GD 20. After termination of the injection 
paradigm, all animals had free access to food and water. 
Offspring 
At birth (i.e. postnatal day 0, PD 0), all offspring from each of the 
experimental groups were fostered to untreated, lactating dams in order to 
eliminate the possible influence of drug-induced differences in nurturing. At the 
time of fostering, the litters were culled to no more than 9 pups per litter (5 males, 
4 females). All pups were weaned on PD 21. Males and females were 
subsequently housed separately in groups of 2 or 3 rats per cage, and had free 
access to food and water. Only male animals were used for the remainder of the 
experimental protocols. The number of samples (N) for each postnatal treatment 
group was obtained by using a single pup from each of the litters. Progeny were 
sacrificed by decapitation as described below at PD 28 or at PD 70. These ages 
represent pre- and postpubescent time points, respectively. 
Postnatal Experimental Protocols 
Assessment of the Neurochemical and Functional Status of Serotonergic Neurons 
Offspring were sacrificed 1 hr after receiving a single injection of either 
saline or the 5-HT releaser p-chloroamphetamine (PCA; 5 mg/kg, i.p.). The brains 
were quickly removed, placed on a cold petri dish and the hypothalamus, striatum, 
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hippocampus, midbrain and frontal cortex dissected as described below. 
These brain regions were chosen to represent: ( 1) areas which complete synapse 
formation at differing postnatal ages (Lauder et al., 1982; Lidov and Molliver, 
1982a,b; Wallace and Lauder, 1983; D' Amato et al., 1987); and/or (2) areas 
receiving varying degrees of serotonergic innervation from the dorsal and median 
raphe nuclei, in order to assess whether prenatal fluoxetine exposure may disrupt 
select brain 5-HT pathways which follow differential developmental time courses. 
The brain regions were immediately placed in cryovials, frozen in liquid nitrogen, 
and then placed in a -70 • C freezer until analyzed for 5-HT and 5-HIAA content by 
high performance liquid chromatography (HPLC; appendix 1 ). Basal levels of 5-HT 
and 5-HIAA were determined in each brain region from animals receiving the saline 
injection prior to sacrifice. As an index of "5-HT turnover", the ratio of 5-HT to 5-
HIAA values was calculated in individual animals in each prenatal treatment group. 
This index provides rudimentary information regarding the turnover process (i.e. 
synthesis, release, reuptake and degradation of the neurotransmitter). A detailed 
investigation of these neuronal processes are beyond the scope of this 
dissertation. 
The functional status of presynaptic serotonergic terminals was assessed by 
measuring the ability of the serotonin releaser PCA to reduce 5-HT content in 
various brain regions. PCA enters the serotonergic nerve terminals via the 5-HT 
uptake site, and then inhibits 5-HT synthesis and stimulates the release of 5-HT, 
resulting in a significant decrease in regional 5-HT content (Fuller et al., 1965; 
Fuller, 1980, 1992; Kuhn et al., 1985; Adell et al., 1989; Fattaccini et al., 1991; 
Rudnick and Wall, 1992). Therefore, differences in the magnitude of the 
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reductions in regional 5-HT content, in control versus fluoxetine-exposed offspring, 
following PCA administration would indicate differences in the functional integrity 
of either the 5-HT transport mechanism and/or the neurotransmitter release 
process. On the other hand, similar decreases in regional 5-HT content, in control 
versus fluoxetine-exposed offspring, would indicate the inability of prenatal 
fluoxetine to produce global changes in 5-HT transport mechanisms or release 
processes in specific brain regions (appendix 2). 
Dissection Technique 
Rats were killed by decapitation, their brains removed and rinsed in ice cold 
saline then placed on a cold glass plate kept on ice. The brains were dissected 
according to a modification of the procedure outlined by Glowinski and Iversen 
( 1966). Briefly, the olfactory bulbs were removed with fine forceps and the brain 
was placed on its dorsal surface. Next, the hypothalamus was delineated rostrally 
by the fusion of the optic chiasm and caudally by the mammillary bodies and was 
excised with the use of curved, fine forceps. After the removal of the hypo-
thalamus, the brain was placed on its ventral surface, and a vertical cut was made, 
with a thin steel razor blade, anterior to the corpus callosum. The area rostral to 
the cut was taken as frontal cortex. The cortical hemispheres, including the 
striatum and hippocampus, were dissected free from the remainder of the brain. 
Using a gentle rocking motion, the striatum was dissected with curved forceps 
using the external walls of the lateral ventricles as an internal boundary and the 
corpus callosum as an external boundary. The hippocampus was removed from 
the cortex by blunt dissection with a spatula. Finally, two vertical cuts were 
required for the removal of the midbrain. First, a vertical cut was made with a 
steel razor blade rostral of the superior colliculi, and then the midbrain was 
separated from the pons by a vertical cut just rostral to the cerebellum. 
Assessment of the Functional Status of 5-HT 1A and 5-HT 2A12c Receptor Systems 
Neuroendocrine Challenge Tests 
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Functional alterations in postsynaptic components of serotonergic systems 
were determined at PD 28 or PD 70 by measuring the 5-HT receptor-mediated 
stimulation of plasma hormones following a single s.c. injection of either saline, the 
5-HT1A agonist 8-0H-DPAT (0.5 mg/kg) or the 5-HT2A12c agonist DOI (2 mg/kg) (see 
appendices 3 and 4). The rats were sacrificed 30 min post-injection by 
decapitation, and trunk blood was collected into centrifuge tubes containing 0.5 ml 
of 0.3 M EDTA (pH 7.4) for subsequent analyses of plasma ACTH, corticosterone 
and renin levels. The doses of 8-0H-DPA T and DOI were chosen based on 
previous reports that 0.5 mg/kg 8-0H-DPAT and 2 mg/kg DOI elicit maximal 
increases in plasma ACTH and corticosterone (Li et al., 1993a,b). In addition, 2 
mg/kg DOI maximally increases plasma renin (Li et al., 1993a). The brains from 
saline-challenged rats were removed and the hypothalamus and frontal cortex 
dissected as previously described, placed in cryovials, frozen in liquid nitrogen, and 
then placed in a -70 ° C freezer until used for radio ligand binding assays. 
Percentage of High Affinity 5-HT 2A Receptors 
5-HT1A and 5-HT2A receptors belong to a family of membrane-bound 
receptors which interact with guanine nucleotide regulatory proteins (G-proteins) 
as the initial phase in the activation of second messenger systems. These G-
protein linked receptors have been demonstrated to exist in 2 states; one state of 
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the receptor is coupled to the G-protein while the other state of the receptor is 
uncoupled from the G-protein (appendix 5). Because agonists interact with the 
receptor and subsequently promote the formation of the agonist-receptor-
transducer complex, agonists exhibit differential affinities for these two states of 
the receptor. Agonists exhibit a high affinity for the coupled state of the receptor 
and a low affinity for the uncoupled state of the receptor. In contrast, antagonists 
do not promote the formation of the ternary complex and therefore antagonists 
interact with these receptors as a homogenous population of intermediate affinity. 
Since agonists exhibit a high affinity for only one state of the receptor (the coupled 
state), radiolabelled agonists (such as [1251)001 and [3H]8-0H-DPAT) will only label 
the high affinity state of the receptor within the concentration range employed in 
saturation studies. In other words, the density of agonist-labelled receptors 
represents only a portion of the total population of receptors present in a given 
brain region. In contrast, radiolabelled antagonists will label the total population of 
receptors present in a given tissue. An alteration in the maximal density of 
agonist-labelled (high affinity) receptors would be indicative of an alteration in the 
number of receptors coupled to G-proteins. Changes in the number of G-protein 
coupled receptors could occur as a result of 2 distinct mechanisms. The treatment 
could have produced: (1) an alteration in the coupling efficiency of the receptors in 
the absence of any changes in the total number of receptors present; or (2) an 
alteration in the number of coupled receptors as a consequence of an alteration in 
the total number of receptors present in a given tissue. The percentage of high 
affinity labelled receptors would be altered in the first situation, and the percentage 
would remain constant in the second scenario. Alternatively, it is theoretically 
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possible for a given drug treatment to change the total number of receptors 
without affecting the number of receptors coupled to the G-protein. In this case, 
the percentage of high affinity receptors to the total population would also be 
altered. In order to provide a comprehensive examination of changes in G-protein 
linked receptors following a given drug treatment, the densities of both the agonist 
and antagonist labelled receptors need to be determined. Because commercially, 
radiolabelled 5-HT,A antagonists are currently not available, only the density of the 
high affinity state of the 5-HT,A receptor could be examined autoradiographically in 
the present studies. In contrast, radiolabelled 5-HT 2A agonists and antagonists are 
commercially available. Therefore, the present studies utilize both a radiolabelled 
agonist and antagonist to determine whether changes in 5-HT2A receptor densities 
(as determined by receptor autoradiography) reflect changes in the total receptor 
density or the number of high affinity G-protein coupled receptors. In addition, as 
an index of the ability of 5-HT2A receptors to couple to their respective G-proteins 
(Gq/G 11 ), the percentage of high affinity agonist ([1 251]001) labelled 5-HT2A receptors 
was calculated for each animal and in each brain region by dividing the maximal 
density of [1251)001 labelled receptors by the maximal density of the total (high and 
low affinity) 5-HT 2A receptor population and multiplying by 100. As the receptor 
must couple to the G-protein in order to activate second messenger systems, 
changes in either the absolute number or in the percentage of high affinity 
receptors may have functional consequences for the organism. 
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Determination of Site-Specific Alterations in 5-HT Recognition Sites 
For all autoradiographic determinations, rats were killed by decapitation at 
either PD 28 or PD 70, their brains were quickly removed, frozen on powdered dry 
ice, secured with parafilm and plastic wrap then stored at -70 • C until sectioned for 
in vitro autoradiography. 
Neurochemical Determinations 
High Performance Liquid Chromatography 
HPLC determination of brain biogenic amines was carried out as described 
by Saller et al. (1984) with some modifications. Brain regions were sonicated in 
10 volumes of ice-cold 0.1 N perchloric acid containing 0.5 µM 
dihydroxybenzylamine (DHBA) as the internal standard used to calculate the 
recovery of the biogenic amines. The homogenate was then centrifuged at 20,000 
x G for 15 min at 4 • C. Fifty micro liter aliquots of the supernatant were injected 
onto an HPLC system. The HPLC system consisted of a delivery pump (Model 
Waters 501, Waters, Marlbourgh, MA) in conjunction with a Waters 717 
autosampler (Waters, Marlbourgh, MA) and analytical column (Microsorb C18 5 µm, 
150 mm X 4.6 mm, Rainin, Woburn, MA) protected by a guard column (Microsorb 
C18 5 µm, 150 mm X 4.6 mm, Rainin, Woburn, MA). An electrochemical detector 
(Model LC-4C, Bioanalytical Systems West Lafayette, IN) with a glassy carbon 
electrode was used at a voltage setting of + 0. 75 V versus an Ag/AgCI reference 
electrode. The mobil phase was composed of 9 g/L monochloracetic acid, 0.25 
mM EDTA, 0.375 g/L 1-octanesulfonic acid, and 1 % tetrahydrofuran (pH 3.0). 
The solvent flow was maintained at 2.0 ml/min. Standard solutions of 5-HT and 
5-HIAA were prepared in ice-cold 0.1 N perchloric acid containing 0.5 µM DHBA. 
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The system was run by Millennium 2010 Chromatography Manager, a computer 
program that performs data acquisition, processing and management of 
chromatographic information (Waters, Marlbourgh, MA). Tissue precipitates were 
resuspended in 0. 1 N NaOH to achieve a tissue concentration of approximately 30 
mg/ml, then 20 µI aliquots were taken for protein determination according to the 
method of Lowry et al. (1951 ). For each brain region, samples from prepubescent 
and adult progeny were assayed simultaneously for brain monoamine content. 
Radioimmunoassay of Plasma Hormones 
Plasma ACTH 
Radioimmunoassay of ACTH was performed on unextracted plasma samples 
according to a previously published protocol (Carnes et al., 1986). Briefly, the 
ACTH antiserum was obtained from lgG Corp (Nashville TN). ACTH (1-39) 
standards were obtained from Calbiochem and 1251-ACTH from INCSTAR 
(Stillwater, MN). The sequence recognition of the antiserum is amino acids 5-18 
of ACTH. In addition, this antiserum does not significantly recognize a-MSH, P-
MSH, P-endorphin, P-lipotropin, ACTH 11-24 or ACTH 1-16-amide. In this double 
antibody radioimmunoassay, samples or standards were incubated with the ACTH 
antibody (final dilution 1 :30,000, 22% total binding) at 4 ° C for 24 hr in a 0.01 M 
phosphate buffer (PBS, pH 7.6) containing 1 % bovine serum albumin (Sigma, St. 
Louis, MO), 0.025 M EDTA, 0.5% normal rabbit serum (CalBiochem, San Diego, 
CA) and 25 KIU/ml aprotinin (Sigma Chemical Co, St. Louis, MO). 1251-ACTH (2000 
cpm, INCSTAR, Stillwater, MN) was added and incubated for 24 hr at 4 ° C in a 
total volume of 0.3 ml. The second antibody (goat anti-rabbit-v-globulin, 
CalBiochem, San Diego, CA) was added at a final dilution of 1 :50 and incubated 
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overnight at 4 ° C. 1.5 ml of cold PBS was added to the tubes and they were then 
centrifuged at 15,000 X G at 4 ° C for 40 min. The radioactivity of the pellet 
containing the antibody bound ligands was counted by a Micromedic 4/200 plus 
counter. The sensitivity of the assay was 0.25 pg/tube and the intra- and inter-
assay variations were 4.2% and 14.6% respectively. 
Plasma Corticosterone 
Radioimmunoassay of corticosterone was performed on unextracted plasma 
samples as previously described {Van de Kar et al., 1985b). Antiserum was 
obtained from ICN Biochemicals {Costa Mesa, CA). The assay buffer was 0.05 M 
sodium phosphate {pH 7.0) containing 0.16 M sodium chloride, 0.015 M sodium 
azide and 2.0 g/L gelatin to prevent adsorption to glassware. Plasma samples (2 µI 
or 5 µI) or standard solutions containing 0 - 5 ng corticosterone per tube were 
placed in a water bath at 80 ° C for 20 min to denature binding proteins. After the 
tubes were cooled to room temperature, the plasma samples were incubated with 
the tracer {[ 3H]corticosterone; 5,000 to 6,000 cpm) and the antibody (1 :5600) at 
4 ° C for 24 hr. The total volume of the assay was 0. 7 ml. To separate the bound 
from the free tracer, the tubes were subsequently incubated for 10 min at 4 ° C 
with 0.2 ml of a cold Dextran T70-charcoal suspension then centrifuged (15,000 X 
G) for 20 min at 4 ° C. The supernatant containing the antibody-ligand complexes 
was decanted into scintillation vials, and 5 ml of Omnifluor scintillation fluid was 
added to each vial. After shaking the vials, the amount of free [3H]corticosterone 
present in the supernatant was counted on a Hewlett Packard MINAXY scintillation 
counter for 2 min. The sensitivity limit was 0.02 ng/tube and the intra- and inter-
assay variations were 4.5% and 11.9% respectively. 
44 
Plasma Renin 
Plasma renin concentration, assayed by generating angiotensin I (ANG I) in 
the presence of a saturating concentration of exogenous renin substrate 
(angiotensinogen), provides a measure for renin secretion. Plasma renin was 
assayed according to a previously published protocol (Richardson-Morton et al., 
1989). Briefly, renin substrate was added to the plasma along with 0.5 M 
phosphate buffer pH 6.0, phenylmethyl-sulfonyl fluoride (2.5 mM) and 8-
hydroxyquinoline (3.4 mM). The mixture was incubated at 37°C for 1 hour, and 
the incubation was terminated by immersion of the samples in boiling water for 3 
min. The radioimmunoassay of ANG I was performed using an antiserum (vdk2) 
generated in New Zealand rabbits against angiotensin I at a dilution of 1: 16,000. 
The cross reactivity of the antibody for angiotensin II is 0.0001 %; and for 
neurotensin, bombesin, oxytocin, Leu 5-enkephalin, Arg 8-vasopressin, and ~­
lipotropin, the cross reactivity is less than 0.0006%. The bound tracer (1251-ANG I) 
was separated from free tracer by the addition of a Dextran T500-charcoal 
suspension followed by centrifugation. The pellet containing the unbound ANGI 
and tracer was counted by a Micromedic 4/200 plus counter. The assay 
sensitivity limit of the radioimmunoassay was 10 pg ANG I per tube and the intra-
assay variability was 4.4%. The inter-assay variation was 12.6%. 
Radioligand Binding Assays in Homogenates 
Tissue Preparation 
Brain tissues were prepared according to a previously described protocol 
(Leonhardt et al., 1992). Briefly, frozen tissue was weighed and placed in. a 
minimum of 10 volumes of ice cold 50 mM Tris-HCI (pH 7.7, 25°C) containing 0.5 
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mM EDTA and 10 mM MgS04 and homogenized using a Tekmar Tissumizer (2 x 5 
sec). The homogenate was centrifuged at 30,000 X G for 1 5 min at 4 • C. Tissue 
was resuspended in 30 volumes of buffer, homogenized, incubated at 37 ° C for 15 
min, and then centrifuged at 30,000 X G for 10 min. Tissue was washed and 
centrifuged once more. Finally, the tissue was resuspended to a volume of 20 -
30 mg wet wt./ml in cold 50 mM Tris-HCI (pH 7.7, 25 °C). 
5-HT Uptake Sites 
5-HT uptake sites were measured in homogenates of the frontal cortex, 
hypothalamus, hippocampus, striatum and midbrain according to a previously 
published protocol (Battaglia et al., 1987). [3 H]Paroxetine binding to 5-HT uptake 
sites was carried out in 5.0 ml total volume containing 1 mg wet wt. of tissue and 
a saturating concentration (0.4 nM) of [3H]paroxetine (20 Ci/mmol) in 50 mM Tris-
HCI (pH 7. 7, 25 ° C), 120 mM NaCl and 5 mM KCI. Nonspecific binding was 
determined by the addition of 1 .0 µM citalopram to a parallel set of tubes. Tubes 
containing drugs and tissue were incubated for 120 min at room temperature, then 
filtered rapidly using a Brandel Harvester fitted with Whatman GF/C filters that had 
been presoaked in 0.5% polyethylenimine. The samples were next washed with 
20 ml of 50 mM Tris-HCI (pH 7.7, 25°C). Filters were then added to scintillation 
vials containing 5 ml of Ultima Gold (Packard Instrument Co., Inc., Downers Grove, 
IL) scintillation fluid. The vials were shaken for 60 min and samples counted for 
2.5 min on a Beckman LS5000TD scintillation counter at an efficiency of 60%. 
For each brain region, samples from prepubescent and adult progeny were assayed 
simultaneously. 
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5-HT 2A 12c Receptors 
5-HT 2A12c receptors were labelled in general accordance with the protocol by 
Leonhardt et al., ( 1 99 2). Saturation studies were carried out in the hypothalamus 
by incubating 1 .0 mg wet wt. of brain tissue with increasing concentrations of 
[ 1251]001 ranging from 0.15 nM to 0.6 nM in 50 mM Tris-HCI, 10 mM MgS04 , 0.5 
mM EOTA, 0.02% ascorbate, and 10µM pargyline (pH 7.7, 25°C) for 90 min at 
room temperature. Nonspecific binding was defined in the presence of 10 µM 5-
HT. For comparative purposes only, 5-HT 2A12c receptor sites were also measured in 
cortical tissue using a single concentration of radioligand (0.05 nM) below its Kd 
value (0.4 nM) to screen for any detectable change in binding. This approach 
renders radioligand binding sensitive to changes in either the affinity and/or density 
of cortical 5-HT 2A12c receptors. Briefly, 0.05 nM [1251]001 in 50 mM Tris-HCI, 10 
mM MgS04 , 0.5 mM EOTA, 0.02% ascorbate, and 10µM pargyline (pH 7.7, 
25 ° Cl was incubated with 1.5 mg wet wt. of cortical tissue for 90 min at room 
temperature. Nonspecific binding was defined in the presence of 10 µM 5-HT. 
Following incubation, tubes containing drugs and tissue were filtered rapidly using 
a Brandel Harvester fitted with Whatman GF/C filters. All the samples were 
washed with 15 ml of 50 mM Tris-HCI (pH 7. 7, 25 ° C). Filters were then added to 
75 x 12 mm plastic test tubes and counted in a Micromedic 4/200 Plus Automatic 
Gamma Counter for 3 min each at an efficiency of 82%. For each brain region, 
samples from prepubescent and adult progeny were analyzed simultaneously. 
Autoradiographic Analysis of Serotonin Recognition Sites 
General Procedures 
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Fifteen micron thick coronal sections of brains were obtained at -20 ° C 
using a cryostat (Hacker Instruments, Inc.). Sections were thaw-mounted onto 
chrome alum/gelatin-coated microscope slides, and stored at -20 ° C until used for 
autoradiographic analysis of 5-HT recognition sites. Coronal sections were taken at 
the following levels according to the rat atlas by Paxinos and Watson (1986): 
Bregma + 3.70 mm, + 1.00 mm, -0.30 mm, -1.80 mm, -2.80mm, -3.14 mm, 
- 4.80 mm, -8.00 mm (figure 1 ). Prior to autoradiographic analysis, slide-mounted 
brain sections were brought to room temperature. 
A. 
Cg3 
B. 
Figure 1 . Schematic drawings representing the levels of rat brain used in the 
autoradiographic analysis of 5-HT recognition sites. 
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Figure 1 Continued. Schematic drawings representing the levels of rat brain used 
in the autoradiographic analysis of 5-HT recognition sites. 
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Figure 1 Continued. Schematic drawings representing the levels of rat brain used 
in the autoradiographic analysis of 5-HT recognition sites. 
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G. H. 
Figure 1 Continued. Schematic drawings representing the levels of rat brain used in 
the autoradiographic analysis of 5-HT recognition sites. Cross-hatched areas indicate 
brain regions where the density of 5-HT recognition sites was determined. Bregma 
+ 3.70 mm (A), + 1.00 mm(~), - 0.30 mm (C), - 1.80 mm (0), - 2.80 mm (~), 
-3.14 mm (f), - 4.80 mm (G), - 8.00 mm (H). Abbreviation: cc, corpus callosum. The 
remainder of the abbreviations are described in Table 10. All the data analysis was 
carried out using the rat atlas by Paxinos and Watson (1986). However, for 
illustrative purposes only, the above drawings were adapted from the computer 
generated atlas by Swanson (1992) and chosen to represent levels which correspond 
to appropriate Paxinos and Watson (1986) levels as stated in the Materials and 
Methods section. 
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Following the in vitro labelling of 5-HT recognition sites, the slides were 
allowed to dry overnight in slide boxes containing desiccant before apposing them 
to Hyperfilm-3H (Amersham Corporation, Arlington Heights, IL) at 4 ° C for 4 days 
with [1251]001, 30 days with [3H]citalopram, or 60 days with [3H]ketanserin and 
[3H]8-0H-DPA T to generate the autoradiograms. Slides containing tritium or [1251] 
standards (Amersham Corporation) were included with each film to control for 
exposure differences between films. The films were developed by placing them in 
Kodak Developer D-19 for 5 min, then in Kodak Indicator Stop Bath solution for 
30 sec, followed by 5 min in Kodak Fixer. The films were subsequently placed in a 
running water bath containing Kodak Photo-Flo 200 Solution for 1 5 min, then air 
dried. Autoradiograms were quantitated on a Macintosh Quadra 950 computer 
using the public domain NIH Image program (developed at the U.S. National 
Institutes of Health and available from the Internet by anonymous FTP from 
zippy.nimh.nih.gov). The amount of radioactivity present in each layer of the 
standard polymers was carried out by the supplier (Amersham Corporation). In 
addition, the supplier generated optical density vs. radioactivity curves using both 
brain paste and polymer standards in order to determine the amount of 
radioactivity present in each lay of the polymer standards per mg tissue equivalent. 
Radioactive standards expressed as nCi/mg tissue equivalent (corrected for 
radioactive decay) were converted to fmol of sites/mg tissue equivalent according 
to following equations: 
( 1) [nCi/mg tissue equivalent]* [ 1 µCi/1000 nCi] * [2 .22E6 DPM/1 µCi] = 
DPM/mg tissue equivalent 
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(2) [DPM/mg tissue equivalent] I [specific activity of radioligand * 2.221 
fmol sites/mg tissue equivalent 
Best-fit standard curves of film grey scale values generated by tritium or 
[ 1251] standards co-exposed with labelled slides resulted when an exponential 
function was used to describe the relationship between radioactive standards and 
grey scale value. For each brain region and for each radioligand, a mean 
determination of the fmol of sites labelled per mg tissue equivalent was carried out 
by averaging the values obtained from 3-4 adjacent sections (measurements were 
taken from both the right and left sides of the autoradiograms where applicable). 
The determination of nonspecific binding was carried out in duplicate adjacent 
sections from each animal and for each autoradiographic assay. Nonspecific 
binding was subtracted from the total signal. For assays using [125 1], final values 
were corrected for differences between the tissue section and standard polymer 
thickness. 
5-HT Uptake Sites 
Autoradiographic localization of 5-HT uptake sites was determined 
according to a modification of the protocol by D'Amato et al. (1987). Slide 
mounted sections were preincubated at room temperature for 15 min in 50 mM 
Tris HCI containing 120 mM NaCl and 5 mM KCI (pH 7.7 at 25 °C). Sections were 
then incubated at room temperature in 0. 7 nM [3H]citalopram (specific activity 81 
Ci/mmol; Kct = 0.84 nM) in the absence or presence of 1 µM paroxetine to 
determine nonspecific binding. Following incubation, sections were washed twice 
in ice cold 50 mM Tris HCI containing 120 mM NaCl and 5 mM KCI (pH 7. 7 at 
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25 ° C) for ten minutes each time then dipped in ice cold deionized water, and dried 
rapidly under a stream of cold dry air. 
High Affinity 5-HT,A Receptors 
Autoradiographic localization of 5-HT 1A receptors was determined according 
to a modification of the protocol by Pazos and Palacios (1985). The assay buffer 
consisted of 0.17 M Tris HCI containing 4 mM CaCl2 , 10 µM pargyline and 0.01 % 
ascorbic acid (pH 7.6). Slide mounted sections were incubated at room 
temperature for 1 hr in assay buffer containing 2 nM [3H]8-0H-DPAT (specific 
activity 129.5 Ci/mmol) in the absence or presence of 1 µM 5-HT to determine 
nonspecific binding. Following incubation, sections were washed twice in ice cold 
assay buffer for ten minutes each time then dipped in ice cold deionized water, and 
dried rapidly under a stream of cold dry air. 
High Affinity 5-HT 2A Receptors 
Autoradiographic localization of high affinity 5-HT2A receptors was 
determined according to a modification of the protocol by Appel et al. (1990). The 
assay buffer consisted of 50 mM Tris HCI, 0.5 mM EDTA, 10 mM MgS04, 0.1 % 
ascorbic acid, and 10 µM pargyline (pH 7. 7, 25 ° C). Slide mounted sections were 
incubated at room temperature for 90 min in 0.2 nM [1251]001 (specific activity 
2200 Ci/mmol) in the absence or presence of 100 nM spiperone to determine 
nonspecific binding. Following incubation, sections were washed twice in ice cold 
assay buffer for ten minutes each time then dipped in ice cold deionized water, and 
dried rapidly under a stream of cold dry air. 
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The affinity of [1251)001 for 5-HT 2A receptors was determined in slide 
mounted cortical sections in order to obtain Kd values for [1251)001 so that 
autoradiographic data could be extrapolated to 100 % fractional occupancy. Slide 
mounted sections were incubated with concentrations of [1251)001 ranging from 0.2 
nM to 2.3 nM for 90 min at room temperature. 100 nM spiperone was used to 
define nonspecific binding. Following incubation, sections were washed twice in 
ice cold assay buffer for ten minutes each time then dipped in ice cold deionized 
water. Each section was wiped from the slides using a Whatman GF/C filter, 
placed in a test tube, then counted with a gamma counter for 3 min. The affinity 
of the radioligand was determined using the lnPlot computer program {GraphPad 
Software Inc., SanOiego, CA). 
Total (High and Low) 5-HT 2A Receptors 
Autoradiographic localization of total 5-HT 2A receptors was determined 
according to a modification of the protocol by Pazos and Palacios (1985). The 
assay buffer consisted of 0.17 M Tris HCI {pH 7. 7, 25 ° CJ. Slide mounted sections 
were preincubated in assay buffer for 15 min at room temperature. The sections 
were then incubated for 2 hr at room temperature in 0.4 nM [3H]ketanserin 
(specific activity 77. 1 Ci/mmol) in the presence of 30 nM prazosin to preclude 
binding to alpha-1 receptors. Nonspecific binding was determined in the presence 
of 1 µM cinanserin. Following incubation, sections were washed twice in ice cold 
assay buffer for ten minutes each time then dipped in ice cold deionized water, and 
dried rapidly under a stream of cold dry air. 
The affinity of [3H]ketanserin for 5-HT 2A receptors was determined in slide 
mounted cortical sections in order to obtain Kd values for [3H]ketanserin so that 
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autoradiographic data could be extrapolated to 1 00 % fractional occupancy. Slide 
mounted sections were preincubated in assay buffer for 1 5 min at room 
temperature. Sections were then incubated with concentrations of [3H]ketanserin 
ranging from 0.4 nM to 2.4 nM for 2 hr at room temperature in the presence of 30 
nM prazosin to preclude binding to alpha-1 receptors. Nonspecific binding was 
determined in the presence of 1 µM cinanserin. Following incubation, sections 
were washed twice in ice cold assay buffer for ten minutes each time then dipped 
in ice cold deionized water. Each section was wiped from the slides using a 
Whatman GF/C filter, placed in a scintillation vial with scintillation fluid, shaken for 
60 min, then counted in a scintillation counter for 2.5 min. The affinity of the 
radioligand was determined using the lnPlot computer program (GraphPad 
Software Inc., SanDiego, CA). 
Drugs and Chemicals 
Prazosin, 8-0H-DPAT, DOI, spiperone, serotonin creatinine sulfate, and 5-
hydroxy indoleacetic acid were obtained from Research Biochemicals International 
(Natick, MA). Monochloroacetic acid, 1-octanesulfoneic acid sodium salt and 
tetrahydrofuran were obtained from J.T.Baker (Phillpsburg,NJ). [3H]Citalopram, 
[ 3H]Paroxetine, [3H]8-0H-DPAT, [3H]ketanserin, and [125 l]DOI were obtained from 
New England Nuclear (Boston, MA). Citalopram was provided by Lundbeck 
(Copenhagen, Denmark). Fluoxetine was generously provided by the Eli Lilly 
Company (Indianapolis, IN). Paroxetine was obtained from Smith Kline Beecham 
Pharmaceuticals (Philadelphia, PA). PCA and all other chemicals were obtained 
from Sigma Chemical Company (St. Louis, MO). 
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Statistics 
Statistical analysis of maternal weight gain was performed using a 1-way 
analysis of variance (ANO VA). Statistical analyses of Male:Female ratio and litter 
size were performed by Student's t-test. Statistical analyses of endocrine data 
were carried out by using a three-way ANOVA. All other data were analyzed using 
a 2-way ANOVA unless otherwise indicated (appendix 13). If the F values from 
the ANOV A indicated significant differences, individual group means were then 
compared by a Student-Newman-Keuls' test (Steel and Torrie, 1960) using a 
computer program (SigmaStat, San Rafael, CA). 
CHAPTER IV 
RESULTS 
Growth Parameters 
The administration of fluoxetine to pregnant dams from GD 13-20 did not 
significantly alter maternal weight gain during the course of the treatment (vehicle: 
112.0 ± 8.3 g; fluoxetine: 103.9 ± 8.4 g; Fig. 2). Likewise, the administration of 
a liquid diet did not alter the nutritional intake of pregnant dams as indicated by a 
lack of difference in maternal weight gain between foster (102.5 ± 2.5 g) and 
vehicle (112.0 ± 8.3 g) treated dams during the treatment period. As shown in 
Table 1, despite the lack of effect on maternal weight gain, prenatal exposure to 
fluoxetine resulted in a small (-8%) but statistically significant (p < 0.05) decrease 
in male progeny birth weight. By PD 28, male progeny of fluoxetine-treated dams 
exhibited body weights which were similar to control values. However, at PD 70, 
male progeny of fluoxetine-treated dams again exhibited a significant decrease in 
body weight (-14%; p < 0.05) compared to control animals. As indicated in Table 
2, there were no differences in either the gender distribution per litter or in the 
total progeny number per litter between prenatal treatment groups. In addition, 
there were no between group differences in either the crown-rump lengths or 
anogenital distances (Table 3) in either male or female progeny. 
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Figure 2. Total amount of weight gained by the maternal animals during the course 
of the treatment paradigm. Data represent group means ± SEM from 1 0-21 rats per 
group. The administration of 10 mg/kg/2ml fluoxetine from GD 13-20 did not 
significantly alter maternal weight gain during this period. In addition, the 
administration of a liquid diet had no effect on maternal weight gain as weight gain 
in chow-fed foster dams was not significantly different from either VEH or FLX dams. 
Abbreviations: FSTR, foster dams; VEH, saline dams; FLX, fluoxetine dams. 
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TABLE 1 
MALE PROGENY BODY WEIGHT 
Prenatal Exposure 
Group Body Weight (g) 
PD 0 PD 28 PD 70 
Control 6.7 ± 0.1 105.5 ± 7.1 486.6 ± 6.6 
Fluoxetine 6.2 ± 0.2 * 103.3 ± 2.9 418.9 ± 18.5 * 
At PD 0 data represent the litter mean ± SEM from 10 control and 11 fluoxetine 
exposed litters per group. At PD 28 and PD 70, data represent the mean ± SEM 
from 6-8 rats per postnatal experimental group with each rat within a group being 
obtained from a different litter. A small (-8%) but significant decrease in birth weight 
(PD 0) was observed in progeny prenatally exposed to fluoxetine ( 10 mg/kg/2ml, s.c., 
to dams from GD 13-20). By PD 28 there were no significant weight differences 
between saline and fluoxetine-exposed progeny. However, at PD 70, progeny of 
fluoxetine treated dams exhibited a significant decrease (-14%) in body weight in 
comparison with their age matched controls. Data were analyzed by Student's t-test. 
* Significantly different (p < 0.05) from corresponding controls. 
TABLE 2 
PROGENY NUMBER AND GENDER DISTRIBUTION WITHIN LITTERS 
Prenatal Exposure (N) Male:Female Litter Size 
Group 
Control (10) 0.97 ± 0.11 13 ± 1 
Fluoxetine ( 11) 1.00 ± 0.16 12 ± 1 
Data represent the mean ± SEM from 10-11 litters (N) per treatment 
group. Litters were composed of 8-18 rats prior to culling. The 
administration of fluoxetine from GD 13-20 did not alter the litter size 
or the gender distribution within the litters. Data were analyzed by 
Student's t-test. 
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TABLE 3 
PROGENY GROWTH PARAMETERS 
Prenatal 
Exposure Crown-Rump Anogenital 
Group Length (mm) Distance (mm) 
Males Females Males Females 
Control 47.01 ± 0.38 46.46 ± 0.54 2.57 ± 0.08 1.27 ± 0.05t 
Fluoxetine 46.83 ± 0.58 45.95 ± 0.50 2.66 ± 0.09 1.39 ± 0.04t 
Data represent the mean ± SEM from 10 control and 11 fluoxetine exposed litters per 
group. Litters were composed of 2-11 rats per gender prior to culling. Data were 
analyzed by a 2-way ANOVA followed by a Newman-Keuls post-hoc test. Prenatal 
exposure to fluoxetine did not alter the crown-rump length or anogenital distance of 
either male or female offspring. t Significantly different (p < 0.05) than corresponding 
male progeny. 
Site-Specific Reductions in 5-HT Content in Fluoxetine-Exposed Offspring 
Table 4 reports basal 5-HT levels in several brain regions in prepubescent 
and adult male progeny prenatally exposed to either saline or fluoxetine. Prenatal 
exposure to fluoxetine significantly reduced cortical 5-HT content (-28%) only in 
the frontal cortex of prepubescent male progeny. 5-HT content was not altered in 
either the hypothalamus, hippocampus, striatum or midbrain of fluoxetine-exposed 
offspring at PD 28. In contrast, in adult animals, basal 5-HT content was 
significantly reduced only in the midbrain (-28%) of fluoxetine-exposed offspring 
(Table 4). Adult control and fluoxetine-exposed offspring exhibited similar levels of 
5-HT in cortex, hypothalamus, hippocampus, and striatum. 
TABLE 4 
SEROTONIN LEVELS IN PREPUBESCENT AND ADULT MALE PROGENY 
Prenatal Brain Region 
Exposure 
Frontal Cortex Hypothalamus Hippocampus Striatum Midbrain Group 
Pregubescent 
Saline 23.4 ± 1.1 (7) 45.5 ± 1.8 (8) 14.9 ± 0.8 (7) 20.1 ± 2.4 (8) 40.6 ± 1.8 (7) 
Fluoxetine 16.8 ± 1.5 * (7) 45.3 ± 2.8 (7) 13.1 ± 0.6 (8) 19.2 ± 1.6 (8) 45.5 ± 4.7 (8) 
(-28%) 
Adult 
Saline 27.3 ± 1.8 (7) 49.5 ± 3.0 (8) 18.0 ± 0.8 (8) 22.2 ± 1.2 (8) 65.6 ± 8.2 t (8) 
Fluoxetine 31.1 ± 2.3 t (8) 48.2 ± 3.0 (8) 18.3 ± 1.7 (8) 20.8 ± 1.7 (8) 47.1 ± 2.3 * (8) 
(-28%) 
Data are expressed as pmol 5-HT/mg protein and represent the means ± SEM from 7-8 rats per group with each rat within a group 
being obtained from a different litter. The number of rats per group is shown in parentheses. In prepubescent progeny, prenatal 
exposure to fluoxetine (10 mg/kg/2ml s.c., to dams from GD 13-20) significantly reduced basal 5-HT levels only in the frontal 
cortex (-28 %). In adult progeny, prenatal exposure to fluoxetine produced a significant reduction only in midbrain 5-HT content 
(-28%). Hypothalamic, hippocampal, and striatal 5-HT concentrations were not altered by fluoxetine exposure in either 
prepubescent or adult offspring. Data from each brain region were analyzed separately using a two-way ANOVA followed by a 
Newman-Keuls post-hoc test. *Significantly different from age-matched control values within the respective brain region (p < 0.05). 
t Significantly different from the respective values obtained in prepubescent progeny (p<0.05). 
TABLE 5 
5-HYDROXY INDOLEACETIC ACID LEVELS IN PREPUBESCENT AND ADULT MALE PROGENY 
Prenatal Brain Region 
Exposure 
Frontal Cortex Hypothalamus Hippocampus Striatum Midbrain Group 
Pre12ubescent 
Saline 23.6 ± 2.1 (8) 36.2 ± 0.9 (8) 21.3 ± 1.0 (7) 37.2 ± 2.8 (8) 52.5 ± 2.4 (8) 
Fluoxetine 23.6 ± 2.1 (8) 35.3 ± 2.6 (7) 20.5 ± 1.0 (8) 32.9 ± 1.9 (8) 51.2 ± 3.6(7) 
Adult 
Saline 20.0 ± 1.5 (8) 28.5 ± 2.4 t (8) 14.9 ± 0.8 t (8) 23.0 ± 1.7 t (8) 34.4 ± 3.3 t (7) 
Fluoxetine 22.0 ± 1.5 (8) 27.6 ± 1.5t(8) 14.0 ± 0.9 t (8) 22.1 ± 1.4 t (8) 33.3 ± 3.0 t (8) 
Data are expressed as pmol 5-HIAA/mg protein and represent the means ± SEM from 7-8 rats per group with each rat within a group 
being obtained from a different litter. The number of rats per group is shown in parentheses. Prenatal exposure to fluoxetine ( 10 
mg/kg/2ml s.c., to dams from GD 13-20) did not alter basal 5-HIAA content in the frontal cortex, hypothalamus, hippocampus, 
striatum, or midbrain of prepubescent male progeny. Likewise, 5-HIAA content was not altered in adult male progeny across any 
of the brain regions examined. Data from each brain region were analyzed separately using a two-way ANOVA followed by a 
Newman-Keuls post-hoc test. t Significantly different from the respective values obtained in prepubescent progeny (p<0.05). 
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TABLE 6 
5-HT/5HIAA RATIO IN PREPUBESCENT AND ADULT MALE PROGENY 
Prenatal Brain Region 
Exposure 
Frontal Cortex Hypothalamus Group Hippocampus Striatum Midbrain 
Pre12ubescent 
Saline 1.01 ± 0.11 (8) 1.26 ± 0.05 (8) 0.86 ± 0.14 (7) 0.54 ± 0.04 (8) 0. 79 ± 0.02 (7) 
Fluoxetine 0. 78 ± 0.06 (8) 1 .31 ± 0.10 (7) 0.65 ± 0.04 (8) 0.60 ± 0.07 (8) 0.81 ± 0.04 (8) 
Adult 
Saline 1.50 ± o.o9r (8l 1 .80 ± 0.15 t (8) 1.28 ± 0.06t (7) o.99 ± o.o5r (8l 1.70 ± 0.15t (8) 
Fluoxetine 1.45 ± 0.14t (8) 1. 75 ± o.o8r (8l 1.23 ± 0.11 t (7) 0.94 ± 0.04t (8) 1 .45 ± o.or (8l 
Data represent the means ± SEM of 5-HT/5-HIAA ratios from 7-8 rats per group with each rat within a group being obtained from 
a different litter. The number of rats per group is shown in parentheses. Prenatal exposure to fluoxetine (10 mg/kg/2ml s.c., to dams 
from GD 13-20) did not alter basal 5-HT turnover in the frontal cortex, hypothalamus, hippocampus, striatum, or midbrain of 
prepubescent male progeny. Likewise, in adult male progeny, 5-HT turnover was not altered across any of the brain regions 
examined. Data from each brain region were analyzed separately using a two-way ANOVA followed by a Newman-Keuls post-hoc 
test. t Significantly different than the respective values obtained in prepubescent progeny (p < 0.05). 
65 
In contrast to the reduction in cortical 5-HT content observed in prepubescent 
fluoxetine-exposed progeny, basal 5-HIAA content was not altered in any of the brain regions 
examined (Table 5) at PD 28. Likewise, 5-HIAA content was similar in control and 
fluoxetine-exposed adult progeny in the cortex, hypothalamus, hippocampus, striatum and 
midbrain (Table 5). 
In addition to the determination of regional basal 5-HT and 5-HIAA content, the ratio 
of 5-HT:5-HIAA levels was calculated as an index of 5-HT turnover (Table 6). Despite some 
reduction in basal 5-HT content in fluoxetine-exposed progeny, serotonin turnover was not 
significantly altered by prenatal fluoxetine exposure in either 5-HT target areas (cortex, 
hypothalamus, hippocampus, and striatum) or in a brain region containing 5-HT cell bodies 
(midbrain) regardless of the age of the animal. 
Prenatal Fluoxetine Exposure Alters the Ability 
of a 5-HT Releasing Drug to Reduce 5-HT Content 
PCA administration significantly reduced 5-HT content across all brain regions 
examined {see appendix 6 for statistical analysis). The reduction in 5-HT content ranged 
from approximately 21 - 67 % in control progeny. In fluoxetine-exposed progeny, the 
reduction in 5-HT content ranged from 20 - 59% in different brain regions {Fig. 3). At PD 
28, PCA administration reduced hypothalamic 5-HT content by 21 % in saline-exposed 
progeny and 34% in fluoxetine-exposed offspring in comparison to their respective basal 5-
HT values (Fig. 3A). However, this 13% difference in the magnitude of the reduction 
between prenatal treatment groups did not reach statistical significance. PCA produced 
similar reductions in 5-HT content in both control and fluoxetine-exposed offspring in the 
cortex, hippocampus, striatum and midbrain at PD 28 (Fig. 3A). In adult offspring, PCA 
significantly reduced midbrain 5-HT content in both progeny groups. However, the 
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magnitude of the reduction in 5-HT content in fluoxetine-exposed animals was significantly 
less than observed in saline-treated progeny (Figure 38). PCA reduced 5-HT content to a 
similar extent in control and fluoxetine-exposed offspring in the cortex, hypothalamus, 
hippocampus, and striatum at PD 70. 
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Figure 3. Reduction in brain 5-HT content one hour following a single injection of the 5-HT 
releaser PCA (5 mg/kg, i.p.) in prepubescent (/Y and adult (!J) male progeny prenatally 
exposed to either saline or fluoxetine (10 mglkg/2ml, s.c. to dams from GD 13-20). Data 
represent group means ± SEM from 6-8 rats per group with each rat within a group being 
obtained from a different litter. There were no significant differences in the magnitude of the 
PCA-induced reduction in 5-HT content in any of the brain regions between control and 
fluoxetine exposed offspring at PD 28 irrespective of the brain region examined. In contrast, 
in adult progeny, the magnitude of the PCA-mediated reduction in 5-HT content was 
significantly lower (-42 %) in the midbrain of fluoxetine-exposed rats. Data were analyzed 
by a 2-way ANOVA followed by a Newman-Keuls test. Abbreviations: Ctx, cortex; Hypo, 
hypothalamus; Hipp, hippocampus; Str, striatum; MdBr, midbrain. * Significantly different 
from the reduction in midbrain 5-HT content observed in adult control offspring (p < 0.05). 
t Significantly different from the respective values in prepubescent control offspring 
(p<0.05). 
Age-Related Changes in the Neurochemical Status of 5-HT Neurons 
Basal Monoamine Content 
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Several differences were observed in basal monoamine content as a 
consequence of normal maturation. For example, a 2-way ANOVA indicated a 
significant main effect of age [F( 1,27) = 6. 75; p < 0.05] in the midbrain. As 
indicated in Table 4, midbrain 5-HT levels were significantly greater in the adult 
control progeny than in prepubescent control progeny ( + 61 %). In contrast, 5-
HIAA content was significantly lower in adult control progeny compared to values 
in prepubescent animals in the hypothalamus, hippocampus, striatum, and midbrain 
but not in the cortex (Table 5). These differential changes in 5-HT and 5-HIAA 
levels as a consequence of maturation, resulted in significantly greater 5-HT:5-
HIAA ratios (an index of 5-HT turnover) in adult control animals vs. their 
prepubescent counterparts in all brain regions examined (Table 6). 
PCA Induced Reduction of 5-HT Content 
In saline-exposed progeny, the ability of PCA to reduce 5-HT content was 
significantly greater in the cortex of prepubescent offspring in comparison to their 
adult counterparts (Fig. 3). In contrast, PCA reduced 5-HT content to a greater 
extent in the midbrain of adult control animals. No age-related differences in 
reductions in 5-HT content following PCA administration were observed in the 
hypothalamus, hippocampus or striatum in saline-exposed control progeny. 
Effect of Prenatal Fluoxetine Exposure on the 
Density of 5-HT Uptake Sites in Brain Homogenates 
In order to assess whether global changes in serotonergic innervation 
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occurred as a consequence of prenatal exposure to fluoxetine, 5-HT uptake sites 
were initially measured in homogenates of the cortex, hypothalamus, hippocampus 
and striatum. For comparative purposes, the density of 5-HT uptake sites was 
also determined in the midbrain. As shown in Table 7, prenatal exposure to 
fluoxetine did not alter the density of 5-HT uptake sites in prepubescent progeny in 
any of the brain regions examined. Likewise, in adult progeny, no alterations in 
the density of 5-HT uptake sites were observed as a consequence of fluoxetine-
exposure in either the cortex, hypothalamus, hippocampus, striatum or midbrain 
(Table 7). The density of 5-HT uptake sites was similar between prepubescent and 
adult progeny in the cortex, hippocampus, striatum and midbrain. However, 5-HT 
uptake sites were significantly lower in the hypothalamus of adult progeny in 
comparison to their prepubescent counterparts. 
The lack of widespread changes in the density of 5-HT uptake sites in 
homogenates does not preclude the possibility of more subtle changes in 5-HT 
uptake sites in discrete neuroanatomic loci. This possibility was addressed in the 
autoradiographic studies discussed later in this chapter. 
Treatment Group 
Pre12ubescent 
Saline 
Fluoxetine 
Adult 
Saline 
Fluoxetine 
TABLE 7 
THE DENSITY OF 5-HT UPTAKE SITES IN HOMOGENATES OF 
BRAIN REGIONS IN PREPUBESCENT AND ADULT MALE PROGENY 
Brain Region 
Frontal Cortex Hypothalamus Hippocampus Striatum 
452 ± 8 (6) 749 ± 60 (6) 332 ± 9 (8) 456 ± 21 (8) 
438 ± 27 (8) 819 ± 38 (6) 327 ± 15 (8) 496 ± 18 (8) 
394 ± 19 (8) 506 ± 4ot (7) 327 ± 27 (8) 470 ± 23 (8) 
429 ± 28 (8) 476 ± 26t (7) 333 ± 19 (8) 516 ± 25 (7) 
Midbrain 
459 ± 14 (8) 
489 ± 18 (8) 
498 ± 17 (8) 
474 ± 20 (8) 
Data are expressed as fmol/mg protein and represent the means ± SEM from 6-8 rats per group with each rat within a group being 
obtained from a different litter. The number of rats per group is shown in parentheses. No significant differences were observed 
in the density of 5-HT uptake sites as a consequence of prenatal fluoxetine exposure. Data were analyzed by a two-way ANOVA 
followed by a Newman-Keuls post-hoc test. 5-HT uptake sites were labelled by using a saturating concentration (0.4nM) of 
[3H]paroxetine and nonspecific binding was determined in the presence of 1µM citalopram. t Significantly different than the 
respective values in prepubescent progeny (p<0.05). 
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Lack of Effect of Prenatal Fluoxetine Exposure on 
the 5-HT 1A Mediated Increase in Hormone Secretion 
Plasma ACTH 
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Figure 4 illustrates basal and 8-0H-DPAT induced increase in plasma levels 
of ACTH in prepubescent and adult male progeny. Basal values of ACTH (saline 
challenged) were unaffected in either prepubescent (Fig. 4A) or adult (Fig. 48) 
progeny by prenatal exposure to fluoxetine. In both age groups, a single injection 
of a maximally effective dose of the 5-HT1A agonist 8-0H-DPAT (0.5 mg/kg) 
significantly elevated plasma ACTH levels above basal values in both saline and 
fluoxetine-exposed progeny. Likewise, the magnitude of the ACTH response to 8-
OH-DPAT was similar in control and fluoxetine-exposed progeny regardless of the 
age of the animals. 
Plasma Corticosterone 
Consistent with the ACTH data, basal levels of corticosterone were not 
significantly different between control and fluoxetine-exposed progeny (Fig. 5). 
Likewise, 8-0H-DPAT significantly elevated plasma corticosterone levels above 
basal values in both saline and fluoxetine-exposed progeny regardless of the age of 
the offspring. Prenatal exposure to fluoxetine did not alter the magnitude of the 
corticosterone response to 8-0H-DPAT in either prepubescent or adult progeny. 
Plasma Renin 
Figure 6 illustrates basal and stimulated levels of plasma renin in 
prepubescent and adult progeny prenatally exposed to either saline or fluoxetine. 
As observed for ACTH and corticosterone, basal levels of renin were unaffected by 
prenatal fluoxetine exposure. In prepubescent progeny, 8-0H-DPAT significantly 
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elevated plasma renin levels above basal values (Fig. 6A). The magnitude of the 
renin response to 8-0H-DPAT was similar in control and fluoxetine-exposed 
prepubescent progeny. In adult progeny, 8-0H-DPAT did not significantly elevate 
plasma renin levels above basal values in either control or fluoxetine-exposed 
progeny (Fig. 68). In addition, there were no between-group differences in the 
magnitude of the renin response to 8-0H-DPAT in adult progeny. 
Age-Related Changes in Plasma Hormones 
A significant main effect of age was observed for plasma ACTH 
[F(1,45)=5.39; p<0.05], corticosterone [F(1,46)=7.50; p<0.01) and renin 
[F(1,44) = 93. 74; p < 0.01] values as shown in Figures 4 through 6. A Newman-
Keuls post-hoc analysis revealed that both basal and stimulated renin values in 
prepubescent progeny were significantly lower than adult values (p<0.05). 
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Figure 4. Basal and stimulated plasma ACTH levels following a single injection of either 
saline or a maximally effective dose of 8-0H-DPAT (0.5 mg/kg, s.c.) in prepubescent 
(/V or adult (!1) male progeny prenatally exposed to either saline or fluoxetine (10 
mg!kg/2ml, s.c., to dams from GD 13-20). Data represent group means ± SEM from 
6-8 rats per group with each rat within a group being obtained from a different litter. 
Basal levels of ACTH were not altered by prenatal fluoxetine exposure in either 
prepubescent or adult progeny. 8-0H-DPAT significantly increased ACTH in all 
progeny groups. The magnitude of the ACTH response to 8-0H-DPAT was not 
significantly different between saline and fluoxetine-exposed progeny regardless of the 
age of the offspring. * Significantly different from the corresponding saline-injected 
group (p<0.05). Data were analyzed by a 3-way ANOVA followed by a Newman-
Keuls test. 
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Figure 5. Basal and stimulated plasma corticosterone levels following a single 
injection of either saline or a maximally effective dose of 8-0H-DPA T (0. 5 mg/kg, s.c.} 
in prepubescent (/j) or adult (fl} male progeny prenatally exposed to either saline or 
fluoxetine (10 mglkg/2ml, s.c., to dams from GD 13-20). Data represent group means 
± SEM from 6-8 rats per group with each rat within a group being obtained from a 
different litter. Basal levels of corticosterone were not altered by prenatal fluoxetine 
exposure in either prepubescent or adult progeny. Likewise, there were no significant 
differences between groups in the magnitude of the corticosterone response to 8-0H-
DPAT regardless of the age of the offspring. * Significantly different from the 
corresponding saline-injected group (p < 0.05). Data were subjected to a log 
transformation and then analyzed by a 3-way ANOVA followed by a Newman-Keuls 
test. 
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Figure 6. Basal and stimulated plasma renin levels following a single injection of either 
saline or a maximally effective dose of 8-0H-DPAT (0.5 mg/kg, s.c.) in prepubescent 
(~ or adult (fl} male progeny prenatally exposed to either saline or fluoxetine (10 
mg!kg/2ml, s.c., to dams from GD 13-20). Data represent group means ± SEM from 
5-8 rats per group with each rat within a group being obtained from a different litter. 
Basal levels of renin were not altered by prenatal fluoxetine exposure in either 
prepubescent or adult progeny. The renin response to 8-0H-DPAT was similar in 
saline and fluoxetine-exposed offspring regardless of the age of the animals. 
* Significantly different from the corresponding saline-injected group (p < 0.05). 
#Significantly different from the respective prepubescent group (p < 0.05). Data were 
subjected to a log transformation and then analyzed by a 3-way ANOVA followed by 
a Newman-Keuls test. 
Reduction in 5-HT 2AJ2c Mediated Neuroendocrine 
Function Following Prenatal Exposure to Fluoxetine 
Plasma ACTH 
Figure 7 illustrates basal and DOI-induced increase in plasma ACTH in 
prepubescent and adult male progeny prenatally exposed to either saline or 
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fluoxetine. Basal levels of plasma ACTH were unaltered by prenatal exposure to 
fluoxetine in prepubescent {Fig. 7 Al and adult {Fig. 78) progeny. At PD 28, a 
single injection of the 5-HT 2A12c agonist DOI significantly elevated plasma ACTH 
levels above basal values in control and fluoxetine-exposed progeny. The 
magnitude of the ACTH response to DOI was similar in saline and fluoxetine-
exposed progeny at PD 28 {Fig. 7A). In adult progeny, DOI elevated plasma ACTH 
levels in both control and fluoxetine-exposed progeny groups. However, the ACTH 
response to DOI was markedly attenuated (-58%; p<0.05) in adult progeny 
prenatally exposed to fluoxetine {Fig. 78) compared to the corresponding saline-
exposed controls. 
Plasma Corticosterone 
As shown in Figure 8, basal levels of corticosterone were not altered by 
prenatal exposure to fluoxetine in either prepubescent {Fig. SA) or adult (Fig. 88) 
progeny. DOI significantly elevated corticosterone above basal values in 
prepubescent and adult progeny from both treatment groups. At PD 28, the 
magnitude of the corticosterone response to DOI was not significantly altered by 
prenatal exposure to fluoxetine. Likewise, in adult progeny, there were no 
significant differences between groups in the magnitude of the corticosterone 
response to DOI. 
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Figure 7. Basal and stimulated plasma ACTH levels following a single injection of either 
saline or a maximally effective dose of DOI (2 mg/kg, s. c.) in prepubescent (/Y or adult 
(!1) male progeny prenatally exposed to either saline or f/uoxetine (10 mg/kg/2ml, s.c., 
to dams from GD 13-20). Data represent group means ± SEM from 6-8 rats per group 
with each rat within a group being obtained from a different litter. Basal levels of 
ACTH were not altered by prenatal fluoxetine exposure in either prepubescent or adult 
progeny. However, the ACTH response to DOI was significantly attenuated (-58%) in 
adult male progeny prenatally exposed to fluoxetine. *Significantly different from the 
corresponding saline-injected group {p < 0.05). t Significantly different from the adult 
vehicle-exposed/DOI-injected group {p<0.05). # Significantly different from the 
respective value in prepubescent progeny. Data were analyzed by a 3-way ANOVA 
followed by a Newman-Keuls test. 
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Figure 8. Basal and stimulated plasma corticosterone levels following a single injection 
of either saline or a maximally effective dose of DOI (2 mg/kg, s.c.) in prepubescent 
(A) or adult (8) male progeny prenatally exposed to either saline or fluoxetine (10 
mg/kg/2ml, s.c., to dams from GD 13-20). Data represent group means ± SEM from 
6-8 rats per group with each rat within a group being obtained from a different litter. 
Basal levels of corticosterone were not altered by prenatal f luoxetine exposure in either 
prepubescent or adult progeny. Likewise, there were no significant differences 
between groups in the magnitude of the corticosterone response to DOI regardless of 
the age of the offspring. * Significantly different from the corresponding saline-injected 
group (p < 0.05). #Significantly different from the respective value in prepubescent 
progeny (p<0.05). Data were subjected to a log transformation and then analyzed by 
a 3-way ANOVA followed by a Newman-Keuls test. 
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Figure 9. Basal and stimulated plasma renin levels following a single injection of either 
saline or a maximally effective dose of DOI (2 mg/kg, s. c.) in prepubescent (A) or 
adult (8) male progeny prenatally exposed to either saline or fluoxetine (10 mg!kg/2ml, 
s.c., to dams from GD 13-20). Data represent group means ± SEM from 6-8 rats per 
group with each rat within a group being obtained from a different litter. No 
differences were observed between treatment groups in either basal levels of plasma 
renin or in the ability of DOI to increase plasma renin regardless of the age of the 
offspring. * Significantly different from the corresponding saline-injected group 
(p < 0 .05). # Significantly different from respective values in prepubescent progeny 
(p < 0.05). Data were subjected to a log transformation and then analyzed by a 3-way 
ANOV A followed by a Newman-Keuls test. 
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Plasma Renin 
As observed for ACTH and corticosterone, basal levels of renin were 
unaffected by prenatal fluoxetine exposure (Fig. 9). In prepubescent progeny, DOI 
did not significantly elevate plasma renin levels above basal values in either 
treatment group. Nonetheless, the renin response to DOI was not affected by 
prenatal exposure to fluoxetine at PD 28. In contrast to PD 28 progeny, at PD 70, 
DOI significantly elevated plasma renin levels above basal values in both control 
and fluoxetine-exposed progeny. However, the magnitude of the renin response 
was not significantly different between saline and fluoxetine-exposed progeny at 
PD 70. 
Age-Related Changes in Plasma Hormones 
A significant main effect of age was observed for plasma ACTH 
[F(1,46)=6.14; p<0.05], corticosterone [F(1,46)=11.23; p<0.01], and renin 
[F(1,40)=12.18; p<0.01]. A comparison between Figures 9A and 98 reveals that 
while basal renin values are approximately 2-fold greater at PD 28 than at PD 70, 
the magnitude of the response to DOI is similar at both developmental time points. 
Therefore, the higher renin basal values in prepubescent progeny could account for 
the inability of DOI to significantly elevate renin above basal levels at PD 28. In 
contrast, no developmental change in basal corticosterone or ACTH values were 
observed between PD 28 and PD 70. However, the ACTH and corticosterone 
responses to DOI were stastically significantly different between adult versus 
prepubescent progeny only in the fluoxetine-exposed animals (Figs. 7 and 8). 
Effect of Prenatal Fluoxetine Exposure on 5-HT 2A12c 
Receptors in Homogenates of Hypothalamus and Cortex 
In order to discern whether global changes in the density of 5-HT zAizc 
receptors occurred concomitantly with the reduction in the 5-HT 2A,2c mediated 
ACTH response, 5-HT2A12c receptors were measured in homogenates of the 
hypothalamus. As indicated in Table 8, the maximal density (Bmax) of 
hypothalamic 5-HT 2A12c receptors in rats at PD 28 was not significantly different 
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between progeny of control and fluoxetine-treated dams. Likewise, no changes in 
the affinity (Kd) of [1251]001 for hypothalamic 5-HT2A12c receptors were observed at 
PD 28 following prenatal exposure to fluoxetine. In contrast to PD 28 progeny, in 
adult progeny, the maximal density of hypothalamic 5-HT2A12c receptors was 
significantly decreased (-35 % ; p < 0.05) in fluoxetine-exposed offspring (Table 8). 
Consistent with the PD 28 data, the affinity (Kd) of [1251JDOl-labelled 5-HT2A,2c 
receptors in adult progeny was not significantly altered by prenatal fluoxetine 
exposure. In order to determine whether the reduction of 5-HT zAi2c receptors 
observed in the hypothalamus reflected a generalized reduction in brain 5-HT zAi2c 
receptors, these sites were also measured in cortex. As shown in Table 9, 
prenatal exposure to fluoxetine did not alter [1251]001 binding to cortical 5-HT2A12c 
receptors in either prepubescent or adult offspring. 
Taken together, the changes in 5-HT2A12c receptors in the hypothalamus 
along with the specific attenuation of the DOI-stimulated ACTH response, 
suggested that prenatal exposure to fluoxetine may have differentially affected 
specific brain regions or select brain 5-HT pathways. Therefore, autoradiographic 
studies were carried out to identify alterations in 5-HT recognition sites in discrete 
neuroanatomic loci following prenatal fluoxetine exposure. 
TABLE 8 
MAXIMAL DENSITY (Bmaxl AND AFFINITY (Kd) OF [125l]DOI 
LABELLED 5-HT2A12c RECEPTORS IN HYPOTHALAMIC HOMOGENATES 
FROM PREPUBESCENT AND ADULT PROGENY 
PRENATAL 
EXPOSURE GROUP 
Prepubescent 
Control 
Fluoxetine 
Adult 
Control 
Fluoxetine 
5-HT 2A12c RECEPTORS 
Bmax 
(fmol/mg protein) 
29.5 ± 2.2 
29.1 ± 1.6 
23.0 ± 2.8 
14.9 ± 1.0 * 
(-35%) 
0.31 ± 0.04 
0.45 ± 0.07 
0.49 ± 0.07 
0.29 ± 0.03 
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Data represent the means ± SEM from 6-8 rats per group with each rat within a 
group being obtained from a different litter. In prepubescent progeny, prenatal 
exposure to fluoxetine ( 10 mg/kg, s.c., to dams from GD 13-20) did not alter the 
maximal density (Bmaxl or the affinity (Kd) of 5-HT 2A12c receptors in the hypothalamus. 
In contrast, at PD 70, prenatal exposure to fluoxetine resulted in a significant 35 % 
decrease in the maximal density (Bmaxl of hypothalamic 5-HT 2A12c receptors in progeny. 
Similar to PD 28 males, the affinity of [1251]DOI for hypothalamic 5-HT 2A12c receptors 
(Kd) was comparable in saline and fluoxetine-exposed progeny at PD 70. Bmax and Kd 
values were determined from Scatchard analyses of [12511001 saturation data using 
concentrations of [1251]DOI ranging from 0.15 nM - 0.6 nM. Nonspecific binding was 
determined in the presence of 10 µM 5-HT. Data were analyzed by a two-way 
ANOVA. * Significantly different from age-matched saline exposed progeny 
(p < 0.05). 
TABLE 9 
[ 1251]001 LABELLED 5-HT2A12c RECEPTORS IN CORTICAL 
HOMOGENATES FROM PREPUBESCENT AND ADULT PROGENY 
Prenatal 
Exposure Group 
Prepubescent 
Control 
Fluoxetine 
Adult 
Control 
Fluoxetine 
5-HT 2A12c Receptors 
(fmol/mg protein) 
54.5 ± 3.2 
64.6 ± 5.6 
9.3 ± 0.4 t 
11.0 ± 0. 7 t 
Data represent the means ± SEM from 6-8 rats per group with each rat 
within a group being obtained from a different litter. In contrast to the 
effects observed in the hypothalamus, prenatal exposure to fluoxetine 
( 10 mg/kg, s.c., to dams from GD 13-20) did not alter the binding of 
[1 25 l]DOI to cortical 5-HT 2 A12c receptors in prepubescent or adult 
progeny; indicating no difference in receptor affinity and/or density. 
Data were analyzed by a two-way ANOV A. 5-HT 2 A12c receptor density 
was measured using a single concentration of [1251]001 (0.05 nM). Non-
specific binding was determined in the presence of 10 µM 5-HT. 
t Significantly different from respective values in prepubescent progeny 
(p<0.05). 
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Prenatal Fluoxetine Exposure Produces Site-Specific Alterations in 
5-HT Uptake Sites: Evidence for Alterations in Serotonergic Innervation 
Telencephalon 
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Site-specific alterations in 5-HT uptake sites in telencephalic brain regions 
following prenatal exposure to fluoxetine are shown in Table 11 and illustrated in 
Figure 10. In prepubescent offspring, prenatal fluoxetine exposure altered the 
density of 5-HT uptake sites in select subregions of the hippocampus. For 
example, a significant increase in 5-HT uptake sites was observed in the CA2 
( + 4 7 % ) and CA3 ( + 38 % ) areas of the hippocampus in fluoxetine-exposed 
prepubescent offspring (Table 11 ). In contrast, in prepubescent offspring the 
density of 5-HT uptake sites was not altered in either the dentate gyrus (DG) or in 
the CA 1 area of the hippocampus. 5-HT uptake sites were also significantly 
elevated in select nuclei of the amygdala in prepubescent offspring prenatally 
exposed to fluoxetine. 5-HT uptake sites were significantly increased in the 
basolateral (BLAMY; +32%) and medial (MAMY; +44%) amygdaloid nuclei. 
However, 5-HT uptake sites in the central amygdala (CAMY), caudate putamen 
(CPu), globus pallidus (GP) and ventral pallidum (VP) were similar between control 
and fluoxetine-exposed prepubescent offspring. In contrast, in adult offspring 
(Table 11 ), the density of 5-HT uptake sites was not significantly altered in any 
subregion of the hippocampus (CA 1, CA2, CA3, dentate) by prenatal fluoxetine 
exposure. Likewise, in adult offspring, prenatal fluoxetine exposure did not alter 
the density of 5-HT uptake sites in any of the basal ganglia or amygdaloid nuclei 
examined in the present study (central, basolateral, and medial amygdala; caudate 
putamen, globus pallidus, and ventral pallidum). Prenatal exposure to fluoxetine 
did not alter the density of 5-HT uptake sites in any of the cortical areas examined 
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in either prepubescent or adult progeny [cingulate (Cg3), frontal (Fr2), entorhinal 
(Ent), occipital (Oc2L), parietal (Par1 ), retrosplenial granular (RSG) and temporal 
(Te 1) cortex]. Likewise, the density of 5-HT uptake sites in lateral septa I nuclei 
[dorsal (LSD) and intermediate (LSI) areas] was not affected by fluoxetine exposure 
in either prepubescent or adult progeny. 
Diencephalon and Mesencephalon 
Prenatal fluoxetine induced alterations in the density of 5-HT uptake sites in 
Diencephalic and Mesencephalic brain regions are shown in Table 11 and in Figure 
10. Similar to the hippocampus, in prepubescent progeny, only select subregions 
of the hypothalamus were affected by prenatal fluoxetine exposure. For example, 
5-HT uptake sites in the lateral hypothalamus (LH) were significantly elevated 
( + 21 %) in prepubescent fluoxetine-exposed progeny. In contrast, prenatal 
exposure to fluoxetine significantly reduced (-21 %) the density of 5-HT uptake 
sites in the dorsomedial hypothalamic nucleus (DM) in prepubescent offspring. The 
density of 5-HT uptake sites was similar between control and fluoxetine-exposed 
animals in all other subregions of the hypothalamus examined [anterior (AHC), 
arcuate (Arc), and ventromedial (VMH) nuclei; medial mammillary (MM) and medial 
preoptic (MPA) areas] in prepubescent progeny. In addition to hypothalamic 
alterations, a significant decrease in 5-HT uptake sites was observed in the 
substantia nigra (SN; -19%) in prepubescent fluoxetine-exposed offspring. Despite 
the alterations in 5-HT uptake sites observed in prepubescent progeny in a number 
of regions receiving serotonergic innervation, 5-HT uptake sites were not altered by 
fluoxetine exposure in brain regions composed primarily of serotonin perikarya [i.e. 
dorsal (DR) and median (MnR) raphe nuclei]. In contrast to the changes observed 
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in prepubescent offspring, in adult progeny, the density of 5-HT uptake sites was 
similar between control and fluoxetine-exposed offspring across all subregions of 
the hypothalamus and tegmentum examined (Table 11 ). Consistent with data 
obtained in prepubescent progeny, the density of 5-HT uptake sites in the dorsal 
and median raphe nuclei was not altered by prenatal fluoxetine exposure. 
Changes in the Density of 5-HT Uptake Sites as a Consequence of Maturation 
Figure 11 graphically illustrates the regional specificity of changes in the 
density of 5-HT uptake sites as a consequence of normal maturation (i.e. 
prepubescent versus adult densities of 5-HT uptake sites in control progeny). The 
majority of brain areas examined in the present study possess a comparable 
density of 5-HT uptake sites in prepubescent and adult animals (Table 11 ). 
However, notable increases and decreases were observed in specific 
neuroanatomic loci. Adult control progeny exhibited a significantly greater density 
of 5-HT uptake sites than their prepubescent counterparts in the cingulate cortex 
(Cg3; + 33%), the arcuate nucleus (Arc) of the hypothalamus ( + 56%), the 
basolateral (BLAMY; + 58%) and medial amygdaloid nuclei (MAMY; + 66%), as 
well as in CA 1 ( + 48%) and CA3 ( + 76%) areas of the hippocampus (Table 11 ). 
In contrast, the density of 5-HT uptake sites was significantly lower in control adult 
progeny than in prepubescent animals within the temporal cortex (Te1; -65%), 
substantia nigra (SN; -26%), ventral tegmental area (VTA; -31 %), and median 
raphe (MnR; -25%; Table 11 and Figure 11 ). 
TABLE 10 
LIST OF ABBREVIATIONS USED IN AUTORADIOGRAPHIC STUDIES 
Abbreviation 
AHC 
Arc 
BLAMY 
CA1 
CA2 
CA3 
CAMY 
CHP 
Cg3 
CPu 
DG 
DM 
DR 
Ent 
Fr2 
GP 
LH 
LSD 
LSI 
MAMY 
MM 
MnR 
MPA 
Oc2L 
Par1 
PVN 
RSG 
SN 
Te1 
VMH 
VP 
VTA 
Brain Region 
Anterior hypothalamic area, central 
Arcuate hypothalamic nucleus 
Basolateral amygdaloid area 
CA 1 field of Ammon's horn 
CA2 field of Ammon's horn 
CA3 field of Ammon's horn 
Central amygdaloid area 
Choroid Plexus 
Cingulate cortex, area 3 
Caudate putamen 
Dentate gyrus 
Dorsomedial hypothalamic nucleus 
Dorsal raphe nucleus 
Entorhinal cortex 
Frontal cortex, area 2 
Globus pallidus 
Lateral hypothalamic area 
Lateral septal nucleus, dorsal 
Lateral septal nucleus, intermediate 
Medial amygdaloid area 
Medial mammillary area 
Median raphe nucleus 
Medial preoptic area 
Occipital cortex, area 2, lateral 
Parietal cortex, area 1 
Paraventricular hypothalamic nucleus 
Retrosplenial granular cortex 
Substantia nigra 
Temporal cortex, area 1 
Ventromedial hypothalamic nucleus 
Ventral Pallidum 
Ventral Tegmental Area 
Abbreviations listed are in general accordance with those given in the 
rat atlas by Paxinos and Watson (1986). 
87 
88 
Figure 10. Autoradiograms demonstrating the effect of prenatal f/uoxetine exposure 
on the density of f1HJcitalopram-labelled 5-HT uptake sites in prepubescent progeny. 
Representative autoradiograms of control progeny are shown in panels A, C, £, and 
G. Representative autoradiograms of fluoxetine-exposed progeny are shown in panels 
~. D, f, and H. White areas indicate brain regions with a high density of 5-HT uptake 
sites. Prenatal exposure to fluoxetine resulted in a significant increase (shaded red) 
in the density of 5-HT uptake sites in the LH, CA2, CA3, BLAMY and MAMY. In 
contrast, the density of 5-HT uptake sites was significantly decreased (shaded blue) 
in SN. The density of 5-HT uptake sites in serotonergic cell body regions (DR and 
MnR) was not altered by prenatal exposure to fluoxetine. Abbreviations are defined 
in Table 10. 5-HT uptake sites were labelled with 0. 7 nM [3H]citalopram. Nonspecific 
binding was defined in the presence of 1 µM paroxetine. Abbreviations are described 
in Table 10. 
Brain Region 
TelenceQhalon 
Cortex 
Cg3 
Fr2 
Ent 
Oc2L 
Par1 
RSG 
Te1 
Hippocampus 
CA1 
CA2 
CA3 
DG 
Septum 
LSD 
LSI 
TABLE 11 
THE DENSITY OF [3HJCIT ALO PRAM-LABELLED 5-HT UPTAKE SITES 
IN SELECT BRAIN REGIONS OF PREPUBESCENT AND ADULT OFFSPRING 
Prepubescent Progeny Adult Progeny 
Saline (N) Fluoxetine (N) Saline (N) Fluoxetine 
24 ± 2 (5) 25 ± 3 (5) 32 ± 1 t (5) 34 ± 3t 
14 ± 2 (5) 14 ± 2 (5) 15 ± 1 (5) 13 ± 1 
24 ± 4 (5) 20 ± 1 (4) 30 ± 1 (5) 30 ± 5 
7 ± 1 (5) 6 ± 1 (4) 6 ± 1 (5) 8 ± 1 
13 ± 2 (4) 13 ± 1 (5) 10 ± 1 (5) 9 ± 1 
12 ± 1 (4) 12 ± 1 (5) 10 ± 1 (4) 14 ± 1 
17 ± 4 (5) 14 ± 1 (4) 6 ± 1 t (5) 8 ± 1 
9 ± 1 (5) 12 ± 1 (5) 16 ± 2t (5) 17 ± 2 
19 ± 1 (5) 28 ± 1 * (4) 29 ± 3 (4) 31 ± 4 
21 ± 3 (4) 29 ± 1 * (5) 37 ± 2t (4) 37 ± 2t 
7 ± 1 (4) 10 ± 1 (5) 10 ± 1 (5) 11 ± 2 
20 ± 2 (5) 25 ± 1 (4) 21 ± 3 (4) 25 ± 3 
60 ± 5 (5) 61 ± 3 (4) 57 ± 4 (5) 63 ± 3 
(N) 
(6) 
(6) 
(6) 
(6) 
(5) 
(5) 
(6) 
(5) 
(5) 
(6) 
(6) 
(6) 
(5) 
00 
CD 
Brain Region Saline 
Amygdala 
BLAMY 71 ± 5 
CAMY 13 ± 2 
MAMY 32 ± 1 
Basal Ganglia 
CPu 38 ± 3 
GP 86 ± 5 
VP 63 ± 7 
Dience12halon 
Hypothalamus 
AHC 65 ± 6 
Arc 18 ± 1 
DM 43 ± 2 
LH 71 ± 3 
MM 63 ± 5 
MPA 35 ± 3 
PVN 38 ± 3 
VMH 30 ± 3 
TABLE 11 Continued 
Prepubescent Progeny 
(N) Fluoxetine (N) 
(4) 94 ± 1 * (4) 
(5) 15 ± 2 (5) 
(4) 46 ± 3 * (4) 
(5) 37 ± 2 (5) 
(3) 59 ± 6 (3) 
(4) 55 ± 4 (3) 
(5) 74 ± 4 (5) 
(5) 24 ± 1 (4) 
(4) 34 ± 1 * (4) 
(4) 86 ± 6 * (5) 
(5) 62 ± 5 (4) 
(4) 31 ± 5 (3) 
(5) 43 ± 2 (5) 
(5) 34 ± 1 (5) 
Saline 
112 ± 7t 
17 ± 1 
53 ± 1 t 
33 ± 3 
69 ± 2 
70 ± 2 
54 ± 2 
28 ± 2t 
45 ± 3 
62 ± 3 
58 ± 6 
37 ± 4 
34 ± 2 
35 ± 3 
Adult Progeny 
(N) Fluoxetine 
(4) 113 ± 5 
(5) 17 ± 2 
(5) 50 ± 3 
(5) 28 ± 2 
(3) 56 ± 9 
(4) 61 ± 6 
(4) 67 ± 2 
(4) 22 ± 2 
(5) 44 ± 3t 
(5) 72 ± 3t 
(5) 70 ± 7 
(5) 34 ± 3 
(5) 39 ± 3 
(5) 28 ± 1 
(N) 
(5) 
(6) 
(6) 
(6) 
(5) 
(5) 
(6) 
(6) 
(5) 
(5) 
(6) 
(5) 
(6) 
(5) 
CD 
0 
TABLE 11 Continued 
Prepubescent Progeny Adult Progeny 
Brain Region Saline (N) Fluoxetine (N) Saline (N) Fluoxetine (N) 
Mesence(2halon 
Tegmentum 
SN 121 ± 5 (4) 98 ± 3 * (3) 90 ± 5t (4) 74 ± at (5) 
VTA 114 ± 8 (5) 109 ± 6 (4) 79 ± 5t (5) 86 ± 5t (6) 
Raphe Nuclei 
DR 155 ± 8 (5) 155 ± 14 (4) 138 ±4 (5) 149 ± 5 (6) 
MnR 145 ± 10 (5) 134 ± 5 (3) 108 ± 4t (4) 115 ± 5 (6) 
Data are expressed as fmol of sites/mg tissue equivalent and represent the means ± SEM from 3-6 rats per group with each rat 
within a group being obtained from a different litter. The number of rats per group is shown in parentheses. Prenatal exposure 
to fluoxetine (10 mg/kg/2ml, s.c., to dams from GD 13-20) significantly increased the density of 5-HT uptake sites in CA2 
( +47%), CA3 ( + 38%), BLAMY ( + 32%), MAMY ( +44%), and the LH ( + 21 %) in prepubescent progeny. In contrast, the density 
of 5-HT uptake sites was significantly decreased in DM (-21 %), and SN (-19%) in prepubescent progeny. By PD 70, the density 
of 5-HT uptake sites was similar between saline and fluoxetine-exposed offspring across all brain regions examined. 5-HT uptake 
sites were labelled with 0.7 nM [3H]citalopram. Nonspecific binding was determined in the presence of 1 µM paroxetine. 
Quantification of autoradiograms was performed using computerized digital image analysis as described in Materials and Methods. 
Anatomical abbreviations are described in Table 10. Data were analyzed using a two-way ANOVA followed by a Newman-Keuls 
post hoc test. *Significantly different from the respective control values in prepubescent progeny (p<0.05). t Significantly 
different than the respective values in prepubescent offspring (p < 0.05). 
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Figure 11 . Representative brain regions of control progeny in which the density of 
[ 3 HJcitalopram-labelled 5-HT uptake sites either increased, decreased or remained 
constant as a consequence of maturation. Data are expressed as fmol of sites/mg 
tissue equivalent (fmol/mg TE) and represent the means ± SEM from 4-5 control rats 
with each rat within a group being obtained from a different litter. Adult (PD 70) 
control progeny exhibited a significantly greater density of 5-HT uptake sites in Cg3 
(A; + 33%), CA 1 (f!; + 78%) and BLAMY (C; + 58%) than their prepubescent 
counterparts. The density of 5-HT uptake sites was similar in prepubescent and adult 
control progeny in Fr2 (D), CAMY (~) and LH (f). In contrast, the density of 5-HT 
uptake sites was significantly lower in adult progeny in Te1 (G; -65%), SN (H; -26%) 
and VTA (l; -31 %). 5-HT uptake sites were labelled with 0.7 nM [3H]citalopram. 
Nonspecific binding was determined in the presence of 1 µM paroxetine. Data were 
obtained via the quantification of autoradiograms which was performed using 
computerized digital image analysis as described in Materials and Methods. 
Anatomical abbreviations are described in Table 10. Data were analyzed as in Table 
11 using a two-way ANOVA followed by a Newman Keuls post-hoc test. 
*Significantly different from prepubescent (PD 28) values (p < 0.05). 
Prenatal Fluoxetine Exposure Produces Site-Specific 
Alterations in the Density of 5-HT iA Receptors 
93 
Site-specific alterations in brain 5-HT1A receptors in prepubescent and adult 
progeny prenatally exposed to fluoxetine are shown in Table 12 and illustrated in 
Figure 12. In contrast to the numerous alterations in 5-HT uptake sites observed 
in fluoxetine-exposed offspring, the density of 5-HT1A receptors was only minimally 
affected by the prenatal treatment. In prepubescent progeny, the density of 5-
HT1A receptors was significantly increased only in the paraventricular nucleus of 
the hypothalamus (PVN; + 26%; p < 0.05) and in the entorhinal cortex (Ent; 
+42%; p<0.05) of fluoxetine-exposed offspring. 5-HT 1A receptor density was 
comparable in control and fluoxetine-exposed prepubescent offspring in all other 
cortical (Par1, RSG, Fr2, and Cg3) and hypothalamic (AHC, OM, LH, VMH) areas 
examined. Likewise, prepubescent progeny did not exhibit any alterations in the 
density of 5-HT1A receptors in any of the subregions of the hippocampus, septum, 
tegmentum, or basal ganglia examined in the present study. In addition, the 
density of 5-HT,A receptors was not altered in either the dorsal or median raphe 
nuclei at PD 28. 
In contrast to the increase in 5-HT,A receptor density observed in the 
paraventricular nucleus and in the entorhinal cortex in prepubescent progeny, in 
adult progeny, the density of 5-HT 1A receptors in these two brain regions was 
similar between treatment groups. However, the density of 5-HT 1A receptors in 
the ventromedial hypothalamus (VMH) was significantly reduced (-33%) in adult 
progeny prenatally exposed to fluoxetine. In contrast, at PD 70, the density of 5-
HT1A receptors was not altered by prenatal fluoxetine exposure in any other 
subregion of the hypothalamus examined (AHC, OM, LH, PVN). Likewise, no 
alterations in 5-HT1A receptor density were observed in adult progeny as a 
consequence of prenatal fluoxetine exposure in the hippocampus, septum, 
caudate, or midbrain raphe nuclei. 
Changes in the Density of 5-HT 1A Receptors as a Consequence of Maturation 
94 
Several brain regions exhibited differences in the density of 5-HT1A 
receptors as consequence of maturation, with a majority of the changes being a 
reduction in 5-HT1A receptors as the animals mature (Fig. 13 and Table 12). For 
example, the density of 5-HT1A receptors was significantly lower in the caudate 
putamen (-45%) and in subregions of the cortex (-56 to -65%), septum (-41 to -
43%) and hypothalamus (-49 to -60%; Table 12) in adult control progeny in 
comparison to their prepubescent counterparts. In contrast, in one subregion of 
the hypothalamus, the ventromedial nucleus, the density of 5-HT1A receptors was 
significantly greater ( + 32%) in adult control progeny than in the prepubescent 
animals. No significant alterations were observed in 5-HT1A receptor density as a 
consequence of maturation in either the hippocampus or raphe nuclei. 
D. 95 
E. 
F. 
Figure 12. Representative autoradiograms and figures illustrating the effect of 
prenatal f/uoxetine exposure on f1HJB-OH-DPA T-labelled 5-HT,A receptors. The 
1 autoradiograms shown are representative of [3H]8-0H-OPAT binding in control 
' prepubescent (A, f!) and adult (C) progeny. White areas indicate brain regions with 
' a high density of 5-HT uptake sites. The panels on the right are diagramatic 
representations of the results from densitometric analysis of autoradiograms taken 
from prepubescent (0, £) and adult (f) progeny prenatally exposed to fluoxetine. 
\I Prenatal exposure to fluoxetine significantly elevated (shaded red) 5-HT1A receptors 
in the PVN (0) and in the Ent (E) in prepubescent offspring. In adult offspring, 5-HT1A 
1 receptors were significantly reduced (shaded blue) in the VMH (F) following prenatal 
exposure to fluoxetine. 5-HT1A receptors were labelled with 2 nM [3H]8-0ti-OPAT. 
Nonspecific binding was determined in the presence of 1 µM 5-HT. Abbreviations are 
described in Table 10 and in the legend to Figure 1. 
TABLE 12 
THE DENSITY OF [3H]8-0H-DPAT-LABELLED 5-HT,A RECEPTORS IN PREPUBESCENT AND ADULT OFFSPRING 
Prepubescent Progeny Adult Progeny 
Brain Region Saline (N) Fluoxetine (N) Saline (N) Fluoxetine (N) 
TelenceQhalon 
Cortex 
Cg3 30.7 ± 2.6 (5) 37.8 ± 3.4 (5) 24.0 ± 2.1 (5) 20.2 ± 1.7t (5) 
Fr2 26.9 ± 4.0 (5) 33.6 ± 4.2 (5) 20.1 ± 1.6 (5) 16.7 ± 1.7t (5) 
Ent 73.0 ± 8.5 (5) 104.2 ± 6.3 * (5) 66.4 ± 4.7 (5) 68.0 ± 9.6t (4) 
Par1 33.8 ± 0.8 (3) 34.6 ± 2.6 (5) 11.9 ± 1.3t (5) 10.1 ± 1.2t (5) 
RSG 9.7 ± 1.1 (4) 9.0 ± 0.6 (5) 4.2 ± 0.3t (5) 4.1 ± 0.1 t (5) 
Hippocampus 
CA1 69.8±4.1 (4) 66.1 ±4.6 (5) 65.8 ± 5.3 (5) 64.7 ± 7.6 (5) 
CA2 12.1 ± 2.2 (4) 9.9 ± 1.8 (5) 7.8 ± 0.5 (5) 6.9 ± 0.8 (5) 
CA3 51.6 ± 7.8 (4) 44.2 ± 7.8 (5) 31.7±1.5 (4) 27.2 ± 3.4 (5) 
DG 87.5 ± 1.7 (4) 92.2 ± 3.2 (5) 85.0 ± 4.3 (5) 82.8 ± 4.8 (3) 
Septum 
LSD 87.9 ± 5.4 (5) 83.9 ± 2.8 (5) 52.1 ± 4.0t (4) 51.0 ± 6.4t (5) 
LSI 86.3 ± 3.0 (5) 92.0 ± 2.8 (5) 49.3 ± 4.2t (5) 47.1 ± 3.2t (4) 
Caudate 
Cpu 1.1 ± 0.2 (6) 1.4 ± 0.1 (5) o.6 ± o.2t (4) o.5 ± o.2t (3) 
1 AtsLt:. 1 ;;!. l;ontinued 
Prepubescent Progeny Adult Progeny 
Brain Region Saline (N) Fluoxetine (N) Saline (N) Fluoxetine (N) 
DienceQhalon 
Hypothalamus 
AHC 17.9 ± 1.1 (4) 17.5 ± 1.3 (5) 9.14±0.5t (5) 8.1 ± o.8t (5) 
DM 5.6 ± 0.4 (6) 6.2 ± 1.0 (5) 5.6 ± 0.8 (5) 4.5 ± 0.3 (5) 
LH 10.7 ± 1.1 (4) 10.1 ±0.7 (5) 4.3 ± 0.3t (5) 4.1 ± o.2t (5) 
PVN 9.8 ± 1.0 (6) 12.3±0.7* (5) 1.2 ± o.2t (5) 6.4 ± 0.5t (5) 
VMH 22.7 ± 1.7 (4) 21.4 ± 1.9 (5) 29.9 ± 2.8t (4) 20.0 ± 2.2 * (5) 
Raphe Nuclei 
DR 75.6 ± 2.2 (5) 83.8 ± 2.4 (5) 67.2 ± 6.4 (5) 69.0 ± 5.5 (5) 
MnR 35.8 ± 5.5 (5) 37.4 ± 4.5 (5) 28.2±4.1 (5) 21.8 ± 3.9 (5) 
Data are expressed as fmol of sites/mg tissue equivalent and represent the means ± SEM from 3-6 rats per group with each rat 
within a group being obtained from a different litter. The number of rats per group is shown in parentheses. Prenatal exposure 
to fluoxetine (10 mg/kg/2ml, s.c., to dams from GD 13-20) significantly increased the density of 5-HT,A receptors in Ent ( + 42%) 
and PVN ( + 26%) in prepubescent progeny. 5-HT 1A receptors were significantly reduced in VMH (-33%) in fluoxetine-exposed 
adult progeny. 5-HT,A receptors were labelled with 2.0 nM [3HJ8-0H-DPAT. Nonspecific binding was determined in the presence 
of 1 µM 5-HT. Quantification of autoradiograms was performed using computerized digital image analysis as described in 
Materials and Methods. Anatomical abbreviations are described in Table 10. Data were analyzed using a two-way ANOVA 
followed by a Newman-Keuls post hoc test. *Significantly different from the respective age-matched control values (p<0.05). 
t Significantly different from the respective values in prepubescent offspring (p<0.05). 
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Figure 13. Representative brain regions of control progeny in which the density of 
r3HJ8-0H-DPA T labelled 5-HT7A receptors either increased, decreased or remained 
constant as a consequence of maturation. Data are expressed as fmol of sites/mg 
tissue equivalent {fmol/mg TE) and represent the means ± SEM from 3-5 control rats 
with each rat within a group being obtained from a different litter. Adult {PD 70) 
control progeny exhibited a significantly lower density of 5-HT,A receptors in Par1 {A; 
-65%), RSG {];!; -49%), LSI {C; -43%), AHC {D; -49%), LH (£; -60%) and LSD (f; -
41 %) than their prepubescent counterparts. In contrast, the density of 5-HT,A 
receptors was significantly greater in adult progeny in VMH (G; + 32%). The density 
of 5-HT,A receptors was similar in prepubescent and adult control progeny in MnR (H) 
and CA 1 {!). 5-HT,A receptors were labelled with 2.0 nM [3H]8-0H-DPAT. Nonspecific 
binding was determined in the presence of 1 µM 5-HT. Data were obtained via the 
quantification of autoradiograms which was performed using computerized digital 
image analysis as described in Materials and Methods. Anatomical abbreviations are 
described in Table 10. Data were analyzed as in Table 12 using a two-way ANOVA 
followed by a Newman Keuls post-hoc test. *Significantly different from prepubescent 
(PD 28) values (p<0.05). 
Prenatal Fluoxetine Exposure Produces Site-Specific Alterations 
in the Density of [3HJKetanserin-Labelled 5-HT 2A Receptors 
99 
In contrast to the minimal perturbation in the density of 5-HT1A receptors 
reported above, a number of site-specific alterations were observed in the density 
of [3H]ketanserin-labelled 5-HT 2A receptors in both prepubescent and adult progeny 
prenatally exposed to fluoxetine (Table 13 and Fig. 14). 
Telencephalon 
The site-specific and age-dependent alterations in the density of 
[ 3H]ketanserin-labelled 5-HT 2A receptors in telencephaloic brain regions are reported 
in Table 13. 5-HT 2A receptors were significantly elevated in the ventral pallidum 
(VP; + 78%), and the dorsolateral septal nucleus (LSD; + 81 %) in prepubescent 
progeny prenatally exposed to fluoxetine (Table 13). In contrast, prenatal 
fluoxetine exposure did not alter the density of 5-HT 2A receptors in any other 
subregion of the basal ganglia [e.g. globus pallidus (GP) and caudate putamen 
(CPu)], or amygdala [basolteral (BLAMY), central (CAMY) and medial (MAMY) 
nuclei] examined in prepubescent offspring. Likewise, in prepubescent offspirng, 
[ 3H]ketanserin-labelled 5-HT 2A receptor density was not affected by prenatal 
fluoxetine exposure in any of the subregions of the cortex [cingulate (Cg3), frontal 
(Fr2), entorhinal (Ent), occipital (0c2L), parietal (Par1), retrosplenial granular (RSG), 
temporal (Te1 )] or hippocampus [CA3 and dentate gyrus (DG)] examined in the 
present study. [3HJKetanserin-labelled 5-HT 2A receptors were undetectable in the 
CA 1 and CA2 areas of the hippocampus. In contrast, in adult offspring, prenatal 
fluoxetine exposure significantly increased the density of 5-HT 2A receptors in the 
entorhinal cortex (Ent; + 70%), dentate gyrus (DG; + 71 %) and basolateral 
100 
amygdala (BLAMY; +48%). However, 5-HT2A receptors were significantly 
reduced in the globus pallidus (GP; -70%) in adult fluoxetine-exposed offspring. 
No other alterations in [3H]ketanserin-labelled 5-HT 2A receptors were observed in 
telencephalic brain regions in adult progeny of fluoxetine-treated dams. 
Diencephalon and Mesencephalon 
Site-specific and age-dependent alerations in [3H]ketanserin labelled 5-HT 2A 
receptors in diencephalic and mesencephalic brain regions are shown in Table 13. 
In prepubescent offspring, a significant increase in the density of 5-HT2A receptors 
was observed in the medial preoptic area (MPA; + 41 %) of the hypothalamus 
following prenatal exposure to fluoxetine. In addition, in prepubescent progeny, 
prenatal fluoxetine exposure also resulted in a significant reduction in the density 
of [3H]ketanserin-labelled 5-HT2A receptors in the lateral hypothalamus (LH; -38%). 
[ 3H]ketanserin-labelled 5-HT2A receptors were not altered in any other subregion of 
the hypothalamus examined in prepubescent progeny [anterior (AHC) and 
dorsomedial (DM) areas; medial mammillary (MM), paraventricular (PVN) and 
ventromedial (VMH) nuclei]. In contrast, in adult offspring, the paraventricular 
nucleus of the hypothalamus (PVN) was the only subregion of the hypothalamus 
examined that was affected (91 % increase) by prenatal fluoxetine-exposure. No 
alterations in the density of [3H]ketanserin-labelled 5-HT2A receptors were observed 
in the substantia nigra (SN), ventral tegmental area (VT A) or in midbrain raphe 
nuclei [dorsal (DR) and median (MnR)] in either prepubescent or adult progeny 
prenatally exposed to fluoxetine. 
Changes in the Density of [3HJKetanserin-Labelled 
5-HT 2A Receptors as a Consequence of Maturation 
101 
In contrast to the numerous differences observed between prepubescent 
and adult control progeny in the density of 5-HT uptake sites and 5-HT1A receptors, 
minimal changes were observed in 5-HT 2A receptors as a consequence of 
maturation. As illustrated in Figure 15, 5-HT 2A receptor density was significantly 
greater in adult control progeny in the dorsomedial hypothalamus {DM; + 76%) and 
in the basolateral amygdala {BLAMY; + 136%) than in their prepubescent 
counterparts. In addition, 5-HT 2A receptors were significantly lower in the lateral 
hypothalamus {LH; -57%) of adult progeny in comparison to prepubescent animals. 
In all other brain regions examined, the density of 5-HT 2A receptors were 
comparable in control prepubescent and adult progeny. 
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D. 
E. 
F. 
Figure 14. Representative autoradiograms and figures illustrating the effect of 
prenatal fluoxetine exposure on [ 3HJketanserin-labelled 5-HT 2A receptors. The 
autoradiograms shown are representative of [3H]ketanserin binding in control 
prepubescent (A) and adult (.6., ~) progeny. White areas indicate brain regions with 
a high density of 5-HT 2A receptors. The panels on the right are diagrammatic 
representations of the results of significant receptor changes from densitometric 
analysis of autoradiograms taken from prepubescent (D) and adult (£, .El progeny 
prenatally exposed to fluoxetine. Prenatal exposure to fluoxetine significantly elevated 
(shaded red) 5-HT 2A receptors in the MPA and VP (0) in prepubescent offspring. In 
adult offspring, 5-HT 2A receptors were significantly elevated (shaded red) in the PVN 
(E), CA3, and BLAMY (F) following prenatal exposure to fluoxetine. 5-HT2A receptors 
were labelled with 0.4 nM [3H]ketanserin in the presence of 30 nM prazosin. 
Nonspecific binding was determined in the presence of 1 µM cinanserin. 
Abbreviations are described in Table 10 and in the legend to Figure 1. 
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TABLE 13 
THE DENSITY OF [3H]KETANSERIN-LABELLED 5-HT2A RECEPTORS IN PREPUBESCENT AND ADULT OFFSPRING 
Prepubescent Progeny Adult Progeny 
Brain Region Saline (N) Fluoxetine (N) Saline (N) Fluoxetine 
Telence~halon 
Cortex 
Cg3 50.1 ± 13.1 (6) 58.6 ± 15.9 (5) 52.2 ± 3.9 (5) 66.0 ± 11.8 
Fr2 16.7 ± 3.3 (6) 10.3 ± 1.5 (4) 27.8 ± 5.8 (5) 25.0 ± 5.2 
Ent 16.1 ± 2.8 (6) 18.5 ± 4.2 (4) 21.6 ± 2.2 (4) 36.8 ± 3.7 * 
Oc2L 9.4 ± 2.4 (5) 9.3 ± 3.5 (4) 6.2 ± 0.9 (5) 9.6 ± 1.9 
Par1 26.5 ± 3.0 (6) 26.4 ± 3.6 (5) 25.6 ± 1.8 (4) 23.6 ± 0.9 
RSG 7.9 ± 1.8 (6) 10.6 ± 0.9 (4) 10.5 ± 0.4 (3) 6.1 ± 0.9 
Te1 12.0 ± 2.6 (6) 14.7 ± 3.4 (5) 13.0 ± 2.2 (5) 17.9 ± 3.4 
Hippocampus 
CA3 4.5 ± 1.1 (5) 7.9 ± 3.4 (3) 5.0 ± 0.8 (5) 10.1 ± 1.9 
DG 9.6 ± 2.2 (4) 11.5 ± 2.3 (4) 12.9 ± 1.8 (5) 22.1 ± 3.9 * 
Septum 
LSD 15.1 ± 3.9 (6) 27.3 ± 5.1 * (4) 10.3 ± 4.0 (4) 7.6 ± 3.1t 
LSI 15.3 ± 1.2 (5) 18.6 ± 3.4 (5) 8.7 ± 1.0 (5) 13.0 ± 1.2 
(N) 
(6) 
(6) 
(5) 
(5) 
(5) 
(4) 
(6) 
(5) 
(6) 
(4) 
(5) 
0 
w 
TABLE 13 Continued 
Prepubescent Progeny Adult Progeny 
Brain Region Saline (N) Fluoxetine (N) Saline (N) Fluoxetine (N) 
Amygdala 
BLAMY 11.9 ± 3.3 (6) 17.0 ± 5.0 (4) 28.1 ± 2.ot (5) 41.6 ± 3.9 * (5) 
CAMY 7.8 ± 2.5 (4) 9.7 ± 1.0 (3) 12.1 ± 1. 1 (4) 18.8 ± 4.6 (4) 
MAMY 10.9 ± 2.6 (5) 14.0 ± 3.9 (4) 18.0 ± 2.8 (5) 25.1 ± 1.9t (5) 
Basal Ganglia 
CPu 53.3 ± 7.4 (6) 93.3 ± 15.7 (5) 78.1 ± 9.5 (5) 82.3 ± 7.1 (6) 
GP 8.4 ± 1.8 (5) 9.2 ± 1.4 (4) 10.3 ± 2.1 (4) 3.1 ± 0.5*t (6) 
VP 13.4 ± 4.2 (4) 23.9 ± 3.1 * (4) 8.7 ± 1.3 (3) 8.7 ± 1.1t (6) 
Dience(2halon 
Hypothalamus 
AHC 19.2 ± 1.8 (6) 18.4 ± 1 .2 (4) 17.6±3.6 (4) 22.8 ± 2.0 (6) 
DM 23.3 ± 4.3 (6) 23.1 ± 2.8 (5) 41.1 ± 6.1 t (5) 53.3 ± 5.5 (6) 
LH 19.9 ± 1.4 (5) 12.4 ± 0.5 * (4) 8.5 ± 1.9t (4) 11.8 ± 1.3 (5) 
MM 111.1 ± 5.7 (5) 168.1 ± 11.5 (3) 152.0 ± 24.4 (3) 225.6 ± 59.9 (4) 
MPA 22.9 ± 3.0 (4) 32.3 ± 3.8 * (4) 19.2 ± 1.4 (4) 22.9 ± 1.7t (5) 
PVN 28.1 ± 2.1 (5) 25.1 ± 2.8 (5) 20.4 ± 3.4 (4) 39.0 ± 4.0*t (5) 
VMH 36.2 ± 5.5 (6) 31.1 ± 7.4 (5) 22.1 ± 2.3 (5) 30.9 ± 4.3 (6) 
TABLE 13 Continued 
Prepubescent Progeny Adult Progeny 
Brain Region Saline (N) Fluoxetine (N) Saline (N) Fluoxetine (N) 
Mesence(2halon 
Tegmentum 
SN 10.6 ± 2.5 (6) 11.8 ± 4.9 (5) 8.5 ± 1.2 (4) 5.7 ± 0.9 (6) 
VTA 39.9 ± 12.3 (6) 23.5 ± 5.4 (4) 22.8 ± 3.3 (5) 31.3 ± 2.2 (6) 
Raphe Nuclei 
DR 27.0 ± 5.3 (4) 44.0 ± 3.6 (4) 42.8 ± 7.3 (4) 54.9 ± 9.0 (4) 
MnR 16.6 ± 3.7 (4) 21.2 ± 2.8 (4) 16.7 ± 3.0 (5) 13.9 ± 3.1 (4) 
Data are expressed as fmol of sites/mg tissue equivalent and represent the means ± SEM from 3-6 rats per group with each rat 
within a group being obtained from a different litter. The number of rats per group is shown in parentheses. Prenatal exposure 
to fluoxetine significantly increased the density of [3H]ketanserin-labelled 5-HT 2A receptors in LSD ( + 81 %), MPA ( + 41 %), and 
VP ( + 78%) in prepubescent offspring. In addition, at PD 28, 5-HT2A receptors were significantly reduced in the LH (-38%) 
following prenatal exposure to fluoxetine. In adult progeny, prenatal fluoxetine exposure produced a significant increase in 5-HT 2A 
receptors in the Ent ( + 70 % l, DG ( + 71 % l, PVN ( + 91 % ) and BLAMY ( + 48 % l. 5-HT 2A receptors were significantly reduced in 
the GP (-70%) in adult fluoxetine-exposed progeny. 5-HT 2A receptors were labelled with 0.4 nM [3H]ketanserin in the presence 
of 30 nM prazosin. Nonspecific binding was determined in the presence of 1 µM cinanserin. Data are extrapolated to 100% 
fractional occupancy using the experimentally determined Kd value of 2.57 nM from saturation studies in slide mounted sections 
of frontal cortex. 5-HT 2A receptors were undetectable in the CA 1 and CA2 areas of the hippocampus, and in the arcuate nucleus 
of the hypothalamus. Quantification of autoradiograms was performed using computerized digital image analysis as described 
in Materials and Methods. Anatomical terminology is described in Table 1. Data were analyzed using a two-way ANOVA followed 
by a Newman-Keuls post hoc test. *Significantly different from the respective age-matched control values (p<0.05). t 
Significantly different from the respective values in prepubescent offspring (p<0.05). 
0 
O'I 
106 
OM 40 8. BLAMY 24 C. LH 50 
30 * 20 w 40 I- 16 E 30 20 12 
-.... 20 0 8 E 10 10 
- 4 
0 0 0 
D. Cg3 E. CA3 24 
w 60 6 20 I-
O> 16 E 40 4 
-.... 12 
0 
E 20 2 8 
- 4 
0 0 0 
PD28 PD70 PD28 PD70 PD28 PD70 
Figure 15. Representative brain regions of control offspring in which the density of 
[ 3H]ketanserin-labelled 5-HT 2A receptors either increased, decreased or remained 
constant as a consequence of maturation. Data are expressed as fmol of sites/mg 
tissue equivalent (fmol/mg TE) and represent the means ± SEM from 4-6 control rats 
with each rat within a group being obtained from a different litter. Adult (PD 70) 
control progeny exhibited a significantly greater density of 5-HT 2A receptors in DM (A; 
+ 76%) and BLAMY (!!; + 36%) than their prepubescent counterparts. In contrast, 
the density of 5-HT 2A receptors was significantly lower in adult progeny in LH (C; -
43%). The density of 5-HT2A receptors was similar in prepubescent and adult control 
progeny in CA3 (!;) and MPA (f). 5-HT2A receptors were labelled with 0.4 nM 
[ 3H]ketanserin in the presence of 30 nM prazosin. Nonspecific binding was determined 
in the presence of 1 µM cinanserin. Data were obtained via the quantification of 
autoradiograms which was performed using computerized digital image analysis as 
described in Materials and Methods. Data are extrapolated to 100% fractional 
occupancy using the experimentally determined Kd value of 2.57 nM. Anatomical 
abbreviations are described in Table 10. Data were analyzed as in Table 13 using a 
two-way ANOVA followed by a Newman Keuls post-hoc test. *Significantly different 
from prepubescent (PD 28) values (p < 0.05). 
Prenatal Fluoxetine Exposure Produces Site-Specific Alterations 
in the Density of [12511001-Labelled High Affinity 5-HT 2A Receptors 
Telencephalon 
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Site-specific alterations in the density of high affinity 5-HT 2A receptors were 
observed following prenatal exposure to fluoxetine are shown in Table 14 and 
illustrated in Figure 16. Similar to observations made regarding [3H]ketanserin 
labelled 5-HT 2A receptors, high affinity 5-HT 2A receptors were not altered by 
prenatal fluoxetine exposure in the subregions of the cortex [cingulate (Cg3), 
frontal (Fr2), entorhinal (Ent), occipital (0c2L), parietal (Par1 ), retrosplenial granular 
(RSG), and temporal (Te1 )] and hippocampus [CA 1, CA2, CA3, and dentate gyrus 
(DG)J examined in prepubescent progeny. However, prenatal fluoxetine exposure 
resulted in a 6-fold increase in the density of 5-HT 2A receptors in the caudate 
putamen (CPu) of prepubescent rats. No other alterations in the density of high 
affinity 5-HT 2A receptors were observed in telencephalic areas in prepubescent 
progeny. In adult progeny exposed to fluoxetine, the density of 5-HT 2A receptors 
was significantly elevated in the basolateral amygdala (BLAMY; + 109), the 
dorsolateral septal nucleus (LSD; + 306%), and in the CA3 region of the 
hippocampus ( + 118%). Similar to prepubescent progeny, prenatal exposure to 
fluoxetine did not alter the density of the high affinity 5-HT 2A receptors in any of 
the cortical areas examined (Table 14). 
Diencephalon and Mesencephalon 
In contrast to the alterations observed in the density of [3H]ketanserin 
labelled 5-HT 2A receptors in the hypothalamus, high affinity 5-HT 2A receptors were 
not altered in any of the subregions of the hypothalamus examined in 
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prepubescent progeny prenatally exposed to fluoxetine. In adult progeny, high 
affinity 5-HT 2A receptors were significantly elevated only in the medial mammillary 
nucleus {MM; + 73%) of the hypothalamus following prenatal exposure to 
fluoxetine. Prenatal exposure to fluoxetine did not alter the density of 5-HT 2A 
receptors in the tegmentum regardless of the age of the offspring. 
Changes in the Density of [12511001-Labelled 
5-HT 2A Receptors as a Consequence of Maturation 
In contrast to the minimal effects of maturation on [3H]ketanserin- labelled 
5-HT 2A receptors (i.e. the total population) in control progeny, a greater number of 
differences were observed in the density of high affinity 5-HT 2A receptors as a 
consequence of maturation (Fig. 17, Table 14). 5-HT2A receptors were 
significantly lower in adult control progeny than in their prepubescent counterparts 
in the occipital (Oc2L; -59%), parietal (Par1; -71 %) and retrosplenial granular 
(RSG; -43%) areas of the cortex, areas which exhibited no maturation effects on 
[ 3H]ketanserin binding. 5-HT 2A receptors were also significantly lower in the medial 
preoptic area (MPA; -58%) in adult control progeny versus the prepubescent 
group. In contrast, 5-HT 2A receptors were significantly greater in adult progeny 
than in prepubescent progeny in the caudate putamen (CPu; + 371 %) and in the 
anterior (AHC; + 111 %), arcuate (Arc; +482%) and dorsomedial (DM; + 70%) 
nuclei of the hypothalamus. 
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c. 
D. 
Figure 16. Representative autoradiograms and figures illustrating the effect of 
prenatal f/uoxetine exposure on f 25/JDO/-labelled high affinity 5-HT 2A receptors. 
The autoradiograms shown are representative of [1251)001 binding in control 
prepubescent (A) and adult (.6.) progeny. White areas indicate brain regions with a 
high density of 5-HT uptake sites. The panels on the right are diagrammatic 
representations of the results from densitometric analysis of autoradiograms taken 
from prepubescent (,~) and adult (0) progeny prenatally exposed to fluoxetine. 
Prenatal exposure to fluoxetine significantly increased (shaded red) the number of 
high affinity 5-HT2A receptors in the CPu (C) in prepubescent offspring. In adult 
offspring, high affinity 5-HT2A receptors were significantly elevated (shaded red) in 
CA3 and BLAMY (0) following prenatal exposure to fluoxetine . High Affinity 5-
HT2A receptors were labelled with 0.2 nM [1251)001. Nonspecific binding was 
determined in the presence of 100 nM spiperone to preclude binding to 5-HT 2c 
receptors. Abbreviations are described in Table 10 and in the legend to Figure 1. 
TABLE 14 
THE DENSITY OF HIGH AFFINITY [1251]001-LABELLED 5-HT2A RECEPTORS IN PREPUBESCENT AND ADULT OFFSPRING 
Prepubescent Progeny Adult Progeny 
Brain Region Saline (N) Fluoxetine (N) Saline (N) Fluoxetine (N) 
TelenceQhalon 
Cortex 
Cg3 6.02 ± 0.56 (5) 5.27 ± 0.23 (5) 5.20 ± 0.91 (5) 6.19 ± 0.32 (6) 
Fr2 6.28 ± 0.59 (6) 5.70 ± 0.45 (5) 4.90 ± 0.61 (5) 6.55 ± 0.75 (5) 
Ent 1.25 ± 0.13 (6) 1.34 ± 0.40 (4) 3.28 ± 0.24 (5) 4.09 ± 0.94 (6) 
Oc2L 2.95 ± 0.38 (6) 2.53 ± 0.53 (5) 1.21 ± 0.33t (5) 1.69 ± 0.26 (6) 
Par1 17.18 ± 1.67 (6) 16.09 ± 1.24 (5) 4.99 ± 0.71 t (5) 7.26 ± 1.53t (5) 
RSG 2.14±0.24 (6) 2.37 ± 0.45 (5) 1.21 ± 0.23t (5) 1.15 ± 0.25 (4) 
Te1 6.14±0.99 (6) 4.52 ± 0.72 (5) 3.72 ± 0.60 (5) 5.40 ± 0.91 (6) 
Hippocampus 
CA1 0.20 ± 0.03 (6) 0.38 ± 0.08 (4) 0.41 ± 0.15 (3) 0.66±0.14 (5) 
CA2 0.60 ± 0.21 (6) 0.57 ± 0.12 (5) 0.41 ± 0.22 (4) 0.95 ± 0.22 (5) 
CA3 0.45 ± 0.02 (5) 0.66 ± 0.13 (5) 0.57 ± 0.10 (4) 1.24 ± 0.27* (6) 
DG 0.43 ± 0.09 (5) 0.58 ± 0.22 (5) 0.44 ± 0.08 (4) 1.00 ± 0.22 (6) 
Septum 
LSD 0.48 ± 0.16 (5) 0.48 ± 0.13 (5) 0.18 ± 0.03 (4) 0.73 ± 0.13* (6) 
LSI 0.49 ± 0.12 (5) 0.47 ± 0.04 (5) 0.79 ± 0.18 (5) 1.19 ± 0.28 (6) 
0 
TABLE 14 Continued 
Prepubescent Progeny Adult Progeny 
Brain Region Saline (N) Fluoxetine (N) Saline (N) Fluoxetine (N) 
Amygdala 
BLAMY 4.47 ± 0.38 (6) 3.53 ± 0.27 (5) 5.74 ± 0.87 (5) 12.00 ± 1.03*t (6) 
CAMY 0.68 ± 0.11 (6) 0.96 ± 0.25 (5) 0.91 ± 0.22 (4) 1.41 ±0.23 (6) 
MAMY 3.66 ± 0.47 (6) 3.09 ± 0.29 (5) 2.16 ± 0.20 (4) 3.32 ± 0.46 (6) 
Basal Ganglia 
CPu 0.51 ± 0.20 (5) 3.06 ± 0.16* (5) 2.40 ± 0.14t (4) 2.96 ± 0.82 (6) 
GP 0.33 ± 0.07 (6) 0.24±0.10 (5) nd nd 
VP 0.63 ± 0.07 (6) 0.62 ± 0.12 (5) nd nd 
Dience12halon 
Hypothalamus 
AHC 1.69 ± 0.24 (6) 1.97 ± 0.78 (3) 3.56 ± 0.30t (6) 3.42 ± 0.31 t (5) 
Arc 0.28 ± 0.03 (4) 0.38 ± 0.05 (5) 1.63 ± 0.41 t (4) 1.16 ± 0.38 (6) 
DM 1.12 ± 0.27 (6) 0.70 ± 0.04 (4) 1.90 ± 0.26t (5) 2.11 ± o.18t (5) 
LH 2.25 ± 0.17 (5) 2.04 ± 0.20 (5) 2.08 ± 0.28 (5) 2.60 ± 0.37 (5) 
MM 17.27 ± 1.34 (6) 17.99 ± 1.34 (4) 17.46 ± 3.10 (4) 30.19 ± 3.65*t (4) 
MPA 1.50 ± 0.25 (6) 1.44 ± 0.11 (4) 0.63 ± 0.04t (5) 0.68 ± 0.17t (6) 
PVN 1.33 ± 0.16 (5) 1.81 ± 0.48 (5) 1.02 ± 0.25 (4) 1.27 ± 0.22 (3) 
VMH 5.61 ± 0.63 (6) 4.71 ± 0.53 (5) 4.58 ± 1.02 (5) 5.29 ± 0.69 (6) 
TABLE 14 Continued 
Prepubescent Progeny Adult Progeny 
Brain Region Saline (N) Fluoxetine (N) Saline (N) Fluoxetine (N) 
Mesenceghalon 
Tegmentum 
SN 0.30 ± 0.05 (6) 0.19 ± 0.04 (4) 0.59 ± 0.07 (5) 0.96 ± 0.35 (5) 
VTA 1.43 ± 0.31 (6) 2.01 ± 0.36 (5) 1.35 ± 0.12 (5) 2.06 ± 0.26 (5) 
Data are expressed as fmol of sites/mg tissue equivalent and represent the means ± SEM from 3-6 rats per group with each rat 
within a group being obtained from a different litter. The number of rats per group is shown in parentheses. Prenatal exposure 
to fluoxetine ( 10 mg/kg/2ml, s.c., to dams from GD 13-20) significantly increased the density of high affinity 5-HT zA receptors 
in CPu ( + 500%) in prepubescent progeny. In adult progeny, 5-HT2A receptors were significantly elevated in CA3 ( + 118%), MM ( + 73%), BLAMY ( + 109%), and LSD ( + 300%). High affinity 5-HT2A receptors were labelled with 0.2 nM [12511001. Nonspecific 
binding was determined in the presence of 100 nM spiperone to preclude binding to 5-HT zc receptors. Quantification of 
autoradiograms was performed using computerized digital image analysis as described in Materials and Methods. Data are 
extrapolated to 100% fractional occupancy using the experimentally determined Kd value of 0.68 nM for prepubescent and 1. 74 
nM for adult progeny. Anatomical abbreviations are described in Table 10. High affinity 5-HT zA receptors were undetectable in 
the raphe nuclei and in the GP and VP only in adult progeny. Therefore, in the GP and VP, prepubescent data were analyzed by 
a Students' t-test. All other data were analyzed using a two-way ANOVA followed by a Newman-Keuls post hoc test. 
*Significantly different from the respective age-matched control values (p<0.05). t Significantly different from the respective 
values in prepubescent offspring (p < 0.05). nd indicates not determined. 
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Figure 17. Representative brain regions of control progeny in which the density of 
high affinity f 25/JDOJ-labelled 5-HT 2A receptors either increased, decreased or remained 
constant as a consequence of maturation. Data are expressed as fmol of sites/mg 
tissue equivalent (fmol/mg TE) and represent the means ± SEM from 4-6 control rats 
with each rat within a group being obtained from a different litter. Adult (PD 70) 
control progeny exhibited a significantly lower density of 5-HT2A receptors in Oc2L (A; 
-59%), Par1 (~; -71 %) and MPA (C; -58%) than their prepubescent counterparts. The 
density of 5-HT 2A receptors was similar in prepubescent and adult control progeny in 
MM (D), VTA (~)and BLAMY (f). In contrast, the density of 5-HT2A receptors was 
significantly greater in adult progeny in CPU (G; + 371 %), AHC (H; + 111 %), and Arc 
(l; +482%) than in prepubescent offspring. High affinity 5-HT2A receptors were 
labelled with 0.2 nM [1251JDOI. Nonspecific binding was determined in the presence 
of 100 nM spiperone to preclude binding to 5-HT 2c receptors. Data were obtained via 
the quantification of autoradiograms which was performed using computerized digital 
image analysis as described in Materials and Methods. Data are extrapolated to 100% 
fractional occupancy using the experimentally determined Kd value of 0.68 nM for 
prepubescent and 1. 74 nM for adult offspring. Anatomical abbreviations are described 
in Table 10. Data were analyzed as in Table 14 using a two-way ANOVA followed 
by a Newman Keuls post-hoc test. *Significantly different from prepubescent (PD 28) 
values (p<0.05). 
Prenatal Fluoxetine Exposure Produces Site-Specific Alterations 
in the Percentage of High Affinity 5-HT 2A Receptors 
The number of high affinity 5-HT 2A receptors to the number of 
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[3H]ketanserin-labelled receptors was calculated to provide an index of the percent 
of 5-HT 2A receptors able to couple to their respective guanine nucleotide regulatory 
proteins. In order to calculate the percentage of high affinity 5-HT2A receptors, the 
density of [3H]ketanserin and [1251]001-labelled 5-HT 2A receptors representing 100 
% fractional occupancy was determined using the experimentally derived affinity 
for the radioligands reported in Table 15. The percentage of high affinity 5-HT 2A 
receptors calculated for each brain region is shown in Table 16. The percentage of 
high affinity sites was significantly greater in the caudate putamen (CPu; + 300%) 
in fluoxetine-exposed prepubescent offspring. In adult progeny, the percentage of 
high affinity 5-HT 2A receptors was significantly elevated in the dorsolateral septa I 
nucleus (LSD; + 275%) following prenatal exposure to fluoxetine. The percentage 
of high affinity sites was similar in control and fluoxetine-exposed offspring in all 
other brain regions examined. 
Changes in the Percentage of High Affinity 
5-HT 2 A Receptors as a Consequence of Maturation 
As shown in Table 16, the percentage of high affinity 5-HT2A receptors was 
significantly greater in adult controls than in prepubescent progeny in the 
intermediate zone of the lateral septal nucleus (LSI; + 125 %) and in the caudate 
putamen (CPu; + 200%). In contrast, the percentage of high affinity 5-HT2A 
receptors was significantly lower in the parietal (Par1; -83 %) and retrosplenial 
granular (RSG; -70%) areas of the cortex and in the anterior hypothalamus (AHC; -
77%) and medial preoptic area (MPA; -57%) in adult progeny. 
TABLE 15 
[ 12511001 AND [3HJKETANSERIN AFFINITY CONSTANTS IN CORTICAL SLICES 
Kd of [3H]ketanserin for 5-HT 2A receptors Kd of [1251JDOI for 5-HT2A receptors 
(high and low) (high) 
Prenatal 
Exposure Group Prepubescent Progeny Adult Progeny Prepubescent Progeny Adult Progeny 
Saline 2.54 ± 0.11 (3) 2.33 ± 0.29 (3) 0.61 ± 0.12 (5) 1.90 ± 0.26 t (5) 
Fluoxetine 2.49 ± 0.61 (3) 2.90 ± 0.64 (5) 0. 75 ± 0.16 (5) 1.58 ± 0.40 t (5) 
Data represent the means ± SEM from 3-5 rats per group with each rat within a group being obtained from different litter. 
The number of rats per group is shown in parentheses. Affinity values were derived from scatchard analysis of saturation 
studies carried out in cortical brain sections which were wiped from the slides into scintillation vials as described in the 
Materials and Methods section. Prenatal exposure to fluoxetine did not alter the affinity of [3H]ketanserin or [1251]DOI for 5-
HT 2A receptors in either prepubescent or adult offspring. Average Kd for [3H]ketanserin = 2.57 nM; Average Kd for [12511001 
in prepubescent offspring = 0.68 nM; Average Kd for [125IJDOI in adult progeny = 1. 74 nM. Data were analyzed using a 
two-way ANOVA followed by a Newman-Keuls post-hoc test. tSignificantly different from respective values in prepubescent 
progeny (p<0.05). 
TABLE 16 
THE PERCENTAGE OF HIGH AFFINITY 5-HT2A RECEPTORS IN PREPUBESCENT AND ADULT OFFSPRING 
Prepubescent Progeny Adult Progeny 
Brain Region Saline (N) Fluoxetine (N) Saline (N) Fluoxetine 
Telence(Jhalon 
Cortex 
CG3 13 ± 2 (6) 11 ± 2 (5) 10 ± 2 (5) 10 ± 1 
Fr2 49 ± 12 (6) 47 ± 12 (5) 28 ± 9 (5) 28 ± 6 
Ent 9 ± 2 (6) 8 ± 2 (4) 16 ± 1 (4) 13 ± 4 
Oc2L 52 ± 12 (5) 49 ± 11 (3) 20 ± 6 (5) 26 ± 7 
Par1 48 ± 7 (6) 43 ± 3 (5) 8 ± 2t (5) 11 ± 2t 
RSG 23 ± 5 (6) 16 ± 2 (4) 7 ± 4t (4) 5 ± 0 
Te1 49 ± 9 (5) 44 ± 5 (4) 29 ± 3 (5) 34 ± 8 
Hippocampus 
CA3 10 ± 3 (4) 9 ± 2 (3) 13 ± 3 (4) 16 ± 3 
DG 8 ± 4 (5) 3 ± 1 (4) 3 ± 0 (4) 5 ± 1 
Septum 
LSD 3 ± 1 (6) 3 ± 1 (5) 4 ± 1 (4) 15 ± 6 *t 
LSI 4 ± 2 (6) 3 ± 1 (5) 9 ± 2t (5) 7 ± 1 
Amygdala 
BLAMY 42 ± 12 (5) 26 ± 7 (4) 21 ± 4 (5) 35 ± 5 
CAMY 14 ± 7 (4) 16 ± 2 (4) 7 ± 3 (3) 27 ± 11 
MAMY 40 ± 12 (5) 30 ± 10 (4) 18 ± 5 (5) 14 ± 3 
Caudate 
CPu 1 ± 0 (6) 4 ± 1* (5) 3 ± 1 t (5) 3.5 ± 0.9 
(N) 
(6) 
(6) 
(5) 
(6) 
(5) 
(3) 
(6) 
(6) 
(6) 
(4) 
(5) 
(6) 
(6) 
(5) 
(6) 
.... 
.... 
TABLE 16 Continued 
Prepubescent Progeny Adult Progeny 
Brain Region Saline (N) Fluoxetine (N) Saline (N) Fluoxetine (N) 
Dience12halon 
Hypothalamus 
AHC 13 ± 2 (6) 12 ± 2 (5) 3 ± 1 t (4) 5 ± 3t (3) 
DM 4 ± 1 (5) 3 ± 0 (4) 5 ± 1 (5) 4 ± 1 (5) 
LH 7 ± 1 (5) 10 ± 2 (5) 7 ± 2 (5) 9 ± 2 (5) 
MPA 7 ± 1 (5) 4 ± 1 (4) 3 ± ot (4) 4 ± 1 (6) 
PVN 5 ± 1 (6) 5 ± 1 (4) 5 ± 2 (3) 7 ± 3 (3) 
VMH 13 ± 1 (5) 19 ± 5 (5) 22 ± 6 (5) 21 ± 3 (5) 
Mesence12halon 
Tegmentum 
SN 3 ± 1 (6) 3 ± 1 (4) 8 ± 2 (4) 14 ± 5t (5) 
VTA 5 ± 1 (6) 5 ± 1 (4) 7 ± 1 (5) 6 ± 1 (6) 
Data are expressed as fmol of sites/mg tissue equivalent and represent the means ± SEM from 3-6 rats per group with each rat 
within a group being obtained from a different litter. The number of rats per group is shown in parentheses. Prenatal exposure 
to fluoxetine ( 10 mg/kg/2ml, s.c., to dams from GD 13-20) significantly increased the percentage of high affinity 5-HT 2A receptors 
in CPU (+300%) in prepubescent progeny. The percentage of high affinity 5-HT2A receptors was significantly elevated in LSD 
( + 275%) in adult offspring prenatally exposed to fluoxetine. The percentage of high affinity 5-HT2A receptors represents the 
percentage of [1251]001-labelled receptors relative to the total density of 5-HT 2A receptors as labelled by [3H]ketanserin. Anatomical 
abbreviations are described in Table 10. Data were analyzed using a two-way ANOVA followed by a Newman-Keuls post hoc 
test. *Significantly different from the age-matched control values (p<0.05). t Significantly different from the respective values 
in prepubescent offspring (p < 0.05). 
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Figure 18. Regional specificity of statistically significant alterations in the percentage 
of high affinity 5-HT 2A receptors as a consequence of normal maturation. Data are 
expressed as the percentage of high affinity 5-HT2A receptors present (% High 
Affinity) and represent the means ± SEM from 4-6 control rats with each rat within 
a group being obtained from a different litter. Adult (PD 70) control progeny exhibited 
a significantly greater percentage of high affinity 5-HT2A receptors in LSI (A; + 125%) 
and CPu (§.; + 200%) than their prepubescent counterparts. In contrast, the 
percentage of high affinity 5-HT2A receptors was significantly lower in adult progeny 
in Par1 (C; -83%), RSG (D; -70%), AHC (£; -77%), and MPA (f; -57%) than in 
prepubescent offspring. The percentage of high affinity 5-HT 2A receptors was similar 
in prepubescent and adult control progeny in CA3 (G), VTA (H) and Cg3 (!). 
Anatomical abbreviations are described in Table 10. Data were analyzed as in Table 
1 6 using a two-way ANOVA followed by a Newman Keuls post-hoc test. 
* Significantly different from prepubescent (PD 28) values (p < 0.05). 
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Summary of Results 
Prenatal exposure to fluoxetine results in site-specific and age-dependent 
alterations in the neurochemical and functional status of brain 5-HT pathways in 
offspring in the absence of physical abnormalities. The results are summarized in 
Tables 17-18 and in Figures 9-22. 
Neurochemical Status of 5-HT Neurons 
5-HT content was significantly reduced in the frontal cortex of 
prepubescent progeny but was similar to control values by adulthood (Table 17). 
In contrast, midbrain 5-HT content was significantly reduced only in fluoxetine-
exposed adult progeny. Prenatal fluoxetine exposure did not alter the density of 5-
HT uptake sites in homogenates of cortex, hypothalamus, hippocampus, striatum 
or midbrain. However, more detailed autoradiographic analysis in discrete 
neuroanatomic loci detected numerous localized alterations in the density of 5-HT 
uptake sites in prepubescent, but not in adult offspring, prenatally exposed to 
fluoxetine (Figure 19). In addition, most of the changes in 5-HT uptake sites were 
localized to limbic areas of the brain. 
Functional Status of 5-HT Neurons 
The magnitude of the reduction in 5-HT content following the administration 
of a 5-HT releasing drug was attenuated only in midbrain of adult progeny exposed 
prenatally to fluoxetine (Table 17). 
Neurochemical Status of 5-HT Receptor Systems 
5-HT,A receptor density was minimally altered by prenatal exposure to 
fluoxetine (Fig. 20). 5-HT1A receptors were significantly elevated only in the 
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entorhinal cortex and the paraventricular nucleus of the hypothalamus of 
prepubescent but not adult progeny prenatally exposed to fluoxetine. However, 5-
HT1A receptors were significantly reduced in the ventromedial hypothalamus of 
adult but not prepubescent progeny. These were the only alterations in 5-HT1A 
receptor density observed following prenatal fluoxetine exposure. 
In contrast, a greater number of alterations in 5-HT2A receptor density were 
observed in both prepubescent and adult progeny following prenatal exposure to 
fluoxetine (Figs. 21 and 22). The majority of the alterations in the density of 
[ 3H]ketanserin and [1251]DOl-labelled 5-HT 2A receptors were observed in adult 
progeny prenatally exposed to fluoxetine. In addition, the majority of 5-HT 2A 
receptor density alterations were observed in limbic areas of the brain. 
Functional Status of Postsynaptic 5-HT Receptor Systems 
The magnitude of the neuroendocrine responses (ACTH, corticosterone, and 
renin) to a maximally effective dose of the 5-HT1A agonist 8-0H-DPAT were not 
altered by prenatal exposure to fluoxetine (Table 18). In contrast, the magnitude 
of the ACTH response to the 5-HT 2A12c agonist DOI was significantly attenuated in 
adult but not in prepubescent progeny prenatally exposed to fluoxetine (Table 18). 
Neither the corticosterone nor renin responses to DOI were altered by prenatal 
exposure to fluoxetine. 
Effects of Maturation on the Neurochemical and 
Functional Status of 5-HT Pathways 
In addition to investigating the effects of prenatal exposure to fluoxetine on 
5-HT pathways, the experimental design allowed us to detect alterations in 
neurochemical and functional status of brain 5-HT pathways as a consequence of 
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normal maturation (summarized in Table 19). The densities of all the 5-HT 
recognition sites examined in the present study (5-HT uptake sites, 5-HT,A and 5-
HT 2A receptors) were affected to some degree by maturation. Overall, the greater 
number of changes which occurred as a consequence of maturation were changes 
in the density of 5-HT uptake sites. 
TABLE 17 
SUMMARY OF CHANGES IN THE NEUROCHEMICAL AND FUNCTIONAL STATUS OF 5-HT NEURONS 
Brain Region 
Neurochemical Parameter Frontal Cortex Hypothalamus Hippocampus Striatum Midbrain 
5-HT Content 
Prepubescent progeny ~ n.s. n.s. n.s. n.s. 
Adult progeny n.s. n.s. n.s. n.s. ~ 
Extent of Reduction in 
5-HT Content Following PCA 
n.s. n.s. n.s. n.s. n.s. 
Prepubescent Progeny 
Adult Progeny n.s. n.s. n.s. n.s. 
JJ. 
~ = Significant reduction in fluoxetine-exposed progeny 
ti. = Significantly attenuated response to PCA observed in fluoxetine-exposed progeny 
n.s. = No significant effect of fluoxetine exposure on this parameter 
TABLE 18 
SUMMARY OF DIFFERENTIAL 5-HT AGONIST MEDIATED 
NEUROENDOCRINE RESPONSES IN PROGENY PRENATALLY 
EXPOSED TO FLUOXETINE 
Hormone 
Treatment Group ACTH CORT Renin 
5-HT 1A (8-0H-DPA T) 
Prepubescent progeny n.s. n.s. n.s. 
Adult progeny n.s. n.s. n.s. 
5-HT 2A12c (001) 
Prepubescent progeny n.s. n.s. n.s. 
Adult progeny i n.s. n.s. 
CORT = Corticosterone 
n.s. = No significant effect of fluoxetine exposure on this parameter 
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i = Significant attenuation of the ACTH response to DOI in fluoxetine-exposed 
offspring 
A. 
c. 
RSG Par1 ~~·· ... ·~ 
LH 
r@' 
Prepubescent Progeny 
DM 
~.· .. . ·.· 
1->repubescent Progeny 
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B. 
Prepubescent Progeny 
D. 
Prepubescent Progeny 
Figure 19. Summary of alterations in the density of [ 3HJcitalopram-labelled 5-HT 
uptake sites in prepubescent progeny prenatally exposed to fluoxetine. Significant 
increases (A,~; + 21 to + 4 7) in the density of 5-HT uptake sites were observed 
following prenatal exposure to fluoxetine in the brain regions shaded in red (lateral 
hypothalamus, CA2 and CA3 subregions of the hippocampus, and the medial and 
basal amygdaloid nuclei). Significant decreases (C,D; -19% to -21 %) in the density 
of 5-HT uptake sites were observed in brain regions shaded in blue (dorsomedial 
hypothalamus, and substantia nigra). Abbreviations are described in Table 10 and in 
the legend to Figure 1 . 
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A. B. 
PVN 
~@..____...-
Prepubescent Progeny Prepubescent Progeny 
C. CA1 
Adult Progeny 
Figure 20. Summary of alterations in the density of fHJB-OH-DPA T-labelled 5-HT7A 
receptors in prepubescent (!l,!J) and adult (g rat progeny prenatally exposed to 
fluoxetine. Significant increases ( + 26% to + 42%) in the density of 5-HT1A receptors 
were observed in prepubescent progeny prenatally exposed to fluoxetine in the brain 
regions shaded in red (paraventricular nucleus, entorhinal cortex). In contrast, in adult 
progeny, a significant decrease (-33%) in the density of 5-HT1A receptors was 
observed in the brain region shaded in blue (ventromedial hypothalamus). 
Abbreviations are described in Table 10 and in the legend to Figure 1. 
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A. B. 
Prepubescent Progeny Adult Progeny 
c. D. 
Adult Progeny Adult Progeny 
Figure 21. Summary of alterations in the density off 251JDOl-labelled 5-HT2A receptors 
in prepubescent (/l) and adult (ftf;,Q) rat progeny prenatally exposed to fluoxetine. 
Significant increases (red; + 73% to + 500%) in the density of high affinity 5-HT2A 
receptors were observed in progeny prenatally exposed to fluoxetine. In prepubescent 
progeny, 5-HT2A receptors were significantly elevated only in the caudate putamen. 
In adult progeny, high affinity 5-HT2A receptors were significantly elevated in the 
dorsolateral septa I nucleus, CA3 subregion of the hippocampus, basolateral ainygdala, 
and medial mammillary nucleus. Abbreviations are described in Table 10 and in the 
legend to Figure 1 . 
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A. 
Prepubescent Progeny Prepubescent Progeny 
c. 
Prepubescent Progeny 
Figure 22. Summary of alterations in the density of r3HJketanserin-labelled 5-HT2A 
receptors in prepubescent (~{l.,g and adult (!J.,g,f) rat progeny prenatally exposed to 
fluoxetine. 
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0. E. 
PVN CP~ 
f@;®-----
Adult Progeny Adult Progeny 
F. 
Adult Progeny Adult Progeny 
Figure 22 Continued. Summary of alterations in the densitv. of [ 3H]ketanserin-labelled 
5-HT2A receptors in prepubescent fAf!..,g and adult ({l,f,~ rat progeny prenatally 
exposed to fluoxetine. Significant increases (red; + 41 % to + 91 %) and decreases 
(blue; -38% to -70%) in the density of 5-HT2A receptors were observed in progeny 
prenatally exposed to fluoxetine. In prepubescent progeny, 5-HT 2A receptors were 
significantly elevated in the (dorsolateral septa! nucleus, medial preoptic area and 
ventral pallidum). In addition, 5-HT 2A receptors were significantly reduced in the lateral 
hypothalamus in prepubescent fluoxetine-exposed progeny. In adult progeny, 5-HT 2A 
receptors were significantly elevated in the paraventricular nucleus, dentate gyrus, 
basolateral amygdala and entorhinal cortex and significantly reduced in the globus 
pallidus. Abbreviations are described in Table 10 and in the legend to Figure 1. 
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TABLE 19 
SUMMARY OF ALTERATIONS IN 5-HT RECOGNITION SITES AS DETERMINED BY 
AUTORADIOGRAPHIC ANALYSES IN PREPUBESCENT AND ADULT PROGENY 
PRENATALLY EXPOSED TO FLUOXETINE 
Prepubescent Progeny Adult Progeny 
Brain Region CIT DPT KET DOI CIT DPT KET DOI 
Telence(;!halon 
Cortex 
Cg3 ns ns ns ns ns ns ns ns 
Fr2 ns ns ns ns ns ns ns ns 
Ent ns t ns ns ns ns t ns 
Oc2L ns nd ns ns ns nd ns ns 
Par1 ns ns ns ns ns ns ns ns 
RSG ns ns ns ns ns ns ns ns 
Te1 ns nd ns ns ns nd ns ns 
Hippocampus 
CA1 ns ns bd ns ns ns bd ns 
CA2 t ns bd ns ns ns bd ns 
CA3 t ns ns ns ns ns ns t 
DG ns ns ns ns ns ns t ns 
Septum 
LSD ns ns t ns ns ns ns t 
LSI ns ns ns ns ns ns ns ns 
Amygdala 
BLAMY t nd ns ns ns nd t t 
CAMY nd nd ns ns ns nd ns ns 
MAMY t nd ns ns ns nd ns ns 
Basal Ganglia 
CPu ns ns ns t ns ns ns ns 
GP ns nd ns ns ns nd i bd 
VP ns nd t ns ns nd ns bd 
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TABLE 19 Continued 
Prepubescent Progeny Adult Progeny 
Brain Region CIT DPT KET DOI CIT DPT KET DOI 
Dience12halon 
Hypothalamus 
AHC ns ns ns ns ns ns ns ns 
ARC ns nd bd ns ns nd bd ns 
DM i ns ns ns ns ns ns ns 
LH t ns i ns ns ns ns ns 
MM ns nd ns ns ns nd ns t 
MPA ns nd t ns ns nd ns ns 
PVN ns t ns ns ns ns t ns 
VMH ns ns ns ns ns i ns ns 
Mesence12halon 
Tegmentum 
SN i nd ns ns ns nd ns ns 
VTA ns nd ns ns ns nd ns ns 
Raphe Nuclei 
DR ns ns ns bd ns ns ns bd 
MnR ns ns ns bd ns ns ns bd 
t = This parameter was significantly increased (p < 0.05) in fluoxetine-exposed 
progeny. i = This parameter was significantly reduced (p < 0.05) in fluoxetine-
exposed progeny. Abbreviations: [3H]CIT, citalopram-labelled 5-HT uptake sites; DPT, 
[ 3H]8-0H-DPA T-labelled 5-HT 1 A receptors; KET, [3H]ketanserin-labelled 5-HT 2A 
receptors; DOI, [125 l]DOl-labelled 5-HT2A receptors; ns, no significant alteration in this 
parameter was observed in fluoxetine-exposed progeny; nd, not determined; bd, value 
was beyond the detectable limits of the assay. 
TABLE 20 
SUMMARY OF CHANGES IN NEUROCHEMICAL AND FUNCTIONAL 
INDICES OF BRAIN SEROTONIN SYSTEMS IN CONTROL 
PROGENY AS A CONSEQUENCE OF MATURATION 
Index Significant Changes as a Consequence of Maturation 
5-HT t Mdbr 
5-HIAA t Hypo, Hipp, Str, Mdbr 
5-HT/5-HIAA t FCtx, Hypo, Hipp, Str, Mdbr 
PCA Response t Mdbr; + FCtx 
Basal ACTH, corticosterone, renin + renin 
ACTH, corticosterone and renin responses to 8-0H-DPAT + renin 
ACTH, corticosterone and renin responses to DOI n.s. 
[ 3H]citalopram-labelled 5-HT uptake sites t Cg3, CA1, CA3, BLAMY, MAMY, Arc; + Te1, SN, MnR 
[ 3H]8-0H-DPAT-labelled 5-HT1A receptors t VMH; + Par1, RSG, LSD, LSI, CPu, AHC, LH, PVN 
[ 1251]DOl-labelled 5-HT2A receptors t CPu, AHC, Arc, DM; + OC2L, Par1, RSG, MPA, 
[ 3H]ketanserin-labelled 5-HT 2A receptors t BLAMY, DM; + LH 
Percentage of high affinity 5-HT 2A receptors t LSI, CPu; + Par1, RSG, AHC, MPA 
t = Significantly greater in adult control progeny in comparison to their prepubescent counterparts. 
+ = Significantly lower in adult control progeny in comparison to their prepubescent counterparts. 
n.s. = No significant difference observed between adult and prepubescent control progeny. 
w 
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CHAPTERV 
DISCUSSION 
The studies reported herein provide data demonstrating that prenatal 
exposure to fluoxetine produces alterations in both pre- and postsynaptic 
components of brain 5-HT pathways in offspring in the absence of visually 
apparent physical abnormalities. The neurochemical alterations are not 
widespread, as they occur only in specific neuroanatomic loci. In particular, 
serotonergic pathways to limbic and motor areas of the brain are selectively altered 
in offspring prenatally exposed to fluoxetine. In addition, the nature {i.e. location, 
magnitude and direction) of the observed neurochemical changes are dependent on 
the age of the offspring. Some of the statistically significant alterations in brain 
serotonergic pathways are observed only in prepubescent animals, while other 
alterations are manifested only upon maturation of the offspring prenatally exposed 
to fluoxetine. Additional studies are required to determine whether these "delayed" 
alterations persist or may be accentuated in senescent offspring. Overall, the data 
presented in this dissertation support the hypothesis that fluoxetine-induced 
disruption of the regulation of 5-HT systems during fetal brain development can 
produce neurochemical and functional alterations in brain 5-HT pathways in 
offspring. The implications of the specific effects of prenatal fluoxetine exposure 
on the neurochemical and functional status of pre- and postsynaptic components of 
brain 5-HT pathways will be discussed individually in the following paragraphs. 
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Neurochemical Status of Brain 5-HT Neurons 
Monoamine Content 
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The present data indicate that alterations in brain 5-HT content in progeny 
prenatally exposed to fluoxetine can occur in both terminal (i.e. cortex) and cell 
body regions (i.e. midbrain). Deficits in the frontal cortex are present in 
prepubescent offspring and return to control values by adulthood. In contrast, 
midbrain 5-HT content is reduced (-28%; p < 0.05) only following maturation in 
rats prenatally exposed to fluoxetine suggesting a delayed effect or compensatory 
response to other alterations. 5-HT content was not reduced in any other brain 
regions examined (striatum, hippocampus and hypothalamus) regardless of the age 
of the offspring. Thus, these experiments indicate that the reductions in 5-HT 
content are region-specific and age-dependent rather than widespread in progeny 
prenatally exposed to fluoxetine. However, the data do not preclude the possibility 
that in brain regions where global changes in 5-HT content were not detected, 
more localized alterations in 5-HT content and/or 5-HT innervation may have 
occurred either in specific neuroanatomic loci and/or in specific 5-HT pathways. 
For example, Akbari et al. ( 1992) was not able to detect changes in [3H]paroxetine 
binding to 5-HT uptake sites in hippocampal homogenates in prepubescent 
offspring prenatally exposed to cocaine, despite observing a loss of 5-HT 
immunoreactive fibers in the hippocampus in slide-mounted sections. These data 
suggest compensatory changes in 5-HT uptake sies may have occured during 
development or that the changes in 5-HT innervation were too subtle to detect in 
homogenate binding assays. Likewise, in the present dissertation studies, changes 
in 5-HT uptake sites in several brain regions evident by in vitro autoradiography 
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were not detected in homogenate binding assays. Therefore, subsequent studies 
using more sensitive immunohistochemical techniques may be more applicable to 
detect changes in 5-HT content in discrete brain nuclei. 
Reductions in 5-HT content were observed in fluoxetine-exposed offspring 
in the absence of any significant alterations in brain 5-HIAA content, suggesting 
that the observed reductions in 5-HT content are the result of a decrease in 
regional 5-HT synthesis. The decreased 5-HT synthesis could be the result of 
either ( 1) alterations in the availability of the 5-HT precursor L-tryptophan, or (2) 
alterations in the amount and/or function of synthetic enzymes or their required 
cofactors (see appendix 1 ). Individual values of brain 5-HT content were divided 
by their respective 5-HIAA values as an index of 5-HT turnover for each animal. 
As brain 5-HIAA content was not significantly altered by prenatal fluoxetine 
exposure, no significant alterations in the 5-HT /5-HIAA ratios were observed in 
progeny prenatally exposed to fluoxetine. 
The studies discussed thus far examined the effect of prenatal fluoxetine 
exposure on serotonergic neurochemical markers in the cortex, hypothalamus, 
striatum, hippocampus and midbrain. These brain regions were chosen to represent 
( 1 ) areas which complete synapse formation at differing postnatal ages (Lauder et 
al., 1982; Lidov and Molliver, 1982a,b; Wallace and Lauder, 1983; D' Amato et al., 
1987) and/or (2) areas receiving varying degrees of serotonergic innervation from 
the dorsal and median raphe nuclei. For example, the midbrain dorsal raphe 
synapses become apparent prior to birth, and synapse formation continues to 
increase for several weeks postnatally (Lauder and Bloom, 1975). Similarly, the 
establishment of the extent and pattern of serotonergic innervation of the cortex 
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takes place from gestational day 19 through postnatal day 21 (D' Amato et al., 
1987). In contrast, the striatum does not begin to receive substantial 5-HT 
innervation until 2 weeks after birth {Wallace and Lauder, 1983), and serotonergic 
innervation in the hippocampus continues to increase as long as 3 months 
postnatally {Azmitia et al., 1983). The two brain regions in which 5-HT was 
significantly reduced {cortex and midbrain) follow developmental time courses 
which are similar to each other, but differ somewhat from the other brain regions 
examined, with respect to the initiation and completion of serotonergic innervation 
in these areas. Therefore, the data suggest that the differential sensitivity of 
developing brain regions to late-term prenatal fluoxetine exposure may be related, 
at least in part, to the extent of serotonergic innervation of a particular brain region 
at the time of the prenatal insult. Fluoxetine administration throughout the pre-
weanling period may have produced additional changes in brain regions receiving 
significant 5-HT innervation after birth. 
The examination of brain regions with differential sources of serotonergic 
innervation facilitates evaluating whether prenatal fluoxetine exposure may 
selectively alter a specific ascending serotonergic pathway. With respect to 
differential sources of innervation, the hippocampus receives serotonergic 
innervation primarily from the median raphe nucleus while the striatum receives 
serotonergic projections primarily from the dorsal raphe nucleus {Lorens and 
Guldberg, 1974; Van de Kar and Lorens, 1979). In contrast, the cortex as well as 
the hypothalamus receive extensive serotonergic innervation from both the dorsal 
and median raphe nuclei (Van de Kar and Lorens, 1979). The lack of changes in 5-
HT in these regions suggests little difference between 5-HT pathways. The 
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presence of changes in 5-HT content in an area which contains both dorsal and 
median raphe cell bodies (i.e. midbrain) and in an area which receives 5-HT 
projections from both dorsal and median raphe nuclei (i.e. cortex) suggests that 
both ascending pathways may be sensitive to the effects of prenatal fluoxetine 
exposure. Furthermore, the vulnerability of these 5-HT pathways may be due to 
the time of drug exposure. The lack of alterations in 5-HT content in striatum, 
hippocampus, and hypothalamus indicate that sensitivity to prenatal fluoxetine 
exposure appears to be region-specific rather than dependent on the specific 
serotonergic projections which innervate the particular area. Therefore, the data 
from the experiments discussed thus far do not provide any evidence for a 
differential susceptibility of ascending median or dorsal raphe serotonergic 
pathways. 
Comparison Between Prepubescent and Adult Control Progeny 
Relatively few studies have quantitatively examined age-dependent changes 
in monoamine content. Consistent with the data presented in this dissertation, 
Schwabe et al. (1992) reported lower 5-HIAA but not 5-HT values in the striatum 
of adult rats in comparison to prepubescent animals. In addition, data from this 
dissertation indicate that in adult rats, basal 5-HIAA content is significantly lower 
in the hypothalamus, hippocampus, and midbrain than in prepubescent animals 
(Table 5). In the present studies, as the animals matured, a selective increase in 5-
HT content was observed only in the midbrain. This general lack of changes in 5-
HT content with maturation is consistent with previous reports in which 5-HT was 
measured in whole rat brain (Nomura et al., 1976). 
5-HT Uptake Sites 
Radioligand Binding Assays in Homogenates 
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In regions where changes in 5-HT content were observed in fluoxetine-
exposed offspring, there were no accompanying alterations in the density of 5-HT 
uptake sites as measured by radioligand binding assay in homogenates. The 
radioligand binding data in homogenates of specific brain regions indicate that 
widespread global changes in the density of 5-HT uptake sites were not present in 
offspring prenatally exposed to fluoxetine. In contrast to these homogenate 
studies, Montero et al. (1990) reported that prenatal exposure to either fluoxetine 
or clomipramine (a tricyclic antidepressant which selectively inhibits 5-HT uptake) 
resulted in decreased [3H]imipramine binding to cortical 5-HT uptake sites in 
prepubescent but not in adult offspring. This same group also reported that 
prenatal exposure to the monoamine oxidase inhibitors clorgyline or deprenyl 
resulted in decreased [3H]imipramine binding to cortical 5-HT uptake sites in both 
prepubescent and adult offspring. Several differences between the procedures 
used in the present dissertation studies and that of Montero et al. (1990) may 
account for the divergent observations: ( 1) the study by Montero et al. ( 1990) 
employed a lower dose of fluoxetine (2.5 mg/kg/day), but for a longer duration (15 
days); (2) this group also administered fluoxetine in the drinking water; and (3) 
while no more than 1 pup per litter was utilized in each treatment group in the 
present dissertation studies, similar protocols were not specified by Montero et al. 
( 1990). Nevertheless, the Montero study demonstrates age-dependent changes in 
the density of 5-HT uptake sites as a result of prenatal exposure to fluoxetine. 
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Autoradiographic Studies 
As discussed above for 5-HT content, the lack of alterations in the density 
of 5-HT uptake sites in homogenates does not preclude the possibility that 
changes limited to discrete neuroanatomic loci may have occurred in progeny 
prenatally exposed to fluoxetine. This possibility was addressed as part of this 
dissertation project using quantitative in vitro autoradiographic analysis of 5-HT 
uptake sites in slide-mounted brain tissue sections, where changes in discrete 
neuroanatomic loci could be determined. In contrast to the lack of changes in 5-
HT uptake sites observed in homogenates, region-specific alterations (increases 
and decreases) in the density of 5-HT uptake sites were observed in slide-mounted 
sections taken from prepubescent offspring prenatally exposed to fluoxetine. The 
alterations in the density of 5-HT uptake sites appear to be "short-lived" as, in 
adult offspring, the density of 5-HT uptake sites is similar between the control and 
fluoxetine-exposed treatment groups. In this regard, the present dissertation 
studies are consistent with the age-dependent changes in the density of 5-HT 
uptake sites reported by Montero et al. ( 1 990) following prenatal exposure to 
fluoxetine. In addition, the autoradiographic analysis of 5-HT uptake sites supports 
the suggestion that prenatal fluoxetine exposure produces subtle region-specific 
alterations that may not be detected with less sensitive methods such as 
homogenate binding assays. 
The density of 5-HT uptake sites was markedly altered in several brain 
regions which are integral components of the limbic system in offspring prenatally 
exposed to fluoxetine. For example, 5-HT uptake sites were significantly increased 
in CA2 and CA3 areas of the hippocampus, in the basolateral and medial 
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subregions of the amygdala, and in the lateral hypothalamus of prepubescent 
offspring, prenatally exposed to fluoxetine (Table 11 ). In addition, 5-HT uptake 
sites were also significantly reduced in the dorsomedial nucleus of the 
hypothalamus in prepubescent fluoxetine-exposed offspring. The alterations in the 
density of 5-HT uptake sites may be indicative of alterations in serotonergic 
innervation to the affected brain regions (Descarries et al., 1995). Studies suggest 
that serotonergic neurons projecting to the basolateral amygdala and the prefrontal 
cortex are involved in mediating emotional or cognitive states in response to 
psychological stressors (Kawahara et al., 1993). In addition, serotonergic 
neurotransmission in the lateral hypothalamus has been suggested to be involved 
in regulating food satiety and reward. Extracellular 5-HT increases in the lateral 
hypothalamus during feeding, and when the hungry rats are aroused by the smell 
of food (Hoebel et al., 1989; Schwartz et al., 1989a,c). In addition, excess 5-HT 
in the lateral hypothalamus has been demonstrated to produce anorexia in rats 
(West et al., 1989). Consistent with this idea, local injection of the anorectic drug 
d-fenfluramine into the lateral hypothalamus increased extracellular concentrations 
of 5-HT (Schwartz et al., 1989b). In addition, a peripheral dose of tryptophan 
known to cause anorexia increased extracellular 5-HT in the dialysates of the 
lateral hypothalamus (Schwartz et al., 1988). In contrast, the peripheral 
administration of 8-0H-DPAT reduced satiety and promoted obesity in rats 
(Dourish et al., 1985). The 8-0H-DPAT induced obesity was attributed to a 
reduction in 5-HT neurotransmission via activation of 5-HT 1A autoreceptors. In 
summary, activation of the limbic system mediates emotional responses, "fight or 
flight" reactions, as well as food finding and sexual behaviors. Therefore, 
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alterations in the extent of serotonergic innervation to limbic areas and/or 
alterations in serotonergic function (i.e. via regulation of 5-HT by 5-HT 
transporters) in limbic areas may be of clinical significance to human offspring 
prenatally exposed to fluoxetine. Furthermore, the significant reduction in 5-HT 
uptake sites in the substantia nigra in prepubescent progeny prenatally exposed to 
fluoxetine suggest a consequent effect of prenatal fluoxetine on dopaminergic 
systems. As serotonergic neurotransmission in the substantia nigra has been 
suggested to exert a seizure suppressing action (Pasini et al., 1992), alterations in 
the extent of serotonergic innervation and/or function in the substantia nigra may 
also be of clinical significance in human offspring. In order to more accurately 
determine whether changes in the density of 5-HT uptake sites reflect changes in 
serotonergic innervation and/or function, further studies which can visualize 5-HT 
axons and terminals by utilizing an antibody which recognizes the serotonin 
transporter and studies of 5-HT uptake need to be carried out. 
Prenatal fluoxetine exposure did not alter the density of 5-HT uptake sites in 
brain regions rich in 5-HT perikarya (dorsal and median raphe). Since 5-HT uptake 
sites in the dorsal and median raphe are located primarily on 5-HT perikarya rather 
than on 5-HT axons or terminals, as is the case for most limbic areas of the brain 
(D' Amato et al., 1987), these data indicate little effect on 5-HT cell bodies. 
However, a significant increase in 5-HT uptake sites was observed in the lateral 
hypothalamus, an area in which many of the 5-HT uptake sites may be located on 
axons of passage in the median forebrain bundle. The significance of these latter 
findings is not yet apparent. 
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Fluoxetine-induced alterations in the extent of serotonergic innervation of 
various brain regions may result in, or occur concomitantly with, changes in the 
density of 5-HT receptors. Alterations in either the extent of serotonergic 
innervation or the density of 5-HT receptors can markedly alter the functioning of 
specific brain regions and, consequently, alter the physiologic or behavioral 
responses which are subserved by these serotonergic neurons. For example, 
Guimaraes et al. (1993) reported that 5-HT,A receptors in the hippocampus, which 
receive serotonergic innervation from the median raphe nucleus, participate in the 
organisms ability to tolerate or adapt to aversive events. Thus, alterations in the 
extent of serotonergic innervation to the hippocampus or in the functional status of 
midbrain 5-HT neurons will disrupt the normal pattern of serotonergic stimulation 
of postsynaptic 5-HT,A receptors in the hippocampus. A disruption in 5-HT,A 
receptor function could ultimately impact the animals' responsiveness to aversive 
stimuli. Alterations in receptor-mediated events may also occur consequent to 
changes in the density of the 5-HT receptor subtype itself. Region specific 
changes in the density of 5-HT1A and 5-HT2A receptors were observed in the 
present dissertation studies. The implications of these receptor changes will be 
discussed in greater detail in a subsequent section of the discussion (page 132). 
Although the density of 5-HT uptake sites was not altered in adult offspring 
prenatally exposed to fluoxetine, it is likely that functional deficits in 5-HT nerve 
terminals may be present in the absence of any alterations in the density of 5-HT 
uptake sites. Evidence that functional alterations in 5-HT neurons can occur in the 
absence of alterations in the density of 5-HT uptake sites includes reports by 
Battaglia et al. ( 1988, 1990) demonstrating that, in cortex of rats recovering from 
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MOMA-induced lesion of serotonergic axons, 5-HT uptake sites reached control 
levels at 1 year, yet, 5-HT levels remained markedly below control values 
suggesting a functional alteration in the presynaptic 5-HT neurons. Therefore, it is 
likely that prenatal fluoxetine exposure which affects 5-HT systems during prenatal 
development, may produce functional alterations in 5-HT neurons in adult offspring 
even when the density of 5-HT uptake sites has returned to control values. 
Consistent with this idea, in the present studies, midbrain 5-HT content was 
significantly reduced in adult progeny prenatally exposed to fluoxetine despite the 
lack of changes in the density of dorsal and median raphe 5-HT uptake sites. In 
addition, the significant attenuation in the ability of the 5-HT releasing drug PCA to 
reduce 5-HT content in midbrain of adult offspring prenatally exposed to fluoxetine 
provides supportive evidence of a functional impairment in this region. The 
investigation into the functional status of brain 5-HT neurons following prenatal 
exposure to fluoxetine is discussed below on page 144. 
Comparison Between Prepubescent and Adult Control Progeny 
With respect to postnatal development, initial studies in homogenates of 
control progeny indicated that 5-HT uptake sites did not change in either the 
cortex, hippocampus, striatum or midbrain as a consequence of maturation. 
However, as these measurements were carried out in homogenates, selective 
alterations in discrete neuroanatomic loci could not be detected. Using more 
sensitive autoradiographic techniques, subsequent studies indicated that 5-HT 
uptake sites are significantly greater in adult control offspring in subregions of the 
basal ganglia and hippocampus as well as in the arcuate nucleus of the 
hypothalamus and the cingulate cortex. In contrast to prepubescent offspring, in 
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adult control offspring, 5-HT uptake sites were significantly lower in the temporal 
cortex and the median raphe nucleus. While differences in the degree of tritium 
quenching (i.e. differences in the grey and white matter composition of the brain) 
between prepubescent and adult progeny could result in artifactual differences 
between these groups, this possibility is unlikely to have significantly contributed 
to the autoradiographic results described in these dissertation studies. This 
contention is supported by the absence of a consistent pattern of quenching 
across the two age groups in any specific brain region irrespective of the tritiated 
radioligand used. Thus, the differential autoradiographic signals between 
prepubescent and adult progeny represent differential densities of 5-HT recognition 
sites. 
In humans, Andersson et al. ( 1992) did not observe any age-related 
changes in [3H]paroxetine binding to 5-HT uptake sites in homogenates of 
cingulate cortex, amygdala, frontal cortex, or hypothalamus. These authors 
suggested that brain 5-HT terminals are stable with increasing age in humans. 
However, as our autoradiographic measurements (which can reveal changes in 
discrete neuro-anatomic loci which are beyond the detection limit of homogenate 
radioligand binding assays) revealed age-dependent alterations, it is likely that age-
related changes in 5-HT uptake sites in humans may have existed and would have 
been detectable using comparable techniques. In rats, consistent with the results 
obtained in the present dissertation studies, Whitaker-Azmitia et al. (1990c) did 
not report any differences between prepubescent and adult progeny in the density 
of 5-HT uptake sites in brainstem homogenates. In contrast, Whitaker-Azmitia et 
al. ( 1990c) reported that [3H]paroxetine-labelled 5-HT uptake sites were 
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significantly greater at PD 60 than at either PD 30 or at PD 90 in frontal cortex 
homogenates. The values obtained for the densities of 5-HT uptake sites in 
homogenates in the present study are similar to those obtained by Whitaker-
Azmitia et al. at PD 30 and PD 90. Therefore, it appears that 5-HT uptake sites in 
the frontal cortex peak at PD 60, then rapidly decrease to adult values as early as 
PD 70. In addition to examining the effects of maturation on 5-HT uptake sites in 
homogenates, the present dissertation studies demonstrate changes in 5-HT 
uptake sites in several discrete neuroanatomic loci as a consequence of 
maturation. Some of the changes in the density of 5-HT uptake sites in the 
mesencephalon were reductions which were detected in adult progeny. This age-
dependent reduction in 5-HT uptake sites has been suggested to be a normal 
phase of development related to the removal or pruning of excess 5-HT terminals 
(Whitaker-Azmitia et al., 1990c). 
Functional Status of Brain 5-HT Neurons 
The functional status of brain 5-HT neurons was assessed by measuring the 
ability of the 5-HT releasing drug PCA to reduce 5-HT content in the frontal cortex, 
hypothalamus, hippocampus, striatum and midbrain. The magnitude of the 
reduction in 5-HT content was significantly attenuated only in the midbrain of adult 
progeny prenatally exposed to fluoxetine (Figure 3) where basal 5-HT content was 
also significantly reduced (-28%). In contrast, despite an identical reduction (-
28 % ) in basal 5-HT content in the frontal cortex of prepubescent fluoxetine-
exposed offspring, the magnitude of the PCA-induced reduction in frontal cortical 
5-HT content was similar in control and fluoxetine-exposed offspring. As 
previously mentioned, PCA enters 5-HT neurons via the 5-HT transporter and 
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facilitates the release of 5-HT (Kuhn et al., 1985; Rudnick and Wall, 1992). 
Evidence suggests that PCA releases 5-HT primarily from the cytoplasmic pool of 
5-HT found within 5-HT terminals (Rudnick and Wall, 1992; Kuhn et al., 1985; 
Adell et al., 1989). For example, Sanders-Bush and Martin ( 1982) demonstrated 
that the PCA-mediated release of 5-HT was ca+ 2 independent, and therefore, did 
not involve the exocytosis of 5-HT from storage vesicles. Rudnick and Wall 
(1992) more recently proposed that PCA releases 5-HT via a PCA-mediated 
exchange mechanism involving the reversal of the 5-HT transporter. Once inside 
the serotonergic neuron, PCA has also been demonstrated to inhibit 5-HT synthesis 
by inhibiting the rate limiting enzyme in the synthesis of 5-HT, tryptophan 
hydroxylase (Sanders-Bush et al., 1972). Therefore, alterations in the ability of 
PCA to reduce 5-HT content are indicative of ( 1) alterations in the size of the 
releasable pool of 5-HT or (2) alterations in the 5-HT uptake or release processes 
within the serotonergic neurons. With this in mind, there are several possible 
explanations for the dichotomous results obtained in the frontal cortex and 
midbrain. With respect to the midbrain, the PCA-mediated reduction in 5-HT 
content was significantly attenuated, suggesting that the cytoplasmic pool of 5-HT 
is reduced in the midbrain. This reduction in the releasable form of 5-HT may 
occur in the absence or presence of changes in the amount of 5-HT stored in 
secretory vesicles. Alternatively, prenatal fluoxetine exposure may have altered 
either the ability of PCA to enter midbrain 5-HT neurons or to facilitate the release 
of neuronal 5-HT into the extracellular space within the midbrain. Alterations 
leading to a reduced ability of PCA to enter 5-HT terminals can include ( 1) changes 
in the density of 5-HT uptake sites (either collectively or the number of 
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sites/neuron), (2) changes in the affinity (Km) of PCA for the 5-HT transporter, or 
(3) changes in maximal transport velocity of PCA (V maxl· Likewise, as PCA-
mediated 5-HT release is believed to be affected primarily via a reversal of the 5-
HT transport mechanism, changes in the kinetic parameters for 5-HT transport 
(Vmax• Km), as well as changes in the number of 5-HT uptake sites may also affect 
the release of 5-HT from serotonergic neurons. As decreases in midbrain 5-HT 
uptake sites were not observed in fluoxetine-exposed progeny, changes in 5-HT 
uptake sites do not appear to be the reason for the attenuated PCA-induced effect. 
In order to determine which of the other aforementioned scenarios may be 
responsible for the attenuated response to PCA in the midbrain, additional 
experiments investigating the active uptake of 5-HT would have to be carried out 
in synaptosomal preparations. Similar to observations made in the midbrain, basal 
5-HT content was also significantly reduced in the cortex of fluoxetine-exposed 
offspring. However, in contrast to the midbrain, the ability of PCA to reduce 5-HT 
content in cortex was similar in control and fluoxetine-exposed rats. Therefore, 
despite comparable reductions in 5-HT content in midbrain and cortex, the nature 
of the changes in 5-HT neurons in cortex appears to be different from that 
produced in the midbrain. The most parsimonious explanation for these findings is 
that the cytoplasmic (releasable) pool of 5-HT in the cortex is not affected by 
prenatal fluoxetine exposure. Rather, the reduction in basal cortical 5-HT content 
may be due to a reduction in the amount of 5-HT stored in secretory vesicles. 
Alternatively, the differential effects of the PCA-induced reduction in 5-HT in 
midbrain versus terminal brain regions may reflect an age-dependent effect of 
prenatal fluoxetine exposure on terminal versus dendritic 5-HT uptake and release 
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processes. In cortex, the inability of fluoxetine exposure to alter the magnitude of 
the PCA-mediated reduction in 5-HT content also suggests that cortical 5-HT 
uptake and release processes have not been altered by fluoxetine exposure. 
Likewise, in the other brain regions examined (hypothalamus, hippocampus, and 
striatum), the lack of alterations in basal 5-HT values or in the PCA-mediated 
reduction in 5-HT content indicates that neither the amount of cytoplasmic 5-HT 
nor the uptake or release processes were altered by fluoxetine exposure in these 
areas. 
Comparison Between Prepubescent and Adult Control Progeny 
In addition to the age-dependent changes in basal monoamine levels 
previously discussed, the present study represents the first published report of 
age-dependent differences in the ability of the serotonin releaser PCA to reduce 5-
HT content in rat cortical and midbrain tissue. In adult control progeny, a 
significant increase in basal midbrain 5-HT content occurred concomitantly with a 
significantly greater response to PCA. These data suggest that the releasable pool 
of 5-HT in the midbrain is greater in adult animals than in their prepubescent 
counterparts. Consistent with this idea, differences in resting 5-HT release from 
raphe neurons between prepubescent and adult rat progeny were recently reported 
by Knoll et al. (1995). 
Neurochemical Status of 5-HT Receptor Systems 
The densities of 5-HT ,A and 5-HT 2A receptors were determined 
autoradiographically in select brain regions following prenatal exposure to 
fluoxetine. Autoradiographic studies were limited to these two 5-HT receptor 
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subtypes for the following reasons: (1) both 5-HT,A and 5-HT2A receptors have 
been demonstrated to be present and functional during fetal rat brain development 
(Daval et al., 1987; Whitaker-Azmitia et al., 1987; Roth et al., 1991; Becquet et 
al., 1992; Hi Ilion et al., 1994); (2) studies suggest that the administration of 
fluoxetine in adult animals can disrupt the neurochemical and/or functional status 
of these receptor systems (Dumbrille-Ross and Tang, 1983; Wong et al., 1985; 
Eison et al., 1991; Li et al., 1993a,b); and (3) alterations in both 5-HT,A and 5-
HT 2A receptors have been implicated in the etiology of and/or have been the target 
receptors for treatment of various psychiatric disorders (Mita et al., 1986; Deakin, 
1988; Cheetham et al., 1990; Pandey et al., 1990; Fuller, 1991; Molcho et al., 
1 991 ; Siever et al., 1 991). In addition, 5-HT 1 A and 5-HT 2A receptors are the most 
well characterized of the 5-HT receptor subtypes, and radioligands are readily 
available to study the presence of these receptors in slide-mounted sections 
(Gozlan et al., 1983; Middlemiss and Fozard, 1983; Pazos and Palacios, 1985; 
Appel et al., 1990). Finally, activation of postsynaptic 5-HT,A and 5-HT2A 
receptors mediate the release of plasma hormones (see Van de Kar, 1991 for 
review). Measurement of 5-HT agonist-stimulated plasma hormones can then 
serve as a peripheral index of the status of hypothalamic postsynaptic 5-HT 
receptor systems. 
Evidence suggests that, in the dorsal and median raphe nuclei, 5-HT,A 
receptors are located primarily on 5-HT perikarya where they serve as 
autoreceptors (Verge et al., 1985, 1986; Weissmann-Nanopoulos et al., 1985; 
Sotelo et al., 1 990). The stimulation of these autoreceptors decreases the firing 
rate of 5-HT neurons reducing serotonergic neurotransmission (Adell et al., 1993; 
149 
Hajos et al., 1995). In contrast, neuronal 5-HT,A receptors located in all other 
brain regions measured in the present studies are exclusively postsynaptic 
receptors (Verge et al., 1986) located on non-serotonergic neurons. Evidence 
suggests that 8-0H-DPAT administration elevates plasma ACTH and corticosterone 
via stimulation of postsynaptic 5-HT1A receptors located in the paraventricular 
nucleus of the hypothalamus (Karteszi et al., 1982; Van de Kar et al., 1985a; Van 
de Kar, 1991 ). In rat brain, neuronal 5-HT2A receptors are exclusively postsynaptic 
receptors (Fischette et al., 1987). 
5-HT iA Receptors 
Autoradiographic studies revealed that the density of 5-HT1A receptors in 
various neuroanatomic loci was minimally affected by prenatal fluoxetine exposure. 
5-HT 1A receptors were significantly elevated only in the paraventricular nucleus of 
the hypothalamus and in the entorhinal cortex in prepubescent fluoxetine-exposed 
offspring. In contrast, in adult progeny, a significant reduction in 5-HT1A receptors 
was observed only in the ventromedial hypothalamus in fluoxetine-exposed 
offspring. No other changes in the density of 5-HT1A receptors were observed in 
16 other brain regions examined in prepubescent and adult rats prenatally exposed 
to fluoxetine. The entorhinal cortex plays a pivotal role in the control of 
hippocampal function (Jones, 1993). Changes in the density of 5-HT1A receptors 
in the entorhinal cortex may, therefore, affect the relay of information from the 
entorhinal cortex to the hippocampus and back through the entorhinal cortex to 
other areas of the brain. The ventromedial nucleus of the hypothalamus plays an 
important role in modulating weight and energy balance (Parkinson and 
Weingarten, 1990; Tokunaga et al., 1986), thermoregulation (Amir, 1990), and 
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sexual behavior (Schulze and Gorzacka, 1991 ). In addition, the ventromedial 
nucleus of the hypothalamus may play a role in modulating cardiovascular function 
(Valladao et al., 1990). Therefore, alterations in the density of 5-HT 1A receptors in 
the ventromedial nucleus may affect one or more of the aforementioned functions 
which may result in significant consequences in offspring. The paraventricular 
nucleus of the hypothalamus plays a key role in regulating the secretion of ACTH 
(Van de Kar, 1991 ), corticosterone, vasopressin and oxytocin (Swanson and 
Sawchenko, 1983), cardiovascular function (Ciriello et al., 1984; Zhang and 
Ciriello, 1985; Herzig et al., 1991; Takeda et al., 1991) and neuroendocrine 
response to various stressors (Richardson Morton et al., 1989; Van de Kar et al., 
1 991 ) . Despite a significant increase in 5-HT 1 A receptors in the paraventricular 
nucleus of the hypothalamus of prepubescent fluoxetine-exposed offspring, 
neuroendocrine responses to a maximally effective dose of the 5-HT,A agonist 8-
0H-DPAT were not significantly altered in this group. This observation of changes 
in receptor number without concomitant changes in the receptor-mediated 
responses could occur as a result of maximally stimulating the 5-HT,A receptor. 
Thus, it is possible that significant differences in the neuroendocrine response to 8-
0H-DPA T may be observed at submaximal levels of the drug. Alternatively, the 
lack of a significant change in 5-HT1A mediated neuroendocrine responses could be 
the result of an influence of 5-HT1A receptor activation in the dorsal raphe. 
Consistent with this idea, 5-HT1A receptors in the dorsal raphe have recently been 
demonstrated to partially mediate the 8-0H-DPAT induced elevation of plasma 
ACTH (Pajot et al., 1995). Lastly, recent evidence suggests that unlike other 
radiolabeled agonists, [3H]8-0H-DPAT may exhibit a moderate affinity for the 
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uncoupled (i.e. not G-protein linked) state of the 5-HT1A receptor such that both 
the uncoupled and coupled states of the receptor can be radiolabelled (Butkerait et 
al., 1995). Thus, changes in the density of [3 HJ8-0H-DPAT binding may reflect 
changes in the number of coupled and uncoupled receptors rather than a change in 
the absolute number of receptors present in a given tissue. Such shifts between 
affinity states would alter the observed radioligand affinity and result in differential 
autoradiographic signals between control and fluoxetine-exposed offspring. Thus, 
should the change in [3H]8-0H-DPAT binding in the paraventricular nucleus may 
not represent an increase in the absolute number of 5-HT1A receptors; and would 
therefore not appear to be inconsistent with the lack of alterations in the 5-HT1A 
agonist-mediated neuroendocrine responses. 
To date, no other published reports have examined the effect of prenatal 
exposure to fluoxetine or other selective 5-HT uptake inhibitors on 5-HT1A receptor 
density. However, we previously reported that prenatal exposure to cocaine (a 
non-selective monoamine uptake inhibitor) did not alter the density of 5-HT1A 
receptors in homogenates of the hypothalamus, cortex, or midbrain of 
prepubescent offspring despite a potentiation in 5-HT1A receptor-mediated 
neuroendocrine responses (Battaglia and Cabrera, 1994). The chronic (21 d) 
administration of fluoxetine to adult male rats has been reported to decrease 5-
HT 1A receptors in the dorsal raphe (Welner et al., 1989). In contrast, 5-HT 1A 
receptor density in cortical or hypothalamic homogenates was not altered by 
chronic fluoxetine administration to adult rats (Li et al., 1993b), despite reductions 
in 5-HT1A mediated ACTH and corticosterone responses in drug-treated animals. 
In the present dissertation studies, it is of interest to note that the density 
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of 5-HT,A receptors was altered in specific brain regions (Ent, VMH, and PVN) 
where 5-HT uptake sites were not affected by fluoxetine exposure. According to 
the generally accepted, yet relatively simplistic view of receptor regulation, 
changes in the density of receptors generally occur secondary to changes in the 
presynaptic stimulus (which can include changes in the number and/or function of 
5-HT terminals). However, this hypothesis has been developed from observations 
in adult animals where homeostasis has been achieved. The correspondence 
between presynaptic innervation (and/or receptor stimulation) and changes in 
postsynaptic receptors may be somewhat different during developmental stages. 
For example, prenatal exposure to the dopaminergic receptor blocker haloperidol 
resulted in a reduction in 0 2 dopamine receptors in neonatal offspring (Rosengarten 
and Friedhoff, 1979). However, the administration of haloperidol to adult rats, 
produces the opposite effect (Rosengarten and Friedhoff, 1979). Nonetheless, 
while receptor regulation does not always follow the simple theoretical model, it is 
possible that alterations in 5-HT,A receptor density in the entorhinal cortex, 
paraventricular nucleus, and ventromedial hypothalamus did occur as a 
consequence of localized alterations in the functional status of serotonergic 
neurons projecting to these brain regions. As previously mentioned, alterations in 
the functional status of serotonergic neurons may occur in the absence of changes 
in the density of 5-HT uptake sites. Furthermore, the detection of discrete 
changes in the functional status of 5-HT neurons requires the use of more sensitive 
techniques than were employed in the present studies. Alternatively, the extent of 
serotonergic innervation (as measured by 5-HT uptake site density) may have been 
altered at time points other than those examined in the present dissertation studies 
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(i.e. prior to PD 28, or between PD 28 and PD 70). Again, changes in the extent 
of serotonergic innervation to these particular brain regions could result in 
alterations in the density of 5-HT1A receptors. Finally, it is also possible that 
fluoxetine administration during fetal brain development resulted in a disruption of 
other neurotransmitter systems or growth factors required for the normal 
development of 5-HT target tissues containing 5-HT1A receptors. Consistent with 
this idea Rubinstein et al. (1993) reported that prenatal exposure to cocaine (a 
non-selective monoamine uptake inhibitor) reduced the glial derived growth factor 
S-1008 immunoreactivity in the adult hippocampus. 
5-HT 2A Receptors 
In addition to the changes observed in the density of 5-HT1A receptors, 
prenatal fluoxetine exposure altered the density of [125 l]DOI and [3H]ketanserin-
labelled 5-HT 2A receptors in a manner which was dependent on both the brain 
region examined and the age of the offspring. In some brain regions, only the 
density of high affinity G-protein coupled ([ 125 l]DOl-labelled) 5-HT 2A receptors was 
significantly altered by prenatal fluoxetine exposure. In other areas, fluoxetine-
induced alterations in the total population of 5-HT 2A receptors (high and low 
affinity; labelled by [3H]ketanserin) occurred either in the presence or absence of 
changes in the density of high affinity coupled receptors (i.e. those labelled by 
[ 1251]DOI). For example, in prepubescent progeny, high affinity ([ 125 l]DOl-labelled) 
5-HT 2A receptors were increased in the caudate putamen. Likewise, in adult 
progeny, high affinity 5-HT 2A receptor density was increased by fluoxetine-
exposure in the CA3 region of the hippocampus, the lateral septal nucleus, and the 
medial mammillary nucleus. Despite the increase in the number of coupled 5-HT 2A 
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receptors in these brain regions, fluoxetine-exposure did not alter the total number 
of receptors present. Therefore, the selective increase in the number of high 
affinity 5-HT 2A receptors in these brain regions is indicative of an increase in the 
number of 5-HT 2A receptors which are coupled to G-proteins in fluoxetine-exposed 
offspring. Since the density of the total 5-HT 2A receptor population was 
unchanged, the increase in [1251)001-labelled sites should result in a significant 
increase in the percentage of high affinity 5-HT2A receptors in these brain regions. 
Consistent with this, the calculated percentage of high affinity 5-HT 2A receptors 
was significantly elevated in the caudate putamen in prepubescent offspring, and 
in the lateral septal nucleus in adult fluoxetine-exposed progeny {Table 16). 
However, despite the significant increase in [1251)001-labelled 5-HT 2A receptors in 
the absence of changes in the total receptor population, the calculated percentage 
of high affinity 5-HT2A receptors was determined to be not significantly different in 
the CA3 region of the hippocampus (despite a 23 % difference between groups) in 
adult fluoxetine-exposed progeny. 
In contrast to the aforementioned selective increases in the number of high 
affinity 5-HT 2A receptors, the total number of 5-HT 2A receptors ([3H]ketanserin-
labelled) was significantly elevated in the lateral septal nucleus, ventral pallidum, 
and medial preoptic area in prepubescent fluoxetine-exposed progeny. None of 
these changes in the total receptor population were accompanied by significant 
changes in the absolute number of [1251)001-!abelled receptors. Thus, although 
fluoxetine exposure increased the total number of 5-HT 2A receptors present in 
these brain regions, the prenatal treatment did not result in a corresponding 
significant increase in the number of 5-HT 2A receptors which are coupled to G-
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proteins. Thus, it can be concluded that the percentage of high affinity receptors 
to the total receptor population should have been altered by fluoxetine exposure in 
these regions. However, the percentage of high affinity receptors as calculated in 
Table 16 was determined to be not significantly different in response to prenatal 
fluoxetine exposure. In adult progeny, the total number of 5-HT2A receptors was 
significantly elevated in the entorhinal cortex, dentate gyrus, and paraventricular 
nucleus of the hypothalamus in fluoxetine-exposed progeny in the absence of any 
alterations in the density of [1251)001-labelled high affinity 5-HT 2A receptors. 
Consequently, the percentage of high affinity 5-HT 2A receptors in these regions 
should also be reduced. However, as mentioned above, the percentage of high 
affinity receptors as calculated in Table 16 was determined to not be significantly 
different in response to prenatal fluoxetine exposure. 
Lastly, in adult progeny, concomitant significant elevations in both [1251)001 
and [3H]ketanserin-labelled receptors were only observed in the basolateral 
amygdala as a consequence of prenatal exposure to fluoxetine. As the percentage 
of high affinity 5-HT 2A receptors was not statistically different between treatment 
groups in the amygdala, the increase in total receptor population in the basolateral 
amygdala resulted in an increase in the absolute number of 5-HT 2A receptors which 
are coupled to G-proteins. 
Only two other studies have examined the consequence of prenatal 
exposure to selective 5-HT uptake inhibitors on the density of brain 5-HT 2A 
receptors. Consistent with the present dissertation studies, Romero et al. (1994) 
did not observe any changes in the density of [3H]ketanserin-labelled 5-HT 2A 
receptors in cortical homogenates from either prepubescent or adult offspring 
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prenatally exposed to fluoxetine. In contrast, prenatal exposure to the 5-HT 
uptake inhibitor clomipramine has been reported to result in a significant decrease 
in [3H]spiperone-labelled 5-HT 2A receptors in prepubescent but not in adult 
offspring (De Ceballos et al., 1985). 
Again, according to the simple model of receptor regulation, the alterations 
in 5-HT 2A receptor density could have occurred secondary to changes in the 
presynaptic stimulus (e.g. the extent of 5-HT innervation). Consistent with this 
model, in the present studies the density of 5-HT uptake sites was significantly 
elevated in the lateral hypothalamus in prepubescent offspring prenatally exposed 
to fluoxetine and a concomitant decrease in [3H]ketanserin-labelled 5-HT2A 
receptors was also observed in the lateral hypothalamus in these offspring. 
Therefore, the observed reduction in these hypothalamic 5-HT 2A receptors, may in 
fact, represent compensatory changes in postsynaptic 5-HT receptors consequent 
to changes in the serotonergic innervation of this area. However, in all other 
instances where 5-HT 2A receptor densities (labelled either by [1251]001 or 
[ 3H]ketanserin) were significantly altered by fluoxetine exposure, no concomitant 
changes were observed in the density of 5-HT uptake sites following prenatal 
exposure to fluoxetine. As indicated for the 5-HT,A receptors, the data do not 
preclude the possibility that the changes in 5-HT 2A receptors were ( 1 ) secondary to 
localized alterations in the functional status of serotonergic neurons, (2) secondary 
to changes in the extent of serotonergic innervation which occurred at time points 
other than those examined in the present studies particularly during pre- or 
postnatal development or (3) consequent to changes in other neurotransmitter 
systems and/or necessary growth factors. 
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Similar to the observations made regarding fluoxetine-induced perturbations 
in 5-HT uptake sites, changes in the density of 5-HT2A receptors were observed 
primarily in limbic and motor areas of the brain. In addition, 5-HT 2A receptor 
density was not affected in either the dorsal or median raphe (areas rich in 5-HT 
perikarya). Alterations in the density of 5-HT 2A receptors in limbic areas may be of 
clinical significance to human offspring prenatally exposed to fluoxetine; as 
activation of the limbic system mediates emotional responses, "fight or flight" 
reactions, as well as food finding, and sexual behaviors. In addition, alterations in 
5-HT2 receptor density have been reported in suicide victims (Mann et al., 1986; 
and Arora and Meltzer, 1989) and in patients suffering from various psychiatric 
disorders such as depression (Yates et al., 1990), schizophrenia (Bleich et al., 
1988), and senile dementia of the Alzheimer's type (Reynolds et al., 1984; Crow 
et al., 1984; Marcussen et al., 1984; Cheng et al., 1991 ). Thus, human offspring 
prenatally exposed to fluoxetine may exhibit altered susceptibility to developing 
these psychiatric disorders or to therapeutic interventions which modulate 5-HT 2A 
receptors. Alternatively, since 5-HT 2 receptors represent one potential target site 
for the pharmacologic treatment of psychiatric patients (Kellar et al., 1 981 , 1 983; 
Clements-Jewery and Robson, 1982; Snyder and Peroutka, 1982; Closse and 
Jaton, 1984, Stockmeir and Kellar, 1985; Andree et al., 1986; Leysen et al., 
1986; Matsubara and Meltzer, 1989; Meltzer et al., 1989), human offspring 
prenatally exposed to fluoxetine may exhibit a differential sensitivity or 
responsiveness to therapeutic interventions which modulate brain 5-HT 2A receptor 
systems. Finally, changes in the efficiency of 5-HT 2A receptors to couple to their 
respective G-proteins, may alter the 5-HT 2A receptor-mediated function including 
the receptor-mediated stimulation of plasma hormones. This possibility was 
addressed in the present dissertation studies and is discussed on page 1 64. 
Differential Sensitivity of 5-HT 1A and 5-HT 2A Receptor Systems 
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In contrast to the limited alterations observed in 5-HT,A receptor density, a 
greater number of alterations in 5-HT 2A receptor density were observed in both pre-
and postpubescent fluoxetine-exposed offspring. However, as the density of 5-
HT,A receptors was examined in fewer brain regions than 5-HT2A receptors, any 
conclusion that 5-HT,A receptors may be "less sensitive" to perturbation than 5-
HT 2A receptor systems must be made with caution. More widespread changes in 
the density of 5-HT,A receptors may have occurred in the amygdala or in 
subregions of the cortex or hypothalamus which were not examined in the present 
studies (e.g. Oc2L, Te1, MPA). However, 5-HT,A receptors are virtually absent 
from the substantia nigra or globus pallid us (Verge et al., 1986) and therefore, it is 
unlikely that an examination of these brain regions would result in detectable 
differences between control and fluoxetine-exposed offspring. In general, the 
presence of minimal changes in the density of 5-HT,A receptors in fluoxetine-
exposed offspring is consistent with the lack of significant alterations in 5-HT,A 
receptor-mediated neuroendocrine responses in offspring prenatally exposed to 
fluoxetine. The apparent resistance of 5-HT,A receptor systems to disruption of 
brain 5-HT pathways during development is consistent with published reports 
(Pranzatelli and Martens, 1992; Pranzatelli et al., 1994). Pranzatelli and his 
colleagues demonstrated that neonatal administration of the 5-HT neurotoxin 5, 7-
dihydroxytryptamine (5,7-DHT) did not alter the density of 5-HT,A receptors across 
several brain regions despite marked reductions in 5-HT uptake sites and 5-HT 
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content. These authors suggested that 5-HT1A receptors and the 5-HT transporter 
binding sites exhibited differential plasticity following the neonatal insult. 
Likewise, the present dissertation studies also reported marked alterations in 5-HT 
uptake sites, but minimal changes in 5-HT1A receptor density. 
Functional Status of 5-HT Receptor Systems 
G-Protein Coupling to 5-HT 2A Receptors 
As an index of the ability of 5-HT 2A receptors to couple to their respective 
G-proteins (Gq), the percentage of high affinity agonist ([ 1251)001) labelled 5-HT 2A 
receptors was calculated in each brain region for each of the animals. As 
previously mentioned, the effects of prenatal fluoxetine exposure on the calculated 
percentage of high affinity receptors frequently did not match what would be 
expected based on the data from significant changes in [1251)001 and 
[ 3H] ketanserin-labelled 5-HT 2A receptors. This discrepancy between theoretical 
expectations and statistically significant alterations in the calculated percentage of 
5-HT 2A receptors is likely due to the degree of variability inherent in such a 
calculation. In order to experimentally calculate the percentage of high affinity 5-
HT 2A receptors, several factors need to be determined. The process is described 
below. The autoradiographic studies presented in this dissertation were carried out 
using a single concentration of each radioligand to label the respective 5-HT 
receptor subtypes. This technique is commonly used, and allows for the detection 
of changes in either the affinity or density of the receptors. As most drug 
treatments do not alter the affinity of receptors, in autoradiographic studies, it is 
generally presumed that changes in the density of the radiolabelled signal are 
indicative of changes in the density of the receptor being labelled rather than 
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changes in the affinity of the radioactive label. The fraction of receptors occupied 
by a given concentration of radioligand in a particular brain region is exclusively 
dependent on the affinity of the ligand for the receptor and the concentration of 
the radiolabelled drug used in the assay according to the following equation: 
Fractional Occupancy = 1 I [1 + K0 *;0·1 
In this equation, K0 * equals the affinity of the radioligand for the recognition site 
and o· equals the concentration of the radioligand used in the assay. Saturation 
studies were carried out in slide mounted cortical sections to determine the actual 
Kd values of [1251]001 and [3H]ketanserin for 5-HT 2A receptors in slide-mounted 
sections (Table 15). The fraction of receptors occupied by the concentration of 
radioligand used in the assays was calculated using the above equation. The mean 
affinity of [3H]ketanserin was determined to be 2.57 nM. Therefore, 13% of the 
total receptor population was labelled by the concentration of [3H]ketanserin used 
in the autoradiographic studies (0.4 nM). The affinity of [1251]001 was 
experimentally determined to be 0.68 nM in prepubescent rats and 1. 74 nM in 
adult rats. Therefore, the concentration of radioligand used in the present studies 
(0.2 nM) labelled 23% of the high affinity receptors present in prepubescent rats 
and 10% of the high affinity 5-HT 2A receptors present in adult rats. In order to 
calculate the percentage of high affinity 5-HT2A receptors, all the experimentally 
derived values for the density of [1251]001 and [3H]ketanserin-labelled 5-HT 2A 
receptors (representing different fractional occupancies) were normalized to 100 % 
fractional occupancy by multiplying the experimentally derived values by the 
appropriate factor for each ligand (Appel et al., 1990). Therefore, any small errors 
inherent in the experimentally determined values may be magnified by such a 
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multiplication factor. Lastly, the maximal density of [1251]001-labelled receptors is 
divided by the maximal density of [3H]ketanserin-labelled receptors to obtain the 
fraction of high affinity receptors for each rat. Therefore, the percentage 
determination is calculated for each rat using 2 values which each have some 
degree of magnified inherent error in their measurement. Thus, as can be seen in 
Table 17, the values for the percentage of high affinity 5-HT 2A receptors have 
larger error values than either the [1251]001 or [3H]ketanserin data alone. Therefore 
a more accurate depiction of changes in the coupling efficiency of 5-HT 2A receptors 
is obtained by examining the consequences of prenatal fluoxetine-exposure on 5-
HT 2A receptors directly labelled by [1251]001 and [3H]ketanserin (as discussed in the 
previous section) without any mathematical transformations to calculate the 
percentage of high affinity receptors present. 
We initially reported that the density but not the affinity of 5-HT 2A12c 
receptors was significantly reduced in hypothalamic homogenates from adult 
progeny prenatally exposed to fluoxetine (Cabrera and Battaglia, 1994). This 
reduction in 5-HT 2A12c receptors was consistent with the attenuated ACTH 
response to the 5-HT2A12c agonist DOI observed in the same group of animals. 
Autoradiographic studies indicated that prenatal exposure to fluoxetine did not 
alter the density of high affinity 5-HT 2A receptors in the majority of the subregions 
of hypothalamus that were measured. In particular, the density of high affinity 5-
HT 2A receptors was not significantly altered in the paraventricular nucleus of the 
hypothalamus in adult progeny. As the 5-HT 2A receptors located in the 
paraventricular nucleus are thought to mediate, in part, the 5-HT-induced secretion 
of ACTH, this finding was unexpected. On the other hand, autoradiographic 
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studies also revealed that in adult progeny [3H]ketanserin-labelled 5-HT2A receptors 
were significantly elevated in the paraventricular nucleus of the hypothalamus 
following prenatal exposure to fluoxetine. At first, this appeared to be 
contradictory to our earlier findings in homogenates and somewhat inconsistent 
with the reduction in the magnitude of the ACTH response to the 5-HT 2A12c agonist 
DOI. In our initial studies, we did not directly determine the density of 
[ 3H]ketanserin-labelled 5-HT2A receptors in hypothalamic homogenates due to the 
limited amount of tissue available. However, the density of [3H]ketanserin labelled 
receptors determined in cortex and midbrain homogenates (Cabrera and Battaglia, 
1994) in adult progeny, revealed no significant differences in the density of 
[ 3H]ketanserin-labelled receptors in these brain regions following prenatal exposure 
to fluoxetine. Therefore, it is also likely that in hypothalamus homogenates in 
adult progeny the density of [3H]ketanserin-labelled receptors was likewise 
unaffected by prenatal fluoxetine exposure. Assuming that the density of 
[ 3H]ketanserin labelled receptors in the hypothalamus did not change in our 
previous studies, despite the decrease in hypothalamic [1251]001 labelled receptors, 
then the percentage of high affinity 5-HT 2A receptors in the hypothalamus would 
have been reduced in hypothalmic homogenates in our initial studies. In the 
autoradiographic studies, while the density of [1251]001 labelled receptors did not 
change in the paraventricular nucleus of fluoxetine-exposed adult progeny, the 
number of [3H]ketanserin labelled receptors increased, resulting in an overall 
reduction in the percentage of high affinity receptors present. Therefore, it is 
possible that the functional responsiveness of the 5-HT2A receptors (in particular, 
those localized to the paraventricular nucleus of the hypothalamus) is more closely 
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related to the percentage of high affinity receptors present rather than the absolute 
number of high affinity 5-HT2A receptors. Alternatively, discrepancies between the 
two studies (homogenates vs. autoradiography) may be attributable to 5-HT 2c 
receptors. [1251]001 possesses a high affinity for both 5-HT2A (Kd = 0.4 nM) and 5-
HT2c (Kd = 1.6 nM; Leonhardt et al., 1992) receptors. In the protocol previously 
used in homogenates, a partial labelling of 5-HT 2c receptors by [1251]001 could have 
contributed to the differences between the two studies. However, the present 
autoradiographic studies were carried out using a methodology in which 5-HT 2A 
receptors were selectively labelled (see Materials and Methods section). However, 
since [1251)001 has a lower affinity for 5-HT 2c receptors, 5-HT 2c receptors would 
have represented only a minimal fraction of the radiolabelled population in the 
homogenate assay. As a result, it is unlikely that the discrepancies between our 
initial studies in homogenates and the autoradiographic studies result from a 
significant involvement of 5-HT 2c receptors. 
Autoradiographic studies revealed alterations in the efficiency of 5-HT 2A 
receptor coupling in several brain regions in both prepubescent and adult offspring 
prenatally exposed to fluoxetine. Consistent with the presence of alteration in 5-
HT 2 receptor systems, Romero et al. ( 1994) recently reported a reduction in 5-HT 2-
mediated stimulation of phosphoinositide hydrolysis in the cortex of prepubescent 
offspring prenatally exposed to fluoxetine. Changes in the number and/or 
efficiency of 5-HT 2 receptors coupled to G-proteins could alter physiologic 
responses (e.g. regulation of body temperature and food intake; Aulakh et al., 
1994) mediated by this receptor subtype including 5-HT 2-mediated increases in 
plasma hormones (Van de Kar, 1991 ). Studies which were carried out to assess 
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the functional status of 5-HT receptor systems are discussed below. 
Neuroendocrine Responses to Directly Acting Agonists 
Prenatal exposure to fluoxetine did not alter the basal levels of any of the 
hormones measured in the present studies (ACTH, corticosterone,and renin) 
regardless of the age of the offspring. This lack of effect on basal endocrine 
status indicates that prenatal fluoxetine exposure did not produce an overall 
disruption of the homeostatic balance of the circulating hormones ACTH, 
corticosterone and renin. As other neurotransmitters are involved in the 
homeostatic regulation of these hormones (e.g. GABA,NE, DA and Ach), any 
disruption in the 5-HT system could be compensated by alterations in other 
neurotransmitter systems, thereby maintaining steady state basal levels. In the 
present studies, deficits in neuroendocrine function were revealed in adult progeny 
only following the administration of a pharmacological challenge. The attenuated 
ACTH response to a maximal dose of DOI, observed in adult fluoxetine-exposed 
progeny, indicates a change in the Emax for the DOI-mediated elevation of plasma 
renin. In addition, the attenuated endocrine response cannot be considered 
"persistent" as it was not observed in prepubescent offspring. Rather, the 
decrease in DOI-mediated ACTH response was only manifested at a postpubescent 
age. The most parsimonious explanation for the appearance of deficits at PD 70 is 
that hormonal changes occurring during maturation unmask or contribute to the 
functional deficits observed later in development. Consistent with this idea, 
several studies have demonstrated that sex steroids can influence brain 5-HT 
receptor systems (Biegon et al., 1982; Kendall et al., 1982; Beck et al., 1989; 
Clarke et al., 1989; Mendelson and McEwen, 1990a,b). This possibility remains to 
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be investigated. No significant alterations in 5-HT 2A12c mediated corticosterone or 
renin responses were observed in adult progeny prenatally exposed to fluoxetine. 
Likewise, no significant disruptions in 5-HT 2A12c mediated neuroendocrine function 
(ACTH, corticosterone, renin) were observed in prepubescent progeny prenatally 
exposed to fluoxetine. These data suggest that the Emax for DOI-mediated 
elevation of plasma renin and corticosterone was not altered by prenatal exposure 
to fluoxetine regardless of the age of the offspring. 
The selective attenuation of the ACTH response to the 5-HT 2A12c agonist 
requires some discussion. In particular, the lack of differences between treatment 
groups in the corticosterone response to DOI may at first appear to be inconsistent 
with the observed attenuation of the ACTH response. However, despite the 
markedly attenuated (-58%) ACTH response in fluoxetine-exposed male progeny in 
comparison to controls, DOI maintained an elevation of plasma ACTH ( > 200 
pg/ml) in both treatment groups. This concentration of plasma ACTH has been 
reported to be sufficient to saturate adrenal gland corticotropin receptors and elicit 
a maximal corticosterone response (Bagdy et al., 1989; Engeland et al., 1981; 
Kaneko et al., 1980, 1981; Van de Kar et al., 1992). These data suggest that the 
prenatal administration of fluoxetine does not affect the adrenal gland's production 
of corticosterone. This dichotomy of alterations in ACTH responsiveness but not 
in corticosterone responses has been observed in male progeny following prenatal 
exposure to cocaine (Cabrera et al., 1993). However, in female progeny prenatal 
cocaine exposure reduced both ACTH and corticosterone suggesting a possible 
discrepancy of the adrenal corticosterone response (Cabrera et al., 1994). In 
situations (i.e. environmental or pharmacological) where the ACTH elevations are 
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below that necessary to produce a maximal corticosterone responses, it would be 
expected that the ACTH impairment observed in fluoxetine progeny would result in 
an attenuated corticosterone response relative to non-fluoxetine exposed controls. 
In addition, since the effect of DOI on plasma corticosterone is mediated both by 
central and peripheral mechanisms (Alper, 1990; Calogero et al., 1990) the effect 
of fluoxetine exposure on the corticosterone response to DOI could be masked by 
changes in peripheral mechanisms. As serotonergic pathways mediate, in part, the 
neuroendocrine response to stressors (Van de Kar et al., 1991), offspring 
prenatally exposed to fluoxetine may exhibit compromised endocrine responses to 
various environmental or psychological stressors. 
Another possible explanation for the selective ACTH attenuation is that 
corticotropin releasing hormone (CRH) or CRH receptors are affected by prenatal 
fluoxetine exposure. If CRH and/or CRH receptors were altered, one would expect 
attenuated ACTH responses to other 5-HT receptor agonists which also stimulate 
ACTH release via a common CRH pathway. However, in adult progeny, the 
magnitude of the ACTH response to the 5-HT 1A agonist, 8-0H-DPAT was not 
altered in fluoxetine-exposed progeny. These data suggest that alterations at the 
level of CRH or CRH receptors are not likely responsible for the attenuated ACTH 
response to DOI. Rather, the simplest explanation is that the attenuated ACTH 
response to DOI is the result of a reduction in the functional responsiveness at the 
level of the 5-HT 2A receptor. Presumably, this may involve the decrease in the 
percentage of high affinity 5-HT 2A receptors reported in the paraventricular nucleus 
of the hypothalamus. 
167 
Similar to the lack of effect on plasma corticosterone, the plasma renin 
response to DOI was unaltered in fluoxetine progeny at either prepubescent or 
adult developmental times. Also, similar to corticosterone, it has previously been 
reported that the effect of DOI on plasma renin involves both central and peripheral 
mechanisms (Rittenhouse et al., 1991 ). Therefore, any potential effect of prenatal 
fluoxetine exposure on the renin response to DOI mediated via central mechanisms 
could be masked by the peripheral effects of DOI on blood pressure (Alper, 1990, 
Rittenhouse et al., 1991). 
In contrast to the disruption in 5-HT 2A12c receptor-mediated ACTH response 
observed following prenatal fluoxetine exposure, neuroendocrine responses to a 
maximally effective dose of 8-0H-DPAT were unaffected by the prenatal 
treatment. This lack of significant alterations in 5-HT1A receptor-mediated ACTH, 
corticosterone, or renin responses suggests that the functional status of 5-HT1A 
receptor systems is less sensitive to perturbation by prenatal fluoxetine 
administration than that of 5-HT 2A receptor systems. These data are consistent 
with the minimal changes observed in the density of 5-HT IA receptors as a 
consequence of fluoxetine exposure. 
While we have not found any other published data on the neuroendocrine 
effects of in utero exposure to fluoxetine or other selective 5-HT uptake inhibitors, 
differences do exist between the present data and the neuroendocrine responses 
following chronic fluoxetine administration to adult male rats (Li et al., 1993a,b). 
For example, in contrast to the marked attenuation of the ACTH response to DOI 
following in utero exposure to fluoxetine, long-term administration of fluoxetine (10 
mg/kg, i.p. x 21 d) to adult males results in a potentiated ACTH response to DOI (Li 
168 
et al., 1993a). Consistent with the potentiation of the ACTH response to DOI, Li 
et al. ( 1993a) reported a 38 % increase in hypothalamic 5-HT 2A12c receptors 
following chronic fluoxetine. More recent studies, further indicate that the 
increase in hypothalamic 5-HT 2A12c receptors occurs after as little as 7 days of 
fluoxetine administration, and is not accompanied by alterations in the density of 
hypothalamic [3H]ketanserin-labelled receptors (unpublished observations). These 
data suggest that the potentiated hormone responses in adults, may result from 
increases in the percentage of high affinity hypothalamic 5-HT 2A12c receptors just as 
the attenuated ACTH response in the present study may result from a decrease in 
the percentage of high affinity hypothalamic 5-HT 2A12c receptors. Furthermore, in 
contrast to the present lack of effect of prenatal fluoxetine exposure on corticos-
terone responses to DOI, the chronic administration of fluoxetine in adult male rats 
resulted in a potentiation of the corticosterone response to DOI suggesting an 
effect of adult fluoxetine exposure directly on adrenal gland modulation of 
corticosterone. Lastly, consistent with the lack of effect of prenatal fluoxetine on 
renin responses that we have observed, Li et al. ( 1993a) report that the renin 
response to DOI was unaffected by chronic administration of fluoxetine to adult 
males. Taken together, the contrasting effects of prenatal versus adult exposure 
to fluoxetine suggest that the effects of prenatal administration of fluoxetine 
represents a unique effect resulting from disruption of serotonergic systems during 
a critical period of brain development and are distinct from fluoxetine-induced 
changes in adult animals which represent the effects of the drug on 5-HT systems 
at homeostasis. 
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Comparison Between Prepubescent and Adult Control Progeny 
Endocrine studies carried out in adult male rats indicate that the stimulation 
of 5-HT 2A12c receptors mediates, in part, the stimulation of plasma renin. In 
contrast, endocrine studies also indicate that 5-HT,A receptors do not mediate 
renin secretion. Thus, the administration of a 5-HT,A agonist to adult rats has not 
been demonstrated to produce a significant elevation in plasma renin above basal 
values. Results from the present dissertation studies that were carried out in adult 
progeny are in agreement with the published data (Lorens and Van de Kar, 1987). 
However, the present studies also administered 5-HT,A and 5-HT 2A12c agonists to 
prepubescent animals with surprising results. First, basal renin values were 
significantly higher in prepubescent animals than in their adult counterparts, 
regardless of the prenatal treatment (Figs. 6 and 9). As a result, DOI 
administration did not significantly elevate plasma renin levels above basal values 
in prepubescent progeny. In contrast, while the 5-HT,A agonist 8-0H-DPAT 
administration did not significantly elevate plasma renin in adult animals as 
previously reported (Van de Kar, 1991 ). 8-0H-DPAT administration to 
prepubescent rats resulted in a significant increase in renin levels above basal 
values. These data suggest that 5-HT,A receptor systems may indeed play a role 
in regulating the secretion of plasma renin in prepubescent animals and possibly in 
adults as well. Therefore, in adults, either 5-HT,A receptor systems cease to play a 
role in renin secretion or the 5-HT,A receptor-mediated stimulation of plasma renin 
is "suppressed" in adults by the presence of other neurotransmitter systems which 
follow a later developmental time course. Alternatively, in prepubescent offspring, 
8-0H-DPAT may be interacting with non-serotonergic receptors early in 
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development. The stimulation of these non-serotonergic receptors may then result 
in an increase in plasma renin secretion. This possibility could result from 
differences in the affinity of "immature" vs. "mature" receptors for 8-0H-DPAT. 
This latter suggestion is supported by the fact that 8-0H-DPA T can significantly 
and markedly elevate plasma renin in adult rats following a 90% inactivation of 5-
HT1A receptors (unpublished observations). However, saturation studies of 8-0H-
DPA T carried out in several brain regions of developing rats (ages ranging from PD 
1 2 - PD 26) suggests that 8-0H-DPAT interacts with a single population of sites 
with no significant change in affinity. 
Growth Parameters 
The inability of fluoxetine to alter nutritional intake in the pregnant rats 
suggests that the effects observed in the progeny are not the result of drug-
induced malnutrition. Likewise, deficits in progeny 5-HT systems cannot be 
attributed to drug-induced differences in nurturing because the offspring were 
fostered to untreated lactating dams at birth. In utero exposure to fluoxetine 
during the last week of gestation did not produce any visually apparent terata, and 
the only evidence of alterations in the physical maturation of offspring were the 
significant changes observed in body weight in fluoxetine-exposed offspring at 
birth and at PD 70. Our data are consistent with other studies that report an 
absence of effects of prenatal fluoxetine administration on the general physical 
appearance and development of offspring (Vorhees et al., 1994; Byrd and 
Markham, 1994) despite the fact that the prenatal treatment procedures used in 
most other studies were generally of longer duration (GD 8 through GD 20-22). 
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Conclusions 
Prenatal exposure to fluoxetine alters both pre- (e.g. 5-HT content, 5-HT 
uptake sites) and postsynaptic (e.g. 5-HT2 receptor number and function) 
components of brain 5-HT pathways in offspring. Marked neurochemical and 
functional changes in central 5-HT systems occur in progeny prenatally exposed to 
fluoxetine in the absence of visually apparent physical abnormalities. In addition, 
the nature of the neurochemical and functional alterations are age-specific; 
indicating that the examination of multiple age groups is required to obtain a more 
comprehensive profile of alterations in brain 5-HT systems in progeny which may 
be produced by prenatal exposure to drugs which can disrupt brain development. 
These dissertation studies indicate that prenatal fluoxetine exposure does 
not produce widespread or global changes in central 5-HT systems. Rather, the 
alterations are localized to discrete neuroanatomic nuclei. In particular, 5-HT 
pathways which are integral components of the limbic system appear to be 
particularly vulnerable to the disruption of brain 5-HT concentrations produced by 
fluoxetine administration during the last week of pregnancy. This conclusion is 
supported by the early onset of alterations in the number of 5-HT uptake sites (an 
index of the extent of serotonergic innervation) in several limbic brain regions (e.g. 
hippocampus, hypothalamus, and amygdala). In addition, a number of limbic areas 
exhibited marked alterations in the number of 5-HT 2 receptors present in both 
prepubescent and adult offspring prenatally exposed to fluoxetine. Activation of 
the limbic system mediates emotional responses, "fight or flight" reactions, as well 
as food finding and sexual behaviors. Thus, alterations in the functional capacity 
of serotonergic projections to limbic areas may be of clinical significance to human 
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offspring prenatally exposed to fluoxetine. These data also indicate that brain 5-
HT pathways remain compromised long-after the initial prenatal insult (i.e. up to 70 
days postnatal). 
As alterations in brain 5-HT pathways have been implicated in the etiology 
of a variety of clinical disorders (e.g. depression, aggression, anxiety), human 
offspring exhibiting neurochemical alterations similar to those described in these 
dissertation studies may be particularly susceptible to developing psychiatric 
disorders which involve dysfunctional 5-HT pathways. Alternatively, human 
offspring exposed prenatally to fluoxetine may exhibit a differential sensitivity or 
responsiveness to therapeutic interventions which modulate brain 5-HT systems. 
The data from the present studies also suggest that offspring prenatally exposed to 
fluoxetine may exhibit altered responses to physiologic or environmental stressors 
which involve the activation of specific 5-HT pathways. As neuroendocrine 
challenge tests can be performed in humans, the present data indicate the potential 
clinical utility of this approach to provide peripheral markers that can be used to 
identify changes in brain 5-HT pathways in human offspring exposed in utero to 
fluoxetine. The differential profile of alterations in brain 5-HT pathways observed 
in young versus adult progeny, suggests that prepubescent and adult offspring 
may manifest differential behavioral, psychological or neuroendocrine 
abnormalities. In addition, as brain 5-HT pathways modulate the release of other 
neurotransmitters (e.g. norepinephrine, dopamine, acetylcholine), alterations in 
specific brain 5-HT pathways, as a consequence of prenatal fluoxetine exposure, 
may indirectly affect the functional status of non-serotonergic neuronal pathways. 
Finally, as the alterations observed in the present studies may be generalizable to 
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other selective serotonin reuptake inhibitors, the implications of these findings may 
be of greater clinical significance than if these effects were attributed exclusively 
to fluoxetine. 
Future Directions of Research 
While the studies put forth in this dissertation represent the first 
comprehensive examination and demonstration of changes in brain 5-HT systems 
following prenatal fluoxetine exposure, a number of questions remain to be 
addressed. For example, the absence of global changes in 5-HT content in a 
number of brain regions as reported herein does not preclude the possibility that 
more discrete changes in neuronal 5-HT content may have occurred which were 
beyond the detection limit of the homogenate assays used in the present studies. 
Therefore, future studies could follow a similar prenatal protocol as outlined in this 
document, but use immunohistochemical techniques to determine whether 5-HT 
immunoreactivity is altered in more discrete loci. In addition, these studies could 
be carried out in offspring representing several age-groups in order to provide a 
more comprehensive investigation of age-dependent alterations in 5-HT content. 
In addition, while evidence suggests that changes in 5-HT uptake sites (as reported 
herein) reflect alterations in the extent of serotonergic innervation, one cannot 
preclude the possibility that the changes in 5-HT uptake sites represent 
compensatory changes in the number of transporters per terminal, independent of 
changes in terminal density. Future studies could more directly determine whether 
the extent innervation and/or the number of transporters per neuron is altered by 
prenatal fluoxetine exposure. This could be accomplished by using 
immunohistochemical techniques using antibodies which selectively recognize the 
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5-HT transporter in combination with 5-HT immunocytochemistry or electron 
microscopy to visualize the extent of innervation density in specific brain regions. 
Also, additional studies could be carried out in synaptosomal preparations in order 
to elucidate whether transporter function (e.g. 5-HT uptake or release) is altered in 
various brain regions. These studies would be particularly important to carry out in 
the median raphe as the present studies suggest abnormal neuron function in this 
area. Fluoxetine was administered only during the last week of gestation in the 
current dissertation studies. Thus, these studies may represent the minimal degree 
of disruption present in brain 5-HT systems following prenatal exposure to 
fluoxetine. Future studies could include changes in the prenatal treatment 
paradigm in order to more closely reflect the human condition and to determine a 
wider spectrum of possible alterations following prenatal fluoxetine exposure. For 
example, future studies could administer the drug orally or prior to conception and 
continue throughout pregnancy. These studies could also include continuing the 
fluoxetine treatment postnatally. 
Although the focus of these dissertation studies was to investigate changes 
in brain 5-HT systems, additional studies could be carried out to assess 
neurochemical and functional changes in other neurotransmitter systems (e.g. the 
catecholamines) consequent to the 5-HT alterations or directly attributed to 
prenatal fluoxetine exposure. 
Future directions of research might also include studies which will 
investigate some of the potential functional implications of the changes in brain 5-
HT pathways outlined in this dissertation. For example, the dissertation studies 
suggest that offspring prenatally exposed to fluoxetine may exhibit abnormal 
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neuroendocrine responses to stressful or aversive stimuli. Therefore, future 
studies could assess whether such stimuli result in abnormal responses in offspring 
prenatally exposed to fluoxetine. In order to assess whether prenatal fluoxetine-
exposed offspring exhibit altered neurochemical responses to therapeutic 
interventions which modulate brain 5-HT systems, offspring could be subjected to 
repeated drug administration protocols which are known to affect 5-HT receptor 
function. In addition to investigations which can be carried out in animal models, 
clinical studies using neuroendocrine challenge tests could be carried in human 
offspring known to have been exposed to fluoxetine in utero in order to determine 
whether animal models are in fact predictive of changes which may occur in 
human offspring. Lastly, all the aforementioned studies, including those described 
within this dissertation, can also be carried out with other selective serotonin 
reuptake inhibitors to assess whether the changes observed in this dissertation are 
in fact generalizable to other drugs within the same class. 
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Appendix 1 . Metabolic pathway for serotonin synthesis and degradation in 5-HT 
neurons. L-tryptophan is taken up into the 5-HT neuron via an amino acid transporter. 
Once inside the neuron, in the rate limiting step, tryptophan is converted to 5-
hydroxytryptophan via tryptophan hydroxylase. 5-hydroxytryptophan is then 
converted to 5-HT via amino acid decarboxylase. 5-HT is either stored in secretory 
vesicles where it is protected from enzymatic breakdown or it is metabolized to 5-
HIAA via monoamine oxidase. 
177 
5-HT 
I 
5-HT 5-HT 
t after 1 hour t 
5-HT Content is reduced 
Appendix 2. Mechanistic illustration of the PCA-mediated reduction in 5-HT content. 
PCA enters 5-HT terminals via the 5-HT transporter (filled hexagon) and facilitates the 
release of the cytoplasmic pool of 5-HT by a reversal of the 5-HT transporter. 
Subsequently, the reuptake of 5-HT back into the nerve terminal is inhibited in the 
presence of PCA. In addition, once inside the neuron, PCA inhibits the synthesis of 
5-HT by inhibiting the enzyme tryptophan hydroxylase. Over time, brain 5-HT content 
is reduced. The extent of the reduction is dependent on the brain region examined. 
Short term, alterations in the ability of PCA to reduce brain 5-HT content are in.dicative 
of: ( 1) alterations in the size of the releasable pool of 5-HT; or (2) alterations in the 5-
HT uptake or release processes within the serotonergic neurons. 
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Appendix 3. Schematic drawing of brain 5-HT pathways. 5-HT cell bodies located 
in the dorsal and median raphe nuclei project to various forebrain regions including the 
hypothalamus. 5-HT neurons directly innervate corticotropin releasing hormone (CRH) 
containing cells in the hypothalamus (Hypo). Activation of these 5-HT neurons 
stimulates the release of CRH. CRH acts at the anterior pituitary to stimulate the 
release of ACTH, which increases plasma ACTH levels and subsequently stimulates 
the release of corticosterone from the adrenal gland. Evidence suggests that 
activation of midbrain serotonergic neurons may result in the secretion of a putative 
renin releasing factor (RRF) from the hypothalamus. This RRF may then act on the 
juxtaglomerular cells of the kidney to stimulate the release of renin which catalyzes 
the conversion of angiotensinogen to angiotensin I. 
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Aooendix 4. Schematic representation of 5-HT synapse in the hypothalamus. 
Activation of serotonergic projections to the hypothalamus results in the release of 
endogenous stores of 5-HT into the synaptic cleft. 5-HT can then interact with 
postsynaptic 5-HT,A and/or 5-HT2A12c receptors. The stimulation of 5-HT,A receptors 
either by endogenous 5-HT or by the 5-HT,A agonist 8-0H-DPAT elicits an increase 
in plasma ACTH and consequently corticosterone. The stimulation of 5-HT2A12c 
receptors either by the endogenous ligand or by the 5-HT 2A12c agonist DOI elicits an 
increase in plasma ACTH, cortiocosterone and renin. Changes in the magnitude of the 
agonist-stimulated elevations in plasma hormones are indicative of alterations in the 
respective receptor systems activated. 
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Appendix 5. Schematic drawing of the steps involved in the 5-HT1A and 5-HT 2A 
receptor activation of second messenger systems. The 5-HT 1 A and 5-HT zA receptors 
are membrane bound proteins. The interaction of the ligand with the receptor 
facilitates the coupling of the receptor with its respective G-protein, forming the 
ternary complex which is a transient intermediate in vivo but stabilized in vitro in the 
absence of exogenous GTP. GTP displaces GDP from the a subunit of the G-protein; 
the a subunit dissociates from the agonistereceptor complex freeing the 15y subunits 
of the G-protein, the receptor and agonist. The activated a subunit interacts with 
intracellular proteins to elicit a physiologic response and the receptor is converted to 
the low affinity state for agonists. The GTPase activity of the a subunit converts the 
GTP to GDP; then the a and 15y subunits reassociate. [1251]001 labels the coupled (high 
affinity) state of the 5-HT zA receptor. [3H]ketanserin labels both the coupled (high 
affinity) and uncoupled (low affinity) state of the receptor. Panel Bis a mathematical 
representation of the ternary complex model illustrated in panel A. Abbreviations: A, 
endogenous ligand or directly acting agonist; H receptor high affinity state; L, receptor 
low affinity state; RH receptor high affinity state; RL, receptor low affinity state; T, 
transducer. a, 15, and y indicate different subunits of the guanine nucleotide regulatory 
protein. The shaded inverted triangle represents the endogenous neurotransmitter or 
receptor agonist. 
APPENDIX 6 
P VALUES FROM 3-WAY ANALYSIS OF VARIANCE OF SEROTONIN LEVELS ACROSS SEVERAL BRAIN REGIONS 
Brain Region 
Factor 
Frontal Cortex Hypothalamus Hippocampus Striatum Mid brain 
Age 0.0000 0.0674 0.0006 0.6843 0.4304 
Prenatal Exposure .9680 .5858 .9150 .4011 .2429 
Postnatal PCA Challenge .0000 .0014 .0000 .0000 .0092 
Age X Prenatal 
Exposure .0002 .6831 .2278 .7315 .3891 
Age X Postnatal 
PCA Challenge .7381 .7330 .0852 .2091 .0073 
Prenatal Exposure X 
Postnatal PCA Challenge .2356 .8253 .3888 .8628 .5209 
Age X Prenatal 
Exposure X 
Postnatal PCA Challenge 0.4955 0.8676 0.8830 0.5623 0.0261 
00 
~ 
APPENDIX 7 
P VALUES FROM 3-WAY ANALYSIS OF VARIANCE OF 5-HYDROXY 
INDOLE ACETIC ACID LEVELS ACROSS SEVERAL BRAIN REGIONS 
Brain Region 
Factor 
Frontal Cortex Hypothalamus Hippocampus Striatum 
Age 0.0047 0.0000 0.0000 0.0000 
Prenatal Exposure .4968 .0530 .4300 .4749 
Postnatal PCA Challenge .7816 .0001 .4992 .5386 
Age X Prenatal 
Exposure .2751 .5460 .9379 .6612 
Age X Postnatal 
PCA Challenge .4855 .8223 .2297 .6068 
Prenatal Exposure X 
Postnatal PCA Challenge .1308 .2023 .7143 .3550 
Age X Prenatal 
Exposure X 
Postnatal PCA Challenge 0.8260 0.5137 0.9916 0.4950 
Midbrain 
0.0000 
.2635 
.0000 
.4729 
.6139 
.6544 
0.5050 
OJ 
N 
APPENDIX 8 
DESCRIPTION OF DRUGS 
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Citalopram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Antidepressant, 5-HT uptake inhibitor 
Clomipramine . . . . . . . . . . . . . . . . . . . . . . . Tricyclic antidepressant, 5-HT uptake inhibitor 
Desipramine . . . . . . . . . . . . . . . . . . Tricyclic antidepressant, noradrenergic uptake inhibitor 
DOI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-HT2N2C agonist 
Fluoxetine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Antidepressant, 5-HT uptake inhibitor 
lpsapirone ......................................... Anxiolytic, 5-HT1A agonist 
lsoproterenol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Beta adrenergic agonist 
Ketanserin ............................................... 5-HT2 antagonist 
5-MT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Nonselective 5-HT agonist 
Nialamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Monoamine oxidase inhibitor 
8-0H-DPAT ................................................ 5-HT1A agonist 
Paroxetine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Antidepressant, 5-HT uptake inhibitor 
PCA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-HT releaser 
Sertraline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Antidepressant, 5-HT uptake inhibitor 
Spiperone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-HT2 antagonist 
TFMPP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-HT18 agonist 
Zimelidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Antidepressant, 5-HT uptake inhibitor 
APPENDIX 9 
PHARMACOLOGIC PROFILE OF 5-HT UPTAKE BLOCKERS AT VARIOUS NEUROTRANSMITTER RECEPTORS 
Fluoxetine1 >10,000 >10,000 >5,000 >6000 >7000 >1000 
Sertraline2 4000 12,000 38,000 10,000 
Paroxetine 1 >10,000 >10,000 >5,000 7700 >10,000 >1000 
Citalopram 1 4500 >10,000 >5,000 >10,000 >10,000 >1000 
1Data represent Kd values (nM) 
2Data represent IC50 values (nM) 
.!::!.1 Muscarinic 
>700 >1300 
>10,000 19,000 
>1000 89 
>1000 2900 
Tissue 
Source 
Rat cortex 
Rat cortex 
whole brain 
Rat cortex 
Rat cortex 
Reference 
Thomas et al, 
1987 
Peroutka and 
Snyder, 1980 
Koe, 1990 
Thomas et al, 
1987 
Thomas et al, 
1987 
APPENDIX 10 
SELECTIVITY OF 5-HT UPTAKE BLOCKERS TO INHIBIT [3H]MONOAMINE UPTAKE IN RAT SYNAPTOSOMAL PREPARATIONS 
[3H]5-HT [3H]NE NE/5-HT Reference 
Fluoxetine 14 - 30 500 20 - 26.5 Bolden-Watson & 
Richelson, 1993 
Thomas et al, 1987 
170 4500 20.5 Wong et al, 1985 
Fuller et al, 1978 
Desmethyl-fluoxetineA 25 410 16.4 Bolden-Watson & 
220 10,000 45.5 Richelson, 1993 
Fuller et al, 1978 
Sertraline 3.4 - 7.3 220 - 1400 65 - 192 Tulloch & Johnson, 1992 
Van Harten, 1993 
Bolden-Watson & 
Richelson, 1993 
Desmethyl-sertralineA 76 420 5.5 Bolden-Watson & 
Richelson, 1993 
Paroxetine 1.1 - 3.2 350 320 Thomas et al, 1987 
Wong et al, 1991 
Metabolite I sulphate 3100 370 ND Haddock et al, 1989 
Metabolite I glucuronide >10,000 >10,000 ND Haddock et al, 1989 
Citalopram 2.6 - 11.2 3900 1500 Thomas et al, 1987 
Wong et al, 1991 
Desmethyl-citalopramA· 1 1.8 8800 4889 Milne & Goa, 1991 
--" 
Data represent K; values (nM); AActive metabolite; 1 Data represent IC50 values (nM). 
(X) 
CJ"1 
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APPENDIX 11 
AFFINITIES OF 5-HT UPTAKE BLOCKERS FOR THE 5-HT TRANSPORTER 
Drug K; (nM) Tissue Source Reference 
Fluoxetine 1.2 rat cerebral cortex Marcusson et al, 1992 
Sertraline 0.57 rat whole brain Koe et al, 1990 
Paroxetine 0.01 rat cerebral cortex Battaglia et al, 1988 
Citalopram 0.63 rat cerebral cortex Marcusson et al, 1992 
APPENDIX 12 
SUMMARY OF STATISTICAL ANALYSES PERFORMED IN THE DISSERTATION STUDIES 
Parameter Statistical Post-Hoc Factors 
Analysis Test 
Growth & Maturation Parameters 
Maternal weight gain 1-way NK In utero exposure group 
Male:Female ratio t-test N/A In utero exposure group 
Litter Size t-test N/A In utero exposure group 
Crown-Rump Length 2-way NK In utero exposure group X gender 
Anogenital distance 2-way NK In utero exposure group X gender 
Birth weight 2-way NK In utero exposure group X gender 
Radioligand Binding Assays 
5-HT Uptake sites in homogenates 2-way NK In utero exposure group X age 
5-HT zAizc receptors in homogenates 2-way NK In utero exposure group X age 
Autoradiography 
5-HT uptake site autoradiography 2-way NK In utero exposure group X age 
5-HT,A receptor autoradiography 2-way NK In utero exposure group X age 
5-HT zA receptor autoradiography (High) 2-way NK In utero exposure group X age 
5-HT zA receptor autoradiography (High & Low) 2-way NK In utero exposure group X age 
Saturation tests for 5-HT zA (high) receptors 2-way NK In utero exposure group X age 
Saturation tests for 5-HT zA (high & low) receptors 2-way NK In utero exposure group X age 
Percentage High Affinity 5-HT zA receptors 2-way NK In utero exposure group X age 
HPLC Determinations** 
Basal levels of 5-HT 2-way NK In utero exposure group X age 
Basal levels of 5-HIAA 2-way NK In utero exposure group X age 
5-HT /5-HIAA 2-way NK In utero exposure group X age 
Reduction in regional 2-way NK In utero exposure group X age 
5-HT content following PCA 
00 
-...J 
APPENDIX 12 Continued 
Parameter Statistical Post-hoc Factors 
Analysis Test 
Functional Assays 
ACTH response to 8-0H-DPA T 3-way NK In utero exposure group X age X postnatal challenge 
Corticosterone response to 8-0H-DPAT 3-way NK In utero exposure group X age X postnatal challenge 
Renin response to 8-0H-DPA T 3-way NK In utero exposure group X age X postnatal challenge 
ACTH response to DOI 3-way NK In utero exposure group X age X postnatal challenge 
Corticosterone response to DOI 3-way NK In utero exposure group X age X postnatal challenge 
Renin response to DOI 3-way NK In utero exposure group X age X postnatal challenge 
Abbrev1at1ons: 1-way, 1-way analysis of variance; 2-way, 2-way analysis of variance; 3-way, 3-way analysis of variance; NK, 
Newman-Keuls post-hoc test; N/A, not applicable. 
Note: Each brain region will be analyzed independently 
* * Initially, a 3-way ANOVA will be carried out for each parameter with In Utero treatment group X age X postnatal challenge as 
the factors. 
(X) 
(X) 
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